CAR-T cell therapy for cancer: current challenges and future directions.

Introduction

Acute myeloid leukemia (AML) is the predominant form of leukemia in adults, with a median age at diagnosis of 68 years. 1 , 2 It is primarily characterized by a high degree of complex clonal heterogeneity. 3 , 4 For patients eligible for high-dose chemotherapy, treatment typically involves a combination of cytarabine and daunorubicin or idarubicin. Additionally, for those classified as intermediate or high risk according to the European Leukemia Net 2022 (ELN22) 5 risk stratification, allogeneic hematopoietic stem cell transplantation (alloHSCT) is often performed following initial chemotherapy. However, elderly patients or those with comorbidities who are ineligible for alloHSCT are typically treated with low-intensity regimens. 5 These regimens include venetoclax combined with hypomethylating agents (HMAs), 6 , 7 low-dose cytarabine, 8 , 9 or targeted molecules such as FLT3-directed tyrosine kinase inhibitors, 10 , 11 as well as HMAs with IDH1/2 inhibitors. 12 , 13

Despite the great efforts that have been made in recent years and the approval of new targeted therapies, relapsed/refractory (R/R) AML remains the leading cause of treatment failure. This challenging scenario occurs in 40-50% of patients younger than 60 years of age 2 , 14 and in up to 80% of patients older than 65 years, many of whom are ineligible for alloHSCT or intensive chemotherapy. 15 – 17 There is currently no standardized treatment protocol for these patients, and the 5-year overall survival (OS) rate is below 20%. 18 Therefore, R/R AML remains an unmet clinical need, and further investigation is urgent. For patients who meet eligibility criteria, alloHSCT is the only potentially curative option in this setting. 2

The success of alloHSCT and other cell therapy-based strategies, such as donor lymphocyte infusion (DLI), relies on the capacity of T and natural killer (NK) cells to target and eliminate leukemic cells, underscoring the sensitivity of AML to immunotherapy. 19 This has prompted interest in novel immunotherapeutic approaches, which are currently being explored. 20 For example, some clinical trials have tested immune checkpoint blockade strategies, including the anti-TIM3 monoclonal antibody (mAb) sabatolimab ( NCT04266301 ), with limited results, 21 or antibodies targeting CD47 (e.g., magrolimab, lemzoparlimab). 22 A clinical trial is currently underway ( NCT03113643 ) testing a recombinant protein consisting of interleukin (IL)-3 fused to a truncated diphtheria toxin payload that targets CD123 (tagraxofusp). 23 Additional ongoing strategies include the use of menin inhibitors targeting the HOX/MEIS1 transcriptional program, in combination with chemotherapy, for KMT2A rearranged- or NPM1-mutated AML, with encouraging results. 24 , 25

However, despite the excellent clinical outcomes observed with several chimeric antigen receptor T (CAR-T) cell products targeting CD19 or BCMA in the treatment of R/R B-cell malignancies and R/R multiple myeloma (MM), no CAR-T cell product has yet received regulatory approval for AML. This review offers an overview of the current development of CAR-T cell therapies for both hematologic and solid tumors, while examining the challenges associated with their application in AML, ongoing clinical trials, and future directions for optimizing CAR-T cell therapy in the treatment of AML.

CAR-T cell structure

CARs are engineered receptors consisting of a combination of an endodomain, an anchoring transmembrane domain, and an ectodomain. 26 , 27 The latter is a ligand-specific extracellular domain consisting of a single-chain variable-fragment (scFv) region and a hinge. 28 The scFv is a fusion protein of the variable regions of the light and heavy chains of immunoglobulins linked by a short flexible peptide linker. 29 The hinge, also known as a spacer, separates the binding units from the transmembrane domain. 30 Most CAR-T cells are designed with immunoglobulin-like domain hinges, which provide flexibility in accessing the target antigen. 31 , 32 The endodomain may consist of the intracellular T cell activation domain of CD3ζ as a single entity or by one or more intracellular co-stimulatory (or activation) domains. 33 While the scFv provides antigen specificity, the co-stimulatory domains are key to the activation of effector T cells. 34 CAR-T cells are classified into five generations based on the endodomain (Fig. 1 ). 35 – 37 Fig. 1 Structure of CARs. First-generation CARs consist of a ligand or scFv ectodomain and a CD3ζ TCR-type intracellular signal. Second-generation CARs contain a scFv extracellular domain and a co-stimulatory domain, 4-1BB or CD28. Third-generation CARs contain two co-stimulatory domains (usually 4-1BB and CD28). Fourth-generation CARs (TRUCKs) contain a domain encoding a specific cytokine or signal blocker/inducer. Fifth-generation CARs contain three synergistic co-stimulatory signals. This figure was created using Biorender.com

The first-generation CAR-T cells comprised a single fragment derived from the CD3ζ chain. 38 – 40 These cells depended on exogenous cytokine production, exhibited insufficient persistence and T cell activation, and consequently, did not achieve the desired results in most studies. 41 – 45 Accordingly, first-generation CARs have been superseded by second-generation CARs, which feature an intracellular signaling domain comprising a variety of co-stimulatory protein receptors situated within the cytoplasmic tail of the CARs, such as CD28 or CD137 (4-1BB). 46 – 49 These co-stimulatory proteins can enhance proliferation, cytotoxicity, and prolong persistence.

Third-generation CARs integrate multiple signaling domains, including CD28, 4-1BB, ICOS, and/or OX40. 50 – 52 Fourth-generation CAR-T cells, also known as “T cells redirected for universal cytokine-mediated killing” or “TRUCKs” 53 are engineered to release cytokines into the tumor microenvironment (TME). They may also express additional proteins such as chemokine receptors, switch receptors, bispecific T cell engagers (BiTEs), and blockers/inducers of specific signaling pathways. 54 – 57

In this context, next-generation CAR-T cells are currently underway. The fifth-generation differs from the previous versions by integrating an additional membrane receptor. Several approaches are being explored, with one of the most promising involving the incorporation of IL-2 receptor signaling to enable antigen-dependent JAK/STAT pathway activation. 58 – 61 This signaling not only sustains CAR-T cell activity and promotes memory T cell formation but also reactivates and stimulates the broader immune system.

Modifying T cells to express CARs typically involves transducing the cells with viral vectors containing the transgene, which leads to the semi-random integration of DNA into the T-cell genome. Interestingly, some fifth-generation strategies use specific site-integrations that provide additional features, which can be achieved through CRISPR mediated editing. One example is the insertion of the CAR into the TRAC locus (T cell receptor alpha constant). The TRAC locus is a constant region within the T cell receptor (TCR) alpha chain gene. This genetic editing allows the suppression of the expression of the endogenous TCR to ensure specific antigen recognition while avoiding potential interference from the natural TCR. By integrating TRAC, fifth-generation CAR-T cells maintain greater stability and identity over time, improving their ability to recognize and eliminate cancer cells. This genetic modification reduces the risk of T-cell exhaustion, graft-versus-host effect, and enhances the overall efficacy of CAR-T therapies, offering a more durable and potent treatment option. 62 In line with this, an additional innovative strategy has integrated the CAR cassette into the PDCD1 gene locus demonstrating a superior ability to eradicate cancer cells both in vitro and in xenograft models. 63 , 64

All six of the currently approved CAR-T cell constructs are second-generation CARs. Axicabtagene ciloleucel (Yescarta®) and brexucabtagene autoleucel (Tecartus®) are CD28-based, 65 whereas the remaining approved constructs are 4-1BB-based. Most approved products employ a murine scFv except for ciltacabtagene autoleucel (Carvykti®), which utilizes a camelid binding domain. 66 As exposed in the following sections, to further improve the efficacy of CAR-T cell therapy, the different CAR components have been engineered, resulting in constructs with enhanced properties. 58 , 67 , 68

CAR-T cell in cancer: current landscape

History of CAR-T cell implementation

Modern CAR-T cell therapy is the culmination of decades of groundbreaking immunology and genetic engineering research. Here, we provide a brief overview of the key contributions that paved the way for its first approvals and subsequent use in thousands of patients worldwide (Fig. 2 ). Fig. 2 The timeline of milestones in CAR-T cell development. The first reports published in scientific journals or conference abstracts, excluding patent applications, are highlighted. The efficacy of CD19 CAR-T cells was reported in patients with B-NHL in 2010, CLL in 2011, and B-ALL in 2013. The figure was created using Biorender.com

The remarkable success of CAR-T cell therapy would not have been possible without foundational discoveries in immunology. The identification of T cell origin, 69 , 70 and the pioneering work of Dr. Eva and Dr. George Klein, who demonstrated that immune cells can eradicate cancer, 71 were crucial milestones. In subsequent years, significant contributions were made by Dr. Steven Rosenberg at the National Cancer Institute (NCI), who pioneered the use of tumor-infiltrating lymphocytes (TILs) to treat selected solid tumors in patients. 72 – 74 While Rosenberg and colleagues highlighted the undeniable potential of cytotoxic T cells to combat cancer, TIL therapy faced challenges, including low reproducibility in TIL expansion and the restriction of its use to immunogenic tumors due to major histocompatibility complex (MHC) dependency. These limitations spurred researchers to address these challenges and explore ways to harness the anticancer potential of T cells across a broader range of malignancies, including poorly immunogenic tumors. This led to the groundbreaking concept of reprogramming T cells for enhanced specificity.

The concept of CARs originated from two groundbreaking studies conducted in the late 1980s. In 1987, Dr. Yoshikazu Kurosawa and colleagues engineered modified cells expressing T cell receptors (TCRs) with their variable regions replaced by the antigen-binding site of an antibody, creating receptors that functioned independently of MHC interaction. 75 Similarly, in 1989, Dr. Zelig Eshhar and his team developed analogous constructs. 76 They successfully generated “T-bodies,” functional chimeric receptors that recognized a hapten, confirmed by their ability to kill target-expressing tumor cells and produce cytokines (Fig. 2 ). Notably, Eshhar and colleagues proposed for the first time the potential use of CAR-modified T cells to combat cancer, laying the groundwork for subsequent innovations. A few years later, the same team introduced pivotal constructs of what are now considered first-generation CARs (Fig. 1 ). These early receptors, containing an anti-hapten antibody-derived scFv linked to the intracellular CD3ζ chain, were successfully expressed in murine cytotoxic T lymphocyte (CTL) hybridoma cells. 77 However, these first-generation CAR-T cells exhibited limited proliferation and killing capacities. 40 , 44 , 78 Moreover, their introduction to murine cells highlighted the need for optimized CAR-T production protocols, particularly to effectively modify and expand human T cells ex vivo. At this time, Dr. Michel Sadelain at Memorial Sloan Kettering Cancer Center (MSKCC) made significant advancements in T-cell engineering by improving retroviral modification methods. 79 Sadelain’s work on CAR design included the introduction of the CD28 co-stimulatory domain, which enhanced CAR T cell persistence and survival. 80 These advances were influenced by earlier research led by Dr. Carl June at Children’s Hospital of Philadelphia (CHOP), whose pivotal study a decade earlier established the critical role of CD28 co-stimulation in T cell proliferation and cytokine production, complementing CD3 signaling. 81 Collectively, the tremendous efforts of scientists in the late 20th century provided the foundational knowledge and technical advancements necessary for the eventual clinical implementation of CAR-T cell therapy.

In the early 2000s, Sadelain’s team emerged as a leader in advancing CAR-T cell research. A pivotal breakthrough came with Maher et al. 82 who introduced second-generation CARs to primary human T cells (Fig. 1 ). Although this was not the first report of CARs incorporating the CD28 co-stimulatory domain upstream of the CD3ζ chain, 83 Maher and colleagues were the first to demonstrate successful modification of primary human T cells to express second-generation CARs targeting prostate-specific membrane antigen (PSMA). These anti-PSMA CAR-T cells exhibited sustained proliferation and responsiveness to repeated stimulation by PSMA-expressing cancer cells, achieving the first fully effective CAR-T product.

Just one year later, researchers from MSKCC delivered another transformative milestone in immunotherapy. While early CAR-T development primarily focused on optimizing signaling constructs to enhance proliferation and persistence, selecting an ideal antigen to target became equally critical. Initial preclinical studies with first- and second-generation CARs targeted solid tumor-associated antigens, including disialogangliosides (GD2, GD3), carcinoembryonic antigen (CEA), and PSMA. 39 However, Sadelain and his team shifted their focus to hematological malignancies, proposing CD19 as a promising antigen nearly 15 years before its clinical implementation in CAR-T therapy. 84 In a landmark 2003 study, the MSKCC team demonstrated the feasibility of expanding CAR-T cells ex vivo using artificial antigen-presenting cells and IL-15. These CD19-targeted CAR-T cells achieved sustained persistence in immunodeficient murine models with established B-cell tumors. Around the same time, other research groups in the US—at institutions such as the National Cancer Institute (NCI), CHOP, and Baylor College of Medicine—also identified CD19 as a highly promising tumor-associated antigen. 49 , 85 – 87 These efforts collectively focused on treating B-cell-derived malignancies, including B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), and B-cell non-Hodgkin lymphoma (B-NHL), which uniformly express CD19 on their surfaces (Fig. 2 ). This concerted effort to target CD19 revolutionized the field and set the stage for CAR-T therapy’s transformative impact on hematologic cancers.

After CD19 was identified as the optimal target for immunotherapy, a critical milestone was the development of scalable manufacturing protocols for clinical-grade CAR-T cells. Until 2010, the efficacy of CD19 CAR-T cells had been primarily evaluated in vitro and in murine models, which required relatively small numbers of effector cells. However, preparing CAR-T cells for clinical use demanded protocols capable of large-scale production. In 2009, Hollyman et al. 88 described a process for autologous T cell activation, transduction, and expansion in bioreactors, enabling the generation of sufficient cell numbers for clinical applications. This advancement opened new opportunities for future clinical trials. By May 2010, nine independent single-center clinical trials were registered across the US, with three more under regulatory review. 89 Investigators published data from individual case studies before collective clinical trial results were available. The first report of CD19 CAR-T therapy in a patient came from Rosenberg’s group at the NCI, detailing a case of relapsed B-NHL. 90 This study used autologous T cells engineered with a second-generation CAR construct incorporating anti-CD19 scFv (anti-FMC63 epitope), a CD28 co-stimulatory domain, and a CD3ζ signaling chain. 90 In the following months, additional studies reported the use of CD19 CAR-T cells in patients with B-cell-derived malignancies. The first clinical results from the CHOP described treating CLL, 91 , 92 while researchers at MSKCC reported outcomes for adult B-ALL. 93 , 94 Notably, the CHOP trials utilized CD19 CAR-T cells designed with the 4-1BB co-stimulatory domain (CD19-BB-z), a construct initially introduced by Dr. Dario Campana and Dr. Chihaya Imai at St. Jude Children’s Research Hospital. 49 These early clinical studies established the foundation for the rapid progression of CAR-T therapy from experimental models to transformative cancer treatments (Fig. 2 ).

While early CD19 CAR-T cell clinical trials primarily enrolled R/R adult patients, a groundbreaking milestone was achieved in 2012 when physicians and scientists from CHOP administered CD19 CAR-T therapy to the first pediatric patient with B-ALL. The treatment garnered worldwide attention as the patient achieved morphologic remission within a month of CAR-T cell infusion. 95 Remarkably, as of 2024, this patient remains cancer-free after 12 years, highlighting the life-saving potential of CAR-T therapy. 96 The treatment, however, was not devoid of high-grade adverse effects and severe cytokine release syndrome (CRS), which was manifested by high IL-6 levels. Fortunately, the CHOP team, led by Dr. Carl June, obtained permission for the “off-label” use of tocilizumab—a humanized monoclonal antibody targeting the IL-6 receptor—originally approved for treating rheumatoid arthritis. The successful management of CRS with tocilizumab was a pivotal moment in CAR-T therapy, and IL-6 receptor antagonists are now the standard of care for CRS management in CAR-T-treated patients, 97 , 98 even prophylactically. This case showcased CAR-T cells’ efficacy in pediatric cancer. 99 , 100 It underscored the importance of effective strategies to manage treatment-associated toxicities, paving the way for safer and more accessible CAR-T therapies. 100

In the subsequent years, additional results from single-center trials demonstrated sustained remissions in patients treated with CD19 CAR-T, including adults and children with B-ALL 101 , 102 and adults with B-NHL or CLL. 103 , 104 The successful responses in these pivotal trials prompted collaborations between scientists, clinicians, and biopharma companies to further develop and implement this treatment, ultimately acquiring the necessary regulatory approvals. Notably, June’s team at CHOP partnered with Novartis, 105 Rosenberg’s team at NCI collaborated with Kite Pharma, 106 and researchers from MSKCC, Seattle Children’s Research Institute, and Fred Hutchinson Cancer Research Center founded Juno Therapeutics. 107 As a result, CD19 CAR-T received breakthrough therapy designation from the FDA in 2014, and the global multi-center trials culminated in the first approvals in 2017. Specifically, Kymriah® (CD19-BB-z) became the first approved cell-based therapy for R/R B-ALL in patients under 25 years old, while Yescarta® (CD19-28-z) was approved for adult R/R B-NHL, based on the ELIANA, 108 , 109 and and ZUMA-1 110 trials, respectively.

These landmark approvals resulted from over 30 years of groundbreaking research and the dedicated efforts of scientists and clinicians. Despite the success of these CAR-T therapies, challenges remain in gaining approval for their use in all blood cancers and solid tumors. In the following sections, we will present an overview of the current role of CAR-T cells in hematologic malignancies with a major focus on AML and solid tumors, followed by the key difficulties involved in implementing adoptive cell therapies for patients with AML.

CAR-T therapies for hematologic malignancies and solid tumors: current scenario

The US Food and Drug Administration (FDA) has approved six CAR-T cell therapies for the treatment of various hematologic malignancies. Kymriah®, a second-generation CAR-T cell therapy targeting the B cell antigen CD19, was the first CAR-T cell therapy to receive approval by the FDA and the European Medicines Agency (EMA) for the treatment of children and young adults with ALL. 109 , 111 , 112 The FDA and EMA have subsequently approved three additional CAR-T cell therapies targeting the CD19 antigen: Yescarta®, 113 – 115 Tecartus®, 65 , 113 and lisocabtagene maraleucel (Breyanzi®). 116 , 117 In addition, two B cell maturation antigen (BCMA) CAR-T cell products have been approved for the treatment of R/R MM, idecabtagene vicleucel (Abecma®) 118 in March 2021 and Carvykti® in February 2022. 66 , 119 , 120 Currently, several clinical trials are ongoing testing these six CAR-T cells for further indications (Table 1 ). Table 1 EMA & FDA approved CAR T cell therapies Tradename (Generic name) Target Approved indication Manufacturer/marketing authorization issued Clinical trial Phase Trial Aim and participation Criteria Status Recruitment Locations Efficacy outcomes Safety outcomes Ref. Kymriah(Tisagenlecleucel (tisa-cel)) CTL019 CD19 Adult patients (up to 25 years of age) with Refractory B-cell precursor ALL R/R Large B-cell lymphoma: DLBC, High grade B-cell Lymphoma and DLBCL arising from FL R/R FL Novartis Pharmaceuticals Corporation EMA (2018) FDA (2017) NCT04134117 I To study the safety of tisa-cel in adult patients (≥60 years of age) with R/R Primary CNS Lymphoma C 9 participants US - CRS: 66.67%, 11% grade3 NE: 55.6% 449 – 451 NCT03630159 PORTIA 2018-000973-57 (EudraCT) I To evaluate the safety and efficacy of the administration of tisa-cel in combination with pembrolizumab in adult patients with R/R DLBCL, not candidates for ASCT C 12 participants US, Austria, Canada ORR: 50% CR: 33.3% CRS: 58.3% ICANS: 8.3% 452 , 453 NCT03876028 I To evaluate the safety and tolerability of the administration of tisa-cel in combination with ibrutinib in adult patients with R/R DLBCL, not candidates for ASCT. T 10 participants Arm 1: 4 participants ibrutinib 560 mg/d for ~4 weeks prior to leukapheresis Arm 2: 6 participants ibrutinib after leukapheresis US CR: Arm 1: 50% Arm 2: 33.3% CRS: grade 1 Arm 1: 25 % Arm 2: 83.3% NE: Arm 2: 16.7% 454 NCT06003179 I To identify an optimized lymphodepletion (LD) regimen by evaluating standard and intermediate doses of Fludarabine (Flu)/Cyclophosphamide (Cy) with or without a fixed dose of total lymphoid irradiation (TLI) in the setting of standard of care CAR T cell therapy. ≥18 years Patients WD Enrollment estimated 20-40 participants Canada - - 455 NCT05310591 CAPTiRALL I, II To determine the safety, efficacy and feasibility of Nivolumab (Opdivo®)- an anti-PD1 treatment- combined to tisa-cel in Patients aged from 1 to 25 years (pediatric and young adults) with a history of CD19 + R/R B-ALL (any relapse after HSCT, 2nd R/R ALL). R Enrollment estimated 26 participants France - - 456 NCT03876769 CASSIOPEIA 2017-002116-14 (EudraCT) II To determine the efficacy and safety of tisa-cel in de novo High Risk (HR) pediatric and young adult B-ALL patients (1 to 25 years) who received first-line treatment and are MRD Positive at the End of Consolidation (EOC) Therapy ANR 121 participants US, Belgium, Canada, Denmark, France, Italy, Netherlands, Norway, Spain, Sweden, UK - - 457 , 458 NCT03568461 ELARA 2017-004385-94 (EudraCT) II To determine the efficacy and safety of tisa-cel in adult patients (≥18 years) with R/R FL (Grade 1, 2, 3A) ANR Arm CTL019: 98 participants who received tisa-cel infusion US, Australia, Austria, Belgium, France, Germany, Italy, Japan, Netherlands, Norway, Spain, UK ORR: 86.2% (94 p.a.) CR: 69.1% (94 p.a.) CRS 30.93% (97 p.a.) 19.59% serious adverse ICANS: 1.03% (97 p.a.) 111 , 459 NCT04234061 TARMAC II To evaluate the efficacy and safety of the combination of ibrutinib and Tisa-cel in ≥18 years of age patients with R/R Mantle Cell Lymphoma (MCL) or who had sub-optimal response to standard therapy in the presence of TP53 mutation. ANR 20 participants Australia - - 460 NCT02445248 JULIET 2014-003060-20 (EudraCT) II To determine the efficacy and safety of (tisa-cel) in adult patients (≥18 years) with histologically confirmed R/R DLBCL after ≥2 lines of chemotherapy, with a life expectancy of ≥12 weeks and not eligible or not consenting to HSCT C 115 participants: Main Cohort (patients treated with tisa-cel US manufacturing facility): 99 participants Cohort A (patients treated with tisa-cel EU manufacturing facility): 16 participants US, Australia, Austria, Canada, France, Germany, Italy, Japan, Netherlands, Norway ORR: Main Cohort: 54.5% Cohort A: 53% CR: Main cohort 39% CRS: Main cohort: any grade 57%, grade 3–4 23% NE: Main cohort: any grade 20%, grade 3 or worse 11% 112 , 461 , 462 NCT03610724 BIANCA 2017-005019-15 (EudraCT) II To assess the efficacy and safety of tisa-cel in pediatric, adolescent and young adult patients with R/R B-NHL including Burkitt Lymphoma and Burkitt Leukemia. C 34 participants (33 infused) US, Australia, Austria, Canada, Denmark, Finland, France, Germany, Italy, Japan, Netherlands, Norway, Spain, UK ORR: 32.1% (28 p.a.) CRS: 24.24% (33 p.a.) NE: 6.06% 463 NCT02228096 ENSIGN 2015-003736-13 (EudraCT) II To determine the efficacy and safety of tisa-cel in pediatric patients (3–21 years) with B-ALL, who were refractory to standard chemotherapy regimen or relapsed after HSCT. C 75 participants US ORR: 70.3% (64 p.a.) CR: 67.2% CRS: 64.06% (64 p.a.) NE: 6.25% (64 p.a.) 464 – 467 NCT05460533 II To see if early reinfusion of tisa-cel can keep participants in B-cell aplasia at 6 months after their first infusion. To evaluate the safety of early reinfusion and how effective it is at treating B-ALL. Pediatric and Young Adult Patients With R/R CD19-Positive B-Cell ALL (REFUEL) R Enrollment estimated 33 patients US - - 468 NCT04225676 II To determine the efficacy and safety of reinfusion of tisa-cel. Pediatric and adolescent young adult (AYA) patients (≤25 years old) with ALL experiencing loss of B cell aplasia and a previous infusion of commercial tisa-cel with ≥1 additional dose available. T 5 participants US Terminated due to slow enrollment CRS: 20% 469 – 471 NCT04161118 TIGER-CTL019 Uni-Koeln-3903 II To determine the efficacy and safety of tisa-cel in elderly Patients (>65 years, or > 60 years old with HCT-CI score >2) with First-Relapsed or Primary Refractory Aggressive B- NHL (treatment with immunochemotherapy containing rituximab and anthracycline) Termination of the funding agreement by the financial sponsor. Small number of patients enrolled 3 participants Germany - - 472 NCT04156659 II To evaluate the efficacy and safety of tisa-cel in Chinese Pediatric and Young Adult Patients (age ≤25 years) With R/R B-ALL WD Without information No location data Not provided - 473 NCT04456023 II To evaluate the efficacy and safety of CTL019 in Chinese adult patients (≥18 years of age) with R/R DLBCL. WD Without information Without information - - 474 NCT03570892 BELINDA 2016-002966-29 (EudraCT) III To compare the efficacy, safety, and tolerability of tisa-cel to SOC in adult patients (≥18 years) with aggressive B-NHL ANR Tisa-cel arm: 162 participants SOC arm: 160 subjects treated with platinum-based immunochemotherapy followed in responding patients by high dose chemotherapy and auto-HSCT US, Australia, Austria, Belgium, Brazil, China, France, Germany, Hong Kong, Italy, Japan, Netherlands, Norway, Singapore, Spain, Switzerland, Tawian, UK ORR: Tisa-cel arm: 46.3% SOC: 42.5% CR: Tisa-cel arm: 46% SOC: 44% CRS: 61.3% NE: 10.3% 475 , 476 NCT05888493 LEDA 2023-503452-27-00 (Registry Identifier) (REGISTRY: EU CT Number) III To compare tisa-cel to SOC in adult patients (≥18 years) with R/R FL after two or more lines of systemic therapy, with progression-free survival (PFS) as the primary endpoint. R 108 participants Arm A: tisa-cel treatment Arm B: SOC. Treatment with R2 or R-CHOP Australia, Canada, Czechia, Hungary, Republic of Korea, Poland, Romania, Singapore, Slovakia, Spain, Taiwan - - 477 NCT04094311 III To evaluate the safety of tisa-cel that is OOS for release as commercial product. Pediatric/young adult patients with R/R B-ALL and adult patients with R/R LBCL including DLBCL not otherwise specified, high-grade B cell lymphoma, and DLBCL arising from FL for Part 1 and and R/R ALL and R/R NHL for Part 2 R Enrollment estimated: 200 participants Canada, Japan - - 478 NCT05199961 Not applicable To evaluate quality of life (QOL) and other patient reported outcomes (PROs) in adults with DLBCL following (CAR) T-cell therapy with tisa-cel T Sponsor requested early termination 4 participants US - - 479 NCT05541341 Observational To determine the efficacy and safety of tisa-cel in pediatric (<18 years) and adult patients (aged 18 years or older) with B-cell malignancies who have received tisa-cel through the commercial setting or OOS use in Brazil. R Enrollment estimated: 200 participants Brazil - - 480 Yescarta (Axicabtagene ciloleucel) CD19 R/R DLBCL High-Grade B-cell Lymphoma (HGBL) Primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy. Adult patients with R/R FL after three or more lines of systemic therapy. Kite Pharma, Inc. Kite Pharma EU B.V EMA (2018) FDA (2017) NCT03153462 ZUMA-9 2015-005007-86 (EudraCT) Expanded Access Expanded access to axi-cel until commercial availability. Age ≥18 years subjects who received an infusion of axi-cel will complete the remainder of the 15-year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968. R/R DLBCL, R/R Primary Mediastinal B Cell Lymphoma,R/R transformed FL, R/R HG B-Cell Lymphoma AFM Cohort 1 (C1): 25 participants Cohort 2 (C2): 36 participants US ORR: 76% CR: 64% CRS: Grade ≥ 3 was not observed in C1. 3% of C2 NE: C1: 36% Grade ≥ 3 C2: 19% Grade ≥ 3 447 , 481 , 482 NCT04608487 I To test the safety and effectiveness of axi-cel (axi-cel) to treat CNS Lymphoma. Age ≥18 years participants with R/R active primary or secondary CNS lymphoma (PCNSL or SCNSL), histologically proven aggressive B cell lymphoma, including DLBCL, HGBL, PMBL, or tFL ANR 18 participants: 13 PCNSL, 4 SCNSL, 1 concurrent systemic & ocular Lymphoma US ORR: 94% CR: 67% CRS: 89%, 0% grade ≥3 ICANS: 44%, 28% grade ≥3 483 , 484 NCT05077527 I To demonstrate safety and feasibility of axi-cel for R/R human immunodeficiency virus (HIV)-associated aggressive B-NHL in participants with well-controlled HIV R 20 participants US - - 485 NCT05794958 I To establish safety of Axi-Cel-2 in patients with LBCL who are at high risk of relapse. Reinfusion (Axi-Cel-2) in patients with R/R second line High-Risk NHL after SOC Axi-Cel R 20 participants enrollment estimated US - - 486 NCT05950802 ODIN I To identify an optimized LD regimen by evaluating standard and intermediate doses of Flu/ Cy with or without a fixed dose of TLI in the setting of standard of care CAR T cell therapy. ≥18 years Patients Receiving CAR T Cell Therapy Axi-cel (ODIN) R Enrollment estimated 40 patients Canada - - 487 NCT03704298 ZUMA-11 I Age ≥18 years participants with R/R LBCL who received an infusion of axi-cel and utomilumab (UT) Phase 1: To evaluate the safety of Axi-cel in combination with UT and to identify the most appropriate dose and timing of UT to carry forward into Phase 2 Phase 2: To evaluate the efficacy of axi-cel and UT as measured by CR. T Development program T 12 participants: Phase 1: Cohort 1: Axi-cel + UT 10 mg: 3 participants Phase 1: Cohort 2: Axi-cel + UT 30 mg+O34:O45: 3 participants Phase 1: Cohort 3: Axi-cel + UT 100 mg: 3 participants Phase 1: Cohort 4: Axi-cel + UT 200 mg: 3 participants US ORR: Phase 1: Cohort 1: 67% Phase 1: Cohort 2: 33% Phase 1: Cohort 3: 100% Phase 1: Cohort 4: 100% Serious adverse effects: Phase 1: Cohort 1: 33.33% Phase 1: Cohort 2: 100.00% Phase 1: Cohort 3: 33.33% Phase 1: Cohort 4: 66.67% 488 NCT04314843 ZUMA-19 2019-004568-23 (EudraCT) I Age ≥18 years participants with R/R LBCL Phase 1: To evaluate the safety of sequenced therapy with lenzilumab and axi-cel Phase 2: To evaluate the incidence of NE with sequenced therapy given at the recommended Phase 2 dose (RP2D) of lenzilumab T Development program T and the decision was not due to any safety concerns. 6 patients Phase 1 Cohort 1: 3 participants Phase 1 Cohort 2: 3 participants Phase 2 was not conducted US ORR: Phase 1 Cohort 1: 67% Phase 1 Cohort 2: 100% CR: Phase 1 Cohort 1: 67% Phase 1 Cohort 2: 67% CRS: Phase 1 Cohort 1: 67% Phase 1 Cohort 2: 67% NE: Phase 1 Cohort 1: 100% Phase 1 Cohort 2: 67% 489 – 491 NCT03105336 ZUMA-5 2017-001912-13 (EudraCT) 2023-505169-10 EMA II To evaluate the efficacy and safety of Axi-cel in adult with R/R Indolent NHL (iNHL): patients with FL or Marginal Zone Lymphoma MZL) ANR 158 participants received lymphodepleting chemotherapy and axi-cel: FL: 127 MZL: 31 US, France ORR: FL: 94% MZL: 77% CR: FL: 79% MZL: 65% CRS: (18-month analysis) FL: 0% MZL: 3% NE: (18-month analysis) FL: 0% MZL: 3% 65 , 492 – 494 NCT05459571 ZUMA-24 II To learn more about the study drug, axi-cel, in age ≥18 years participants with R/R LBCL in the outpatient setting ANR As of November 2, 2023, 23 pts were enrolled and 20 received axi-cel. US ORR: 90% CR: 70% CRS: 85%, 5% Grade ≥3 NE: 75%, 25% Grade ≥3 495 – 497 NCT04002401 ZUMA -14 2019-004803-11 (EudraCT) II To estimate the efficacy of axi-cel in combination with rituximab in age ≥18 years participants with R/R LBCL. C 26 participants US CR: 65% ORR: 88% CRS: There was no Grade ≥3 NE: Grade ≥3 15% 498 – 500 NCT03761056 ZUMA-12 2019-002291-13 (EudraCT) II To estimate the efficacy of axi-cel in age ≥18 years participants with HG LBCL C 40 participants US, Australia, France ORR: 92% (37 p.a.) CR: 86% (37 p.a.) No new cases of CRS or NE of any grade occurred since the prior data cut. 501 – 506 NCT06218602 II To assess the toxicity of combination of FMT with Axi-cel and compare it with SOC Arm B with Axi-cel. Age ≥18 years Lymphoma Patients R 40 Patients US - - 507 NCT06043323 II To determine the safety of SOC axi-cel with bridging radiotherapy (RT) in adult patients with R/R FL assessed by the incidence of grade 3 or higher CRS within 30 days after CAR T-cell infusion. R 20 participants enrollment estimated US - - 508 NCT06213311 II To evaluate the safety of axi-cel and glofitamab as combination therapy in 2nd line LBCL participants R 40 participants US - - 509 NCT03391466 ZUMA-7 2017-002261-22 (EudraCT) III To assess whether axi-cel therapy improves the clinical outcome compared with SOC second-line therapy in age ≥18 years participants with R/R DLBCL after first-line rituximab and anthracycline-based chemotherapy ANR 359 participants Axi-cel: 180 participants SOC : 179 participants US, Australia, Austria, Belgium, Canada, France, Germany, Israel, Italy, Netherlands, Spain, Sweden, Switzerland, UK ORR: Axi-cel: 83% SOC: 50% CR: Axi-cel: 65% SOC: 32% CRS: Axi-cel: 92% , Grade ≥3 6% NE: Axi-cel: 60% SOC: 20% 510 – 514 NCT05605899 ZUMA-23 2022-501489-24-00 EMA III To compare the study drug, axi-cel, versus SOC in first-line therapy in adult participants with high-risk LBCL R 300 participants enrollment estimated US, Austria, Canada, Francia, Germany, Italy, Japan, Netherlands, Portugal, Spain, UK - - 515 NCT05371093 ZUMA-22 2021-003260-28 EMA 2024-511594-30 EMA III To find out how well the drug axi-cel works in patients with R/R FL when compared to SOC. Age ≥18 years participants histologically confirmed FL (Grade 1, 2, or 3a) R/R disease after first-line chemoimmunotherapy and high-risk disease with relapse or progression within 24 months of the initial course of chemoimmunotherapy (ie, POD24), Or R/R disease after ≥2 prior systemic lines of therapy R 230 participants enrollment estimated US, France, Germany, Italy, Japan, Spain, UK - - 516 , 517 NCT06609304 IV To learn if axi-cel works for consolidation after first-line treatment of high-risk LBCL in adult participants untreated CD19-positive LBCL;axi-cel works for consolidation after first-line treatment of high-risk LBCL R 20 participants enrollment estimated China - - 518 NCT05800067 Not Applicable To explore the efficacy and safety of Axi-cel retreatment inadult participants with R/R LBCL in Shanghai Ruijin Hospital in China R 32 participants enrollment estimated China - - 519 Tecartus (Brexucabtagene autoleucel) KTE-X19 Brexu-cel CD19 Adult patients with relapsed or refractory mantle cell lymphoma (MCL) Adult patients with R/R B-cell precursor ALL Kite Pharmaceuticals, Inc. Kite Pharmaceuticals, Inc.EMA (2020) FDA (2020) NCT04162756 ZUMA-18 Expanded Access Cohort 1: to provide access to brexu-cel for individuals R/R MCL until KTE-X19 is commercially available Cohort 2: To provide access to KTE-X19 for individuals with R/R MCL whose commercially manufactured product did not meet commercial release specification(s) AFM 23 patients Cohort 1: 21 participants Cohort 2: 2 participants US ORR: 87% CR: 57%, 30% had a PR, and 9% had progressive disease (PD) CRS: 4% Grade ≥3 NE: 35% 520 , 521 NCT05776134 Expanded Access To provide access to brexu-cel for patients diagnosed with a disease approved for treatment with brexu-cel, that is otherwise out of specification for commercial release. AV - US - - 522 NCT05993949 I To assess the feasibility of oral dasatinib pulses (3 consecutive days per week) during the first month following infusion of brexu-cel in adult participants with R/R B-ALL R 20 participants enrollment estimated US - - 523 NCT03624036 ZUMA-8 2018-001923-38 (EudraCT) I To evaluate the safety and tolerability of brexu-cel (KTE-X19) in ≥ 18 years participants with R/R CLL and small lymphocytic lymphoma (R/R SLL) who have received at least 2 prior lines of treatment, one of which must include a Bruton’s tyrosine kinase (BTK) inhibitor. T Development program T 15 patients received KTE-X19 therapy: Cohort 1: 6 participants R/R CLL Cohort 2: 3 participants R/R CLL Cohort 3: 3 participants R/R CLL and SLL with ≤1% malignant cells in peripheral blood Cohort 4: 3 participants with R/R CLL who previously received two lines of therapy along with ibrutinib with or without anti CD20 antibodies US, Italy ORR: Cohort 1: 50% Cohort 2: 33% Cohort 3: 100% Cohort 4: 0% CRS 80%, 7% grade ≥3 NE: 73%, 20% grade ≥3 524 – 526 NCT02625480 ZUMA-4 2015-005010-30 (EudraCT) I II To evaluate the safety and efficacy of (KTE-X19) in pediatric and adolescent participants with R/R B-precursor ALL or R/R (NHL). Up to 21 years pediatric and adolescent participants ANR 24 patients US, Canada, Czechia, France, Germany, Italy, Netherlands, Poland, Spain, Sweden ORR: 67% CR: 29%, 38% CRi CRS: 88%, 33% grade ≥3 NE: 67%, 21% grade ≥3 527 , 528 NCT02614066 ZUMA-3 2015-005009-35 (EudraCT) I II To determine the safety and efficacy of (KTE-X19) in ≥ 18 years participants with R/R B-precursor ALL C 100 patients Phase 1: 45 patients Phase 2: 55 US, Canada, France, Germany, Netherlands ORR: Phase 1: 69% CR: Phase 1: 53%, 16% achieving CRi Phase 2: 56.4% CRS: Phase 1: 93%, 31% grade ≥3 Phase 2: 24% grade ≥3 NE: Phase 1: 78%, 38% grade ≥3 Phase 2: 25% 529 – 531 NCT06287229 NCI-2024-01756 (OTHER: NCI-CTRP Clinical Registry) I II To learn about the safety of giving the drug brexu-cel to adult participants with R/R B-ALL after treatment with inotuzumab ozogamicin, blinatumomab, and either hyper-CVAD or mini-hyper-CVD R 40 participants enrollment estimated US - - 532 NCT05537766 ZUMA-25 2022-501259-10 EMA II To test how well the study drug, brexu-cel, works in participants with rare B-cell malignancies. ≥18 years participants with R/R Waldenstrom macroglobulinemia (R/R WM) (Substudy A - no longer recruiting), R/R Richter transformation (R/R RT) (Substudy B), R/R Burkitt lymphoma (R/R BL) (Substudy C and/r hairy cell leukemia (R/R HCL) (Substudy D - no longer recruiting). ANR 19 participants US, Austria, France, Germany, Italy, Netherlands, Spain, Switzerland - - 533 NCT02601313 ZUMA-2 2015-005008-27 (EudraCT) 2023-506641-35 EMA II To test how well the study drug, KTE-X19, works in adult participants with R/R MCL who have been treated with up to 5 prior regimens including a Bruton’s tyrosine kinase inhibitor (BTKi) in Cohort 1 and 2 C 92 patients Cohort 1: 68 participants treated with 2 ×10^6 Brexu-cel Cohort 2: 14 participants treated with 0.5 ×10^8 Brexu-cel 2 ×10^6 Axi-cel: 10 participants US, France, Germany, Netherlands ORR: Cohort 1:93% cohort 2: 93% CRS: 15% grade 3 or higher NE: 31% 534 – 536 NCT06553872 II To study the combination of two treatments, Pirtobrutinib and brexu-cel, for patients with R/R MCL Age ≥ 18 years participants with R/R MCL who meet the criteria for standard-of-care FDA label for CD19 CAR T-cell therapy with brexu-cel R 60 participants enrollment estimated US - - 537 NCT04880434 ZUMA-2 2015-005008-27 (EudraCT) III To test how well the study drug, brexu-cel (KTE-X19), works in adult participants with R/R MCL up to 5 prior regimens for MCL ANR 86 participants US, France, Germany, Netherlands, Spain, UK ORR: 91% CR: 73% CRS: 6% ICANS: 21% NE: 27% 538 , 539 Abecma (idecabtagene vicleucel) bb2121 ide-cel BCMA R/R MM Celgene Corporation, a Bristol-Myers Squibb Company Celgene Corporation, a Bristol-Myers Squibb Company Celgene Corporation, a Bristol-Myers Squibb Company EMA (2021) FDA (2021) NCT03274219 I To study the dose escalation trial of bb21217 in adult R/R MM patients who received ≥3 prior regimens, including proteasome inhibitor and immunomodulatory agent, or are double refractory to both classes. C As of March 1, 2020, 46 participants: 24 participants in escalation: 12 at 150, 6 at 300 and 6 at 450 22 in expansion: 8 at 300 and 14 at 450 US CR: 55% CRS: 67% NE: 22% 540 , 541 NCT04771078 Expanded Access To evaluate the safety and efficacy of nonconforming ide-cel in adult participants with MM per the approved prescribing information. AV 31 participants 8 participants received LEN maintenance after ide-cel at the investigator’s discretion US ORR: 87.1% ORR LEN maintenance: 100% CRR: 80.6% CR LEN maintenance: 75% - 542 , 543 NCT06048250 I To study the safety, side effects, best dose and effectiveness of mezigdomide (CC-92480) when given after ide-cel in adult patients with MM that has come back after a period of improvement (relapsed) R 15 participants enrollment estimated US - - 544 NCT04855136 KarMMa-7 2020-003248-10 (EudraCT) I II To determine the safety, tolerability, efficacy, PK of bb2121 in combination with other therapies in adult subjects with R/R MM. ANR 128 participants Arm A: bb2121 in combination with CC-220 ( ± low-dose dexamethasone) Arm B: bb2121 in combination with BMS-986405 (JSMD194) US, Spain ORR: 73% CR: 33% CRS: 84% NE: 18%, 3% had grade 3 and 0 had grade ≥ 4 545 – 547 NCT06518551 I II To evaluate the efficacy of Elotuzumab and Iberdomide therapy post-Ide-cel in adult participants with R/R MM R 49 participants enrollment estimated US - - 548 NCT05032820 BMTCTN1902 II To assess bb2121 to improve post AHCT responses among adult patients with MM and sub-optimal response after AHCT and maintenance Lenalidomide ANR 40 participants US - - 549 NCT06523621 II To evaluate if treatment with adjuvant nivolumab improves depth of response in adult patients withR/R MM who achieve a less-than-ideal response to ide-cel. NYR 50 participants enrollment estimated US - - 550 NCT05393804 II To see if the quality of T cells used to create ide-cel (bb2121) affects how ide-cel prevents cancer from coming back in adult patients with R/R MM, and who have had an HCT R 32 participants enrollment estimated US - - 551 NCT06179888 II To compare iberdomide maintenance therapy to disease monitoring for improving survival in adult patients who have received ide-cel for MM R 78 participants enrollment estimated US - - 552 NCT06045806 KarMMa-9 2022-501346-30 (EudraCT) III To compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed MM (NDMM) who have achieved a suboptimal response post auto-HSCT ANR 618 participants enrollment estimated United States, Australia, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Greece, Israel, Italy, Japan, Republic of Korea, Norway, Poland, Romania, Spain, UK - - 553 , 554 NCT06698887 Observational To monitor the long-term safety of adult participants who received ide-cel treatment as part of the KarMMa-9 (CA089-1043) Phase 3 clinical trial. R 15 participants enrollment estimated Republic of Korea - - 555 Breyanzi (Lisocabtagene maraleucel) JCAR017 CD19 Adult patients with R/R LBCL, including: DLBCL not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B cell lymphoma, primary mediastinal LBCL, and FL grade 3B Juno Therapeutics, Inc., a Bristol-Myers Squibb EMA (2022) FDA (2021) NCT02631044 TRANSCEND-NHL-001 I To evaluate the safety, PK, and antitumor activity of modified T cells (JCAR017) administered to adult patients with R/R B-cell NHL PMBCL, FL grade 3B, and MCL. This study will evaluate and refine the dose and schedule of JCAR017 to optimize safety and antitumor activity. C At data cutoff (01/19/2023): 88 participants received liso-cel Efficacy set (n = 83) US ORR: 83.1% CR: 72.3% CRS: 61% NE: 31% 117 , 556 – 560 NCT05075603 I To evaluate the safety, tolerability, and preliminary anti-tumor activity of NT-I7 administration following standard of care CD19 CAR T-cell therapy for eligible subjects with R/R LBCL. R 57 participants enrollment estimated US - - 561 NCT03331198 TRANSCEND-CLL-004 I II To determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL R 117 patients received liso-cel US, Canada ORR: 44% CRS: 85%, 8% grade >3 NE: 45%, 11% experienced a grade 1, 15% had a grade 2, 18% had a grade 3, and 1% had a grade 4 562 – 564 NCT03743246 2018-001246-34 (EudraCT) I II To evaluate the safety and efficacy of JCAR017 in pediatric subjects aged ≤ 25 years with CD19 + R/R B-ALL and B-NHL T (Absence of significant therapeutic benefit over existing therapies) 21 participants A. 0.05 ×10^6 CAR + T Cells/kg 9 B. 0.15 ×10^6 CAR + T Cells/kg 8 C. 0.50 ×106 CAR + T Cells/kg 3 D. Not Assigned 1 US, France, Germany, Italy, Netherlands, Spain ORR A: 50% B: 25% C:100% CRS A: 0.00% B: 50.00% C: 0.00% D: 0.00% Neurotoxicity A: 14.29% B: 16.67% C: 100.00% D: 0.00% 565 NCT03483103 TRANSCEND-PILOT-017006 II To determine the efficacy and safety of liso-cel in adult subjects who have R/R B-cell NHL and are ineligible for HSCT C 61 received liso-cel (efficacy and safety sets) US ORR: 80% CR: 53% CRS: 38% NE: 31% 116 , 566 – 568 NCT03484702 TRANSCENDWORLD 2017-000106-38 (EudraCT) II To evaluate the efficacy and safety of JCAR017 in adult participants with aggressive B-NHL C 113 patients Cohort 1 C1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy: 45 Cohort 2 C2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy: 32 Cohort 3 C3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2: 14 Cohort 4 C4: Newly Diagnosed HGBL:4 Cohort 5 C5: Primary Central Nervous System Lymphoma:7 Cohort 7 C7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting:11 Austria, Belgium, Finland, France, Germany, Italy, Japan, Netherlands, Spain, Switzerland, UK ORR: C1: 61.1% 36 patients analyzed (p.a) C2: 63% 27 p.a. C3: 70% 10 p.a. C4: 100% 1 p.a. C5: 80% 5 p.a. C7: 88.9% 9 p.a. CR: C1: 33.3% 36 p.a. C2: 48.1% 27 p.a. C3: 50% 10 p.a. C4: 0% 1 p.a. C5: 0% 5 p.a. C7: 88.9% 9 p.a. CRS: C1: 15.56% 45 p.a. C2: 3.13% 32 p.a. C3: 0% 14 p.a. C4: 0% 4 p.a. C5: 0% 7 p.a. C7: 0% 11 p.a. 567 , 569 NCT03744676 TRANSCEND-OUTREACH-007 II To determine the safety, PK, and efficacy of liso-cel (JCAR017) in adult patients who have R/R for aggressive B-NHL in the outpatient setting. C 104 patients US ORR: 80.5% 82 p.a. CRR: 53.7% 82 p.a. CRS: 0% g rade ≥ 3 (82 p.a.) NT: 9.8% grade ≥ 3 (82 p.a.) 570 – 572 NCT05583149 II To assess the effectiveness and safety of acalabrutinib combined with liso-cel for adult patients with R/R aggressive B-cell lymphoma R 27 participants enrollment estimated US - - 573 NCT05672173 II To test how well adding liso-cel to nivolumab and ibrutinib works in treating adult patients with Richter’s transformation R 20 participants enrollment estimated US - - 574 NCT05873712 II To evaluate the efficacy of the combination of zanubrutinib and liso-cel for the treatment of Richter’s syndrome R 24 participants enrollment estimated US - - 575 NCT04245839 TRANSCEND FL 2024-510966-18 EU CTR) II To evaluate efficacy and safety of JCAR017 in adult subjects with R/R FL or MZL R 276 participants enrollment estimated US, Austria, Canada, France, Germany, Italy, Japan, Spain, Sweden, UK - - 576 NCT03575351 TRANSFORM 2018-000929-32 (EudraCT) III To compare safety and efficacy between the SOC strategy versus JCAR017 in adult participants with R/R NHL C 184 participants SOC Arm: 92 participants Liso-cel Arm: 92 participants US, Belgium, Finland, France, Italy, Japan, Netherlands, Spain, Sweeden, Switzerland, UK ORR: SOC Arm: 48.9% 92 p.a . Liso-cel Arm: 87% 92 patients p.a . CRR: SOC Arm: 43.5% 92 p.a. Liso-cel Arm: 73.9% 92 p.a. CRS: SOC Arm: 0.00% only 0/30 Liso-cel Arm: 13.04% only 12/92 NE: 11% 557 , 577 – 579 NCT06313996 2023-507477-18 EudraCT III To evaluate the efficacy and safety of Liso-cel compared to SOC in adults with R/R FL NYR 300 participants enrollment estimated No location data - - 580 NCT06205290 III To compare the efficacy and safety of liso-cel vs Investigator’s Choice options (idelalisib + rituximab or bendamustine + rituximab) in adult participants with R/R CLL or SLL, whose disease has failed treatment with both BTKi and BCL2i targeted therapies. WD 200 participants enrollment estimated US, Austria, Belgium, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, UK - - 581 Carvykti (ciltacabtagene autoleucel) JNJ-68284528 LCAR-B38M BCMA Patients with R/R MM who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide Janssen Biotech, Inc. EMA (2022) FDA (2022) NCT06623630 I To evaluate low-dose total body irradiation (TBI) in combination with Cy as lymphodepletion prior to administration of cilta-cel will be safe and tolerable in patients with MM who have impaired renal function To evaluate low-dose TBI-Cy as lymphodepletion prior to cilta-cel will result in comparable CAR T expansion/persistence and disease response rates as those seen with standard lymphodepleting chemotherapy (flu/cy) R 12 participants enrollment estimated US - - 582 NCT03090659 LCAR-B38M LEGEND-2 I II To determine the safety and efficacy of LCAR-B38M CAR-T cells in treating adult patients diagnosed with R/R MM ANR 74 participants China ORR: 87.8% CR: 73.0% CRS: 91.9%, 9.5% had grade ≥ 3 NE: 1.3% 583 – 587 NCT03548207 CARTITUDE-1 I II To characterize safety of JNJ-68284528 and establish the recommended Phase 2 dose (RP2D) (Phase 1b) and to evaluate the efficacy of JNJ-68284528 (Phase 2). Adult participants with MM The dose selected at the completion of phase 1b will be used in Phase 2. C 106 participants Phase 1b: (US Population) 29 Phase 2: (US Population) 68 Phase 2: (Japan Population) 9 United Staes, Japan ORR: Phase 1b: 29 Phase 2 US: 97.1 68 p.a. Phase 2 Japan: 100% 8 p.a. CRS: Phase 1b : 17.24% Phase 2 US: 22.06% Phase 2: Japan 11.11% Neurotoxicity: Phase 1b : 0.00% Phase 2 US: 2.94% Phase 2 Japan: 0.00% . 120 , 588 , 589 NCT05347485 II To evaluate the efficacy and safety of cilta-cel OOS Age ≥ 18 years participant is suffering from serious or life-threatening MM per USPI (or locally approved label, respectively), and re-apheresis, re-manufacturing, or other anti-myeloma directed therapies is not considered feasible or adequate per investigator C 86 participants US - - 590 NCT03758417 CARTIFAN-1 II To evaluate the efficacy and safety of LCAR-B38M chimeric antigen receptor T (CAR-T) cells. In adult chinese participants with R/R MM R 48 patients received a cilta-cel infusion China ORR: 89.6% CR: 77.1% CRS: 97.9%, 35.4% grade 3/4 591 , 592 NCT04133636 2018-004124-10 (EudraCT) CARTITUDE-2 II To evaluate the overall MRD negative rate of participants who receive JNJ-68284528. ≥ 18 years participants with R/R MM R As of the 8 October 2021 data cutoff 20 were treated with cilta-cel. US, Belgium, France, Germany, Israel, Netherlands, Spain ORR: 60.0% CR: 30% CRS: 60% NE: 20% 593 , 594 NCT06550895 II To define the safety of Cilta-cel and Talquetamab in participants with high-risk MM R 30 participants enrollment estimated US, Australia - - 595 NCT06574126 CAR-HiRiSMM II i) to evaluate the proportion of high-risk SMM adult patients with undetectable MRD at 6, 12, and thereafter every 12 months up to 5 years after cilta-cel administration ii) to annotate frequency and severity of adverse events (SAE) R 20 participants enrollment estimated Spain - - 596 NCT06577025 aMMbition 2023-505792-71-00 EUCT) II To evaluate the rate of response (how effectively treatment is working) with signs of potential cure at 5 years after the start of induction treatment. 18 to 70 years participants with documented new diagnosis of MM R 40 participants enrollment estimated US, Australia, Brazil, Spain - - 597 NCT04181827 CARTITUDE-4 2019-001413-16 (EudraCT) III To compare the efficacy of JNJ-68284528 cilta-cel with SOC, either Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd). Age ≥18 years participants with R/R MM ANR 419 participants: Cilta-cel: 208 participants SOC: 211 participants US, Astralia, Belgium, Denmark, France, Germany, Greece, Israel, Italy, Japan, Republic of Korea, Netherlands, Poland, Spain, Sweden, UK ORR: Cilta-cel: 84.6% SOC: 67.3% CR: Cilta-cel: 73.1% SOC: 21.8% CRS: 76.1, 1.1% grade 3 or 4 ICANS: 4.5% 66 , 598 NCT04923893 2021-001242-35 (EudraCT) III To compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of cilta-cel versus VRd induction followed by Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed MM participants for whom ASCT is not planned as initial therapy in terms of Progression Free Survival (PFS). ANR 743 participants US, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Israel, Japan, Republic of Korea, Netherlands Norway, Poland, Portugal, Spain, Sweden, Switzerland, UK - - 599 , 600 NCT05257083 2021-003284-10 (EudraCT) III To compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Cilta-cel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by ASCT in newly diagnosed MM patients. R 750 participants enrollment estimated US, Australia, Belgium, Canada, Czechia, France, Germany, Greece, Israel, Italy, Japan, Netherlands, Norway, Spain, Sweden, Switzerland, UK - - 601 NCT05201781 2020-005521-84 (EudraCT) IV To collect long-term follow-up data on delayed adverse events after administration of cilta-cel, and to characterize and understand the long-term safety profile of cilta-cel. R 228 participants enrollment estimated United Stated, Belgium, China, France, Israel, Japan, Netherlands, Spain - - 602 Data from https://clinicaltrials.gov as of December 28 2024. ANR active not recruiting. AV Available. C Completed, CNS central nervous system, CR Complete Response, CRS Cytokine Release Syndrome, DLBCL Diffuse Large B-cell Lymphoma, FL Follicular Lymphoma, ICANS Immune effector Cell-Associated Neurotoxicity Syndrome, LBCL Large B-cell Lymphoma, NE Neurologic Events, NYR Not yet Recruiting, ORR Overall Response Rate, OOS Out Of Specification, P,a, participants analyzed, R Recruiting, R/R Relapse/Refractory, SOC Standard Of Care, T Terminated, UN Unknown, WD Withdrawn

CAR-T therapy has been a breakthrough treatment for hematologic cancers, but its effectiveness in solid malignancies has been limited. To date, no CAR-T cell therapy has been granted FDA or EMA approval for solid tumors (Table 1 ), highlighting a critical need for progress in this context. Several factors may contribute to the limited effectiveness of CAR-T cells in solid malignancies, such as the antigen heterogeneity and the tumor microenvironment (TME). The TME is characterized for being highly immunosuppressive, hypoxic, and fibrotic, thus creating a physical and biological barrier that prevent CAR-T cells from accessing the tumor cells. Moreover, several studies have shown limited CAR-T cell expansion and shorter persistence in patients with solid tumors. 121 – 123

A clinical case report indicates a response to multiple doses of intracranial IL-13Ra-targeted CAR therapy in a patient with recurrent multifocal glioblastoma, which was sustained for 7.5 months after starting treatment. 124 Some evidence regarding GD2-specific CAR-T cells in four pediatric patients with H3K27M-mutated glioma has also been reported, with three of four patients exhibiting clinical and radiographic improvement. 125

Recent studies with larger cohorts in the solid tumor field have demonstrated significant antitumor effects. Notably, a claudin18.2-targeted CAR has proven effective in treating gastrointestinal tumors in a study including 37 patients ( NCT04196413 ), with an overall response rate (ORR) and disease control rate (DCR) of 48.6% and 73.0%, respectively. 126 Moreover, a GD2-specific CAR has shown strong results in 27 children with heavily pretreated neuroblastoma ( NCT03373097 ). In this study, ORR was 63%; 9 patients had a complete response, and 8 had a partial response. Among those patients who received the recommended dose, the 3-year overall survival and event-free survival were 60% and 36%, respectively. The security profile was reasonable. 127

While CAR-T cell therapies are not yet approved for solid tumors, other T lymphocyte-based treatments have recently been authorized. One of them is the gp100 peptide-MHC/CD3 bispecific T-cell engager (TCE) tebentafusp which was approved for uveal melanoma in 2022. 128 Moreover, an autologous TCR T cell therapy named afami-cel is currently being tested in heavily pre-treated patients with HLA-A*02 and MAGE-A4-expressing synovial sarcoma. The phase 2 trial ( NCT04044768 ) resulted in an ORR of 37% and durable responses. 129 Other cellular therapies have also shown promising responses in treating certain solid tumors like HPV-associated cancers. 130 – 132

Collectively our understanding of the underlying reasons for the humble clinical activity observed in CAR-T cell trials involving solid tumors remains under investigation. In the following pages, we will examine the current application of CAR-T cells in the treatment of another disease, which, similar to solid tumors, remains challenging for CAR-T cell therapy: acute myeloid leukemia (AML).

CAR-T cell-associated challenges in AML

The experience gained from treating R/R B-cell malignancies and R/R MM with CAR-T cell therapy has identified several characteristics associated with promising outcomes. These include the CAR molecular structure and co-stimulatory domains, the targeted antigen, the method of transduction, the lymphodepletion regimen prior to cell infusion, the infused cell doses, the heterogeneity of the patient population, and the intrinsic features of the tumor cells, among others. The primary challenges in the AML setting are three-fold: i) the clonal heterogeneity of the disease, ii) the highly immunosuppressive bone marrow (BM) microenvironment, and iii) the lack of tumor-specific target antigens (Fig. 3 ). 22 , 133 , 134 Fig. 3 Challenges in CAR-T cell generation for AML: manufacturing, bone marrow niche and tumor heterogeneity role ( a ). Current strategies being tested in clinical trials targeting CD123, CD33, CLL-1 and CD7 antigens ( b ). This figure was created with Biorender.com

AML heterogeneity

Nowadays, acute myeloid leukemia (AML) is a broad category that encompasses various diseases, each with distinct molecular and cytogenetic abnormalities. 135 – 137 This molecular and cytogenetic heterogeneity is reflected in the current diagnostic reality, where there are three major international classifications: the WHO 2022, 138 which defines 11 AML groups based on genetic abnormalities; the ELN 2022, 139 which is based on the previous one, but identifies 14 AML groups and is focused on prognosis and management; and the ICC 2022, 140 which recognizes 18 entities. While new risk-stratifying molecular subgroups of AML may emerge over time, not all gene expression subtypes correlate well with disease-associated gene fusions or mutations. 141

This heterogeneity arises from multiple factors influencing disease presentation, progression, and response to treatment. AML is characterized by a diverse array of genetic mutations that affect key pathways, including signal transduction ( FLT3 ), epigenetic regulation ( DNMT3A, IDH1/2, EZH2 ), and apoptosis ( TP53 ). 4 These mutations drive distinct transcriptional programs, contributing to variability in disease behavior and drug sensitivity. 142 Additionally, chromosomal translocations (e.g., t (8;21), inv(16), t (15;17)) further influence AML prognosis and treatment strategies. Another layer of complexity comes from the clonal evolution of AML, where subclones with distinct genetic profiles contribute to intratumoral heterogeneity. 143 These molecular and cytogenetic alterations serve as the foundation for prognostic classifications, as they are crucial factors influencing treatment outcomes and survival. For instance, AML with a complex or monosomal karyotype, structural abnormalities involving chromosome 3, TP53 mutations, high allelic ratio FLT3 mutations, or mutations in ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1 , and ZRSR2 (classified as AML with myelodysplasia-related gene mutations), 140 are associated with treatment resistance and relapse, placing it in the ELN 2022 adverse prognostic group. 139

AML is thought to mirror normal hematopoiesis, with leukemia stem cells (LSCs) sustaining the disease by driving the production of differentiated blasts. 144 First described in the 1960s, LSCs are characterized by low cycling or quiescence, self-renewal capacity, and transcriptional or epigenetic signatures similar to hematopoietic stem cells (HSCs) and normal multipotent hematopoietic progenitors. LSCs exhibit therapy resistance due to their quiescent state and self-renewal potential. 145 They originate from the sequential accumulation of somatic mutations in HSCs or HSPCs, or even more differentiated cells, where early mutations enhance self-renewal and impair differentiation, leading to the expansion of pre-leukemic clones. Common early mutations involve genes regulating epigenetics ( DNMT3A, TET2, IDH1/2, ASXL1 ) and TP53 , while later mutations, such as those in FLT3 , drive proliferation, block differentiation, and ultimately lead to AML blast formation. 146

This developmental hierarchy is even more complex at relapse, comprising distinct subclones of leukemia cells with disparate phenotypic, genetic and epigenetic features coexisting within a single patient. 4 , 141 , 147 This complexity may impede CAR-T cell development by facilitating antigen escape. 137

BM microenvironment

AML blasts and LSCs present immune evasion mechanisms, in addition to remodeling of the BM microenvironment, which collectively drives disease progression. 19 , 148 While these factors were once considered to have a limited role, recent studies have highlighted their crucial contribution to the advancement of the disease.

First, among the intrinsic factors directly related with the myeloid blast, mutations in NPM1 and FLT3 have been linked to alterations in immune response. 137 , 149 Furthermore, the effects of mutant IDH1/2 and the subsequent increase of the oncometabolite R-2-hydroxyglutarate (R2-HG) have been associated with the augment of regulatory T cells (Tregs) in AML. 150 , 151 TP53 mutations have also been shown to impede immune surveillance. 152 – 154 Other intrinsic features described in AML include downregulation of HLA molecules, leading to defective antigen presentation 155 – 157 ; and alterations in cytokine balance. 158 – 160

Secondly, it is well documented that the highly immunosuppressive BM microenvironment deleteriously affects immune responses and T cell fitness. 161 On one hand, metabolic products within the TME play a significant role in immune suppression, limiting the effectiveness of immunotherapies. AML cells exhibit altered metabolism, producing lactate, adenosine, and kynurenine, which contribute to a hostile microenvironment that impedes the function of CAR-T cells. 162 – 164 Elevated lactate levels, resulting from rapid glycolysis in AML blasts, can acidify the TME, suppressing T cell activation and proliferation. This acidic environment not only limits the effector functions of CAR-T cells but also promotes the accumulation of Tregs and myeloid-derived suppressor cells (MDSCs, pathologically activated neutrophils and monocytes with potent immunosuppressive activity 165 – 167 ), both of which further dampen immune responses. 133 Additionally, adenosine, often elevated in the TME, binds to receptors on CAR-T cells, leading to immune suppression and exhaustion. 168 , 169 Similarly, kynurenine, generated through tryptophan catabolism by AML cells, also inhibits T cell function and promotes an immunosuppressive setting. 170

On the other hand, AML is characterized by an increase in the number of T cells that infiltrate the BM compared to those observed in healthy individuals. 171 These T cells exhibit an increase in the frequency of immune inhibitory and activating co-receptor expression, particularly in R/R AML. 172 – 175 This includes the expression of PD-1, 176 , 177 OX40, 178 TIM3, and LAG3. 179 Overall, T cells display insufficient potency, persistence, and functionality in this context. 180 This T cell exhaustion, which may be present in the apheresis-derived T cells or emerge during the CAR-T cell manufacturing process, 181 , 182 is typically not only characterized by high expression of inhibitory receptors, 183 but also is related to extensive transcriptional and epigenetic alterations, defective cytokine production, increased chemokine expression, and a shift from T cell to NK-like T cell phenotypes. 175 , 184 , 185

In third place, in addition to intrinsic factors directly associated with the myeloid blast, its metabolism and other factors related to T cells, the expansion of M2 macrophages has also been shown to enhance AML immune escape. 186 , 187 Moreover, poor immune synapse function 187 and impaired NK cell function have been identified as mechanisms involved in this process. 188 – 190 Finally, it is also important to consider the role that the bone marrow structure may play beyond the cellular components. BM vascular remodeling may hinder anti-AML immune responses by reducing cell migration and inducing hypoxia. 191 , 192

Target antigen

The identification of an appropriate target for CAR-T cell therapy in AML is crucial. A suitable target should be an HLA-unrestricted antigen/protein expressed on the cell surface of malignant cells with a high expression level. Nonetheless, some preliminary evidence suggests that lower expression levels might be sufficient to direct CAR-T cells. 22 Ideally, the antigen should also be expressed on LSCs to ensure complete disease eradication and minimize early relapses. 179 Importantly, it must be absent in healthy tissues to prevent potentially fatal on-target/off-tumor toxicities. 193 To date, no optimal target for CAR-T cell therapy in AML has been identified. AML neoantigens are relatively uncommon and are known to be mainly intracellular, requiring HLA presentation. 194

One of the earliest demonstrations of the potential of CAR-T cells for AML was a construct developed by Ritchie and colleagues that targeted the Lewis Y (LeY) antigen. 195 This CAR-T was tested in a Phase 1 clinical trial, demonstrating a favorable safety profile and durable in vivo persistence. However, the efficacy of this approach was limited, and all patients relapsed with the detection of LeY-positive AML blasts. In current clinical practice, CD33 and CD123 represent the most utilized molecules for CAR-T cell engineering 196 (Table 2 , Fig. 4 ). Fig. 4 Main characteristics of the most common antigens targeted with current directed therapies for AML and relevant clinical trials. Antibody-drug conjugates (ADC) targeting CD123 shown are Tagraxofusp in monotherapy (208); Tagraxofusp + Azacitidine ± Venetoclax (209); IMGN63 (210); IMGN63 +Venetoclax + Azacitidine (211). Biespecific T-cell Engagers (BiTE) targeting CD123 exposed are Vibecotamab (212); Flotetuzumab (213); JNJ-63709178 (214); and MGD024 (215). Monoclonal Antibodies (mAb) targeting CD38 are isatuximab in combination with chemotherapy (268). BiTE targeting CD33 are AMG330 (233) and AMG673 (235). AZA Azacitidine, Ven Venetoclax, CT chemotherapy, CR complete response, CRi complete response with incomplete hematologic recovery, PR partial response, ND new diagnosed, R/R refractory/relapsed, ORR Overall Response Rate, SD stable disease, This figure was created with Biorender.com Table 2 Current clinical trials with CAR-T cells for AML Target Antigen Clinical trial.gov Identifier Study Summary Trial Phase Disease Status Manufacturer Status Location Reference CD123 NCT04230265 Multicenter, open-label, adaptive design Phase 1 trial with genetically modified T cells carrying universal CAR (UniCAR02-T) in combination with CD123 target module (TM123) for the treatment of hematologic and lymphatic malignancies positive for CD123 I R/R AML GEMoaB Monoclonals GmbH R Germany, multicenter 292 , 603 , 604 CD123 NCT05949125 Multicenter, open-label, Phase 1 study of Allo-RevCAR01-T-CD123 consisting of genetically modified T cells carrying reverse chimeric antigen receptors (Allo RevCAR01 T) in combination with CD123 Target Module (R-TM123) for the treatment of patients with selected hematologic malignancies positive for CD123 I R/R AML Cellex GmbH R Germany, multicenter 605 , 606 CD123 NCT03190278 AMELI-01. Phase 1, open label dose escalation and dose-expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART123 (UCART123v1.2) in R/R AML I R/R AML Cellectis R US, multicenter 300 NCT04106076 Phase 1, Open Label Dose-escalation Study to evaluate the Safety, expansion, persistence and clinical activity of UCART123 in patients with newly diagnosed CD123 positive adverse genetic risk AML I Adverse Genetic Risk AML Cellectis WD N/A CD123 NCT05457010 Evaluate the safety and preliminary activity of (Antigen Receptor Complex-T cell platform) ARC-T cells and SPRX002 in R/R AML or HR-MDS I R/R AML R/R HR-MDS AvenCell’s R US (MDACC) CD123 NCT04318678 CATCHAML: CD123.CD28.ζ-CAR and a CD20 safety switch. CD123-Directed autologous T-cell therapy for AML I AML MDS AvenCell Therapeutics ANR US (St. Jude) 301 CD123 NCT02159495 Phase 1 Study of T cells lentivirally transduced to express a CD123. CD28.ζ-CAR and a truncated EGFR safety switch. CD123-specific, hinge-optimized, cd28-costimulatory chimeric antigen receptor and a truncated EGFR for patients with CD123 + R/R AML and R/R BPDCN I R/R AML BPDCN Mustang Bio, Inc., in collaboration with City of Hope ANR US (City of Hope) 304 , 305 CD123 NCT04272125 Safety and Efficacy of CD123-Targeted CAR-T Therapy for R/R AML I/II R/R AML Chongqing Precision Biotech Co. R China (Chongqing University) - CD123 NCT04265963 CD123-Targeted CAR-T Cell Therapy for R/R AML I/II R/R AML Chongqing Precision Biotech Co. R China (Joint Logistics) CD123 NCT03796390 Phase 1 clinical study to evaluate efficacy and safety of CAR-T targeting CD123 in the treatment of AML I R/R AML Hebei Senlang Biotechnology Inc., Ltd. UN China (Hebei) - CD123 NCT03672851 Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With I R/R AML/ALL Nanjing Legend Biotech Co. T China (Second Affiliated Hospital of Xi’an Jiaotong University) - CD123 NCT03114670 Safety and effectiveness of anti-CD123 CAR-T cells in patients with AML that relapsed after alloHSCT I AML reactivated after alloHSCT Affiliated Hospital to Academy of Military Medical Sciences UN China (Affiliated Hospital to Academy of Military Medical Sciences) - CD33 NCT03971799 Phase 1/2 study of Anti-CD33 chimeric antigen receptor-expressing T cells (CD33CART) in children and young adults with R/R AML I/II R/R AML Biopharmaceutical Development Program at the Frederick National Laboratory for Cancer Research (NCI) R US, multicenter 306 , 310 CD33 NCT03126864 A Phase 1 safety study of adoptive cellular therapy using autologous T cells transduced with lentivirus to express a CD33-specific chimeric antigen receptor in patients with R/R CD33-positive AML I R/R AML MD Anderson Cancer Center T US (MDACC) CD33 NCT03927261 A Phase 1/1b Safety Study of PRGN-3006 adoptive cellular therapy in patients with CD33-positive R/R AML, Minimal Residual Disease (MRD) positive AML, and HR-MDS I R/R AML MDS Precigen, Inc. ANR US (H Lee Moffitt and Mayo Clinic) 607 CD33 NCT04835519 Phase 1/2 Study of enhanced CD33 CAR-T cells in subjects with R/R AML I/II R/R AML Beijing Gobroad Boren Hospital T China (Beijing Boren Hospital) 314 , 608 CD33 NCT05473221 Evaluate the safety and efficacy of CD33 CAR-T cells in patients with R/R AML I R/R AML Zhejiang University NYR China (Zhejiang University) - CD33 NCT06326021 Optimized CD33 (FL-33) CAR-T therapy for R/R AML. Phase 1 clinical trial to explore the safety and efficacy of FL-33 CAR T therapy for R/R AML I R/R AML Beijing Gobroad Boren Hospital R China (Beijing GoBroad Hospital) - CD33 NCT01864902 Treatment R/R CD33 Positive AML by CART-33 (CART33) I/II R/R AML Chinese PLA General Hospital UN China (PLA General Hospital) 609 CD33 NCT02799680 Treatment of R/R CD33-positive AML by Infusions of allogeneic CART-33 I R/R AML Chinese PLA General Hospital UN China (Academy of Military Medical Sciences) - CD33 NCT05445765 Anti-CD33 CAR-T Cells for the Treatment of R/R CD33 + AML I R/R AML iCar Bio Therapeutics UN China (Hebei Yanda Lu Daopei) - CD33 NCT05984199 Phase 1/2 study of donor-derived anti-CD33 CAR expressing T cells (VCAR33) in patients with R/R AML after alloHSCT I/II R/R AML Vor Biopharma R US (multicentrer) 610 – 612 CD33 NCT05105152 PLAT-08: A Study Of SC-DARIC33 CAR-T cells in pediatric and young adults with relapsed or refractory CD33 + AML I R/R AML 2seventy bio R US (Seattle Children’s Hospital) 613 CD33 NCT05945849 Phase 1 Study of lentivirally transduced T Cells engineered to contain anti-CD33 linked to TCRζ and 4-1BB signaling domains in combination with CD33KO-HSPC in subjects with R/R AML I R/R AML University of Pennsylvania R US (University of Pennsylvania) - CD33 NCT05942599 Base edited CAR-T cells against AML (BE CAR-33): deep conditioning ahead of alloHSCT (CARAML) I R/R AML Bridge to alloHSCT Great Ormond Street Hospital (UK) R United Kingdom (Great Ormond) - CD33 NCT04766840 Phase 1study to evaluate the safety and efficacy of CD33 CAR-T in patients with R/R AML I R/R AML Beijing Immunochina Medical Science & Technology Co., Ltd. CD123-CD33 NCT04156256 Phase 1, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD123-CD33 cCAR in patients with R/R, high-risk hematologic malignancies I R/R AML R/R MDS iCell Gene Therapeutics UN China (Peking University) 614 CD123 Tim-3 NCT04014881 Application of anti-Tim-3/CD123 CAR-T cell therapy in R/R AML I R/R AML Wuhan Union Hospital UN China (Xuzhou Medical University) - CD33 or CD123 NCT06420063 Sequential CAR-T cells targeting CD33/CD123 in patients with AML (BAH244) I/II R/R AML Essen Biotech R China (Shanghai) - CLL1 NCT04884984 Anti-CLL1 CAR T-cell therapy in CLL1 positive for R/R AML I/II R/R AML The First Affiliated Hospital of Soochow University R China (Hospital of Soochow) - CLL-1 NCT06128044 A Phase 1, multicenter, open-label study of CB-012, a CRISPR-edited allogeneic Anti-CLL-1 CAR-T cell therapy in patients with R/R AML (AMpLify trial) I R/R AML Caribou Biosciences, Inc. R US, multicenter 322 , 615 CLL1 NCT05252572 Clinical study of CLL1 CAR-T cells in the treatment of hematological malignancies I R/R AML Zhejiang University R China (Zhejiang University) - CLL1 NCT05467202 Evaluate the safety and efficacy of CLL1 CAR-T in patients with R/R AML I R/R AML Zhejiang University NYR China (Zhejiang University) - CLL-1 NCT04219163 Chimeric antigen receptor T-cells for the treatment of AML Expressing CLL-1 Antigen I R/R AML Center for Cell and Gene Therapy, Baylor College of Medicine R US (Baylor College) - CLL-1 NCT04923919 Clinical study of CAR-T in the treatment of R/R AML I R/R AML 920th Hospital of Joint Logistics Support Force of the People’s Liberation Army of China R China (Joint Logistics) - CLL-1 NCT04789408 A Phase 1 open-label, multicenter study evaluating the safety of KITE-222, an autologous anti-CLL-1 CAR T-cell therapy, in subjects with R/R AML I R/R AML Kite, a Gilead Company T US, multicenter - CD123/CLL1 NCT03631576 CD123/CLL1. CAR-T cells for R/R AML (STPHI_0001) II/III R/R AML Fujian Medical University UN China (Fujian University) - CLL1-CD33 NCT03795779 Phase 1, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CLL1-CD33 cCAR in patients with R/R, high risk hematologic malignancies. I R/R AML R/R MDS iCell Gene Therapeutics UN China (Peking University) 616 CLL1 + CD33 NCT05467254 Evaluate the safety and efficacy of CLL1 + CD33 CAR-T in patients with R/R AML I R/R AML Zhejiang University NYR China (Zhejiang University) - CLL1 + CD33 NCT05943314 Clinical study on safety and efficacy of anti-CLL1/ + CD33 CAR T cells in the treatment of AML I R/R AML Guangzhou Bio-gene Technology Co., Ltd WD China (Fujian University) - Dual CD33-CLL1 NCT05016063 Phase 1 study to evaluate the safety and effectiveness of dual CD33-CLL1 CAR-T therapy in R/R AML I R/R AML Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. UN China (Xinqiao Hospital) - CLL1/CD33 NCT05654779 Safety, tolerability, PK, and anti-tumor efficacy of CLL-1/CD33 Targeted LCAR-AMDR cells in subjects with R/R AML I R/R AML Nanjing Legend Biotech Co. T China (Institute of Hematology & Blood Diseases Hospital, China) - Dual CD38-CLL1 NCT06110208 Phase 1 study to evaluate the safety and effectiveness of dual CD38-CLL1 CAR-T therapy in R/R AML I R/R AML Gracell Biotechnologies (Shanghai) Co., Ltd. R China (920th Hospital of Joint Logistics Support Force of People’s Liberation Army of China) - FLT3 NCT05023707 Anti-FLT3 CAR-T cell therapy in FLT3-positive R/R AML I/2 FLT3 + R/R AML PersonGen BioTherapeutics (Suzhou) Co., Ltd. R China (Hospital of Soochow) - FLT3 NCT05445011 Safety and efficacy of anti-FLT3 CAR-T cell (TAA05 Cell Injection) in the treatment of R/R AML I R/R AML PersonGen BioTherapeutics (Suzhou) Co., Ltd. R China (Wuhan) 617 FLT3 NCT03904069 Phase 1 study evaluating the safety, tolerability, and efficacy of FLT3 CAR-T AMG 553 in subjects with FLT3-positive R/R AML I R/R AML Amgen WD US (City of Hope, MDACC) 618 , 619 FLT3 NCT05432401 Clinical study of TAA05 injection in the treatment of adult patients with FLT3-positive R/R AML I FLT3 + R/R AML PersonGen BioTherapeutics (Suzhou) Co., Ltd. R China (HuaZhong) - CD38 NCT04351022 CD38-targeted CAR-T in R/R AML I/II R/R AML The First Affiliated Hospital of Soochow University UN China (Soochow) 323 , 620 CD38 NCT05239689 Clinical Study of CD38 CAR-T cells in the treatment of hematological malignancies I R/R AML Zhejiang University R China (Zhejiang University) - CD38 NCT05442580 Safety and manufacturing feasibility of CART-38 cells in patients with R/R AML or Multiple Myeloma I R/R AML MM University of Pennsylvania R US (University of Pennsylvania) - CD70 NCT06326463 CAR-T cell therapy directed to CD70 for pediatric patients with hematological malignancies I AML, Childhood St. Jude Children’s Research Hospital R US (St. Jude) - CD70 NCT04662294 CD70 CAR-T for patients with CD70 positive malignant hematologic diseases I/II R/R AML Zhejiang University R China (Zhejiang University) - CD19 NCT03896854 Pilot study of the efficacy and safety of CD19 targeted CAR in the treatment of R/R CD19 positive AML I/II R/R AML Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd R China (Shanghai Bio-medicine Technology) - CD19 NCT04257175 Giving CAR-T CD19 transgenic T Cells for AML with t(8;21) and CD19 expression II/III R/R AML With t 8:21 and CD19 Sheba Medical Center R Israel (Chaim Sheba) - CD7 NCT04762485 Humanized CAR-T Cells against CD7 for R/R CD7+ acute leukemia I/II R/R AML PersonGen BioTherapeutics (Suzhou) Co., Ltd. UN China (Soochow University) 260 CD7 NCT04033302 A multi-center study of multiple CAR-T cell therapy for CD7-positive hematological malignancies I/II R/R AML Shenzhen Geno-Immune Medical Institute UN China (Shenzhen Medical Institute) - CD7 NCT05995028 Safety and efficacy of universal 4SCAR7U T-cell therapy targeting CD7-positive hematological malignancies I R/R AML Shenzhen Geno-Immune Medical Institute R China (Shenzhen Medical Institute) - ILT3 NCT04803929 Clinical study of autologous T- cells modified with ILT3 CAR for R/R AML (M4/M5) I R/R AML (M4, M5) Carbiogene Therapeutics Co. Ltd. R China (Zhejiang University) - ADGRE2 NCT05463640 Evaluate the safety and efficacy of ADGRE2 CAR-T in patients with R/R AML I R/R AML Zhejiang University NYR China (Zhejiang University) - NKG2D-Ligands NCT02203825 A Phase 1 study of CAR modified T-cells targeting NKG2D-Ligands (CM-CS1/ CYAD-01) in patients with AML/Advanced MDS-RAEB and MM. I R/R AML R/R MDS R/R MM Celyad Oncology SA T US (Dana–Farber) 327 , 621 NKG2D NCT04658004 NKG2D CAR-T cell therapy for patients with R/R AML I R/R AML Yake Biotechnology Ltd. NYR China (Zhejiang University) - NKR-2 NCT03612739 EPITHINK: Epigenetic drug treatment and therapeutic immunotherapy with NKR-2 I AML, Adult Celyad Oncology SA WD No location data Carried by Celyad SA - Anti-siglec-6 NCT05488132 Administration of anti-siglec-6 CAR-T cell therapy in R/R AML I R/R AML Xuzhou Medical University R China (Xuzhou Medical University) - IL1RAP NCT04169022 Targeting Interleukin 1 Receptor Accessory Protein (IL1RAP) expressing AML cells by CAR-T cells NA R/R AML Centre Hospitalier Universitaire Dijon T France (Centre Hospitalier Besançon) - MLM-CAR44.1 NCT04097301 A Phase 1-2a trial to assess the safety and antitumor activity of autologous CD44v6 CAR-Tcells in AML and multiple myeloma expressing CD44v6) I/II R/R AML MM IRCCS Ospedale San Raffaele AGC Biologics S.p.A. T Italy (IRCCS San Raffaele) 273 , 275 , 622 IL3 NCT04599543 L3 CAR-T cell therapy for patients with CD123 positive R/R AML I R/R AML Yake Biotechnology Ltd. NYR China (Zhejiang University) - CD3 NCT05672147 CD33-CAR T cell therapy for R/R AML I R/R AML City of Hope Medical Center R US (City of Hope) - CI-135 NCT05266950 Safety and efficacy study of CI-135 CAR-T cells for R/R AML I R/R AML Beijing Boren Hospital R China (Beijing Boren Hospital) - CD4 NCT06197672 CAR-T cell redirected to target CD4 positive R/R AML as a bridge to allogeneic stem cell transplant I R/R AML Brown Center for Immunotherapy R US (Indiana University Melvin) 623 Tim-3/CD123 NCT06125652 Administration of anti-Tim-3/CD123 CAR-T cell therapy in R/R AML I/II R/R AML Xuzhou Medical University Xuzhou Medical University R China (Xuzhou Medical University) - CLL-1, CD33, CD38 or CD123 NCT05995041 Universal CAR-T cells targeting CLL-1, CD33, CD38 and CD123 in patients with R/R AML I R/R AML Shenzhen Geno-Immune Medical Institute R China (Shenzhen Medical Institute) - CD33, CD38, CD56, CD123, CD117, CD133, CD34 or Muc1 NCT03473457 The prospective, multi-center and single-arm clinical study of CAR-T cells therapy in R/R AML NA R/R AML Zhujiang Hospital T China (Zhujiang Hospital) - Muc1/CLL1/CD33/CD38/CD56 or CD123 NCT03222674 Multi-center Phase 1/2 clinical trial of multi-CAR T cell therapy for AML I/II R/R AML Shenzhen Geno-Immune Medical Institute UN China (Guangzhou Medical University) 624 , 625 CLL-1 CD123 or CD33 NCT04010877 Multiple CAR-T cell therapy targeting AML I/II R/R AML Shenzhen Geno-Immune Medical Institute UN China (Shenzhen Geno-Immune Medical Institute) 626 CD19 BCMA CD123 CD7 NCT05513612 Safety and efficacy of novel autologous CAR-T cells in patients with hematopoietic and lymphoid malignancies. I R/R AML UTC Therapeutics Inc. WD China (Shanghai Pudong Hospital) - Data from https://clinicaltrials.gov as of September 04 2024. R recruiting, NYR not yet recruiting, ANR active not recruiting, T terminated, WD withdrawn, UN unknown, R/R AML relapse/refractory AML, BPDCN Blastic plasmacytoid dendritic neoplasm, HR-MDS High Risk Myelodysplastic Syndrome

CD123

CD123, also known as the alpha chain of the IL-3 receptor (IL-3Ra), is a membrane protein highly expressed in AML (~90% of cases), 197 , 198 CD123 has also been identified in other myeloid malignancies, such as myelodysplastic syndrome, chronic myelomonocytic leukemia, chronic myeloid leukemia, and myeloproliferative neoplasms, 199 CD123 is involved in the JAK, MAPK, and PI3K/AKT signaling pathways, which regulate cell proliferation and differentiation. 200

Overexpression of CD123 has been identified in up to 95% of LSCs and AML blast cells. 201 About on-target/off-tumor toxicities, there is controversy over its expression in healthy HSCs. Some reports have identified low CD123 expression patterns on HSCs, 199 while other preclinical studies have described a myeloablative effect of CD123-directed CAR-T cells. 202 A significant concern is the potential extra-hematologic toxicities, as CD123 is expressed in endothelial cells, which could result in capillary leak syndrome. 203 , 204

Several unconjugated monoclonal antibodies (mAbs), including the CD123-directed mAbs CSL360 and CSL362 (talacotuzumab), have demonstrated limited efficacy in the treatment of R/R AML. 205 , 206 Consequently, current strategies predominantly entail the use of toxin-conjugated constructs or Bi-specific T-cell engagers (BiTEs). In this line, various agents targeting CD123 have been developed, including tagraxofusp, a recombinant protein comprising a truncated diphtheria toxin fused to IL-3, which has been approved for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). 204 , 207 Tagraxofusp has demonstrated preliminary clinical activity in the context of AML. 208 Additional strategies targeting CD123, including BiTEs such as pivekimab sunirine (PVK, IMGN632), 209 , 210 vibecotamab 211 and flotetuzumab 212 , 213 ; as well as other strategies such as JNJ-63709178, MGD024, 214 and APVO436, 215 are currently under investigation, with promising results ( Fig. 4 ) .

CD33

CD33 is a transmembrane receptor stimulated by sialic acid residues that is expressed in approximately 85% of AML cases. 216 CD33 undergoes internalization and dimerization upon binding, making it an attractive therapy and drug delivery target. Its primary role is related to the downregulation of cytokine production and monocyte activation. 217 , 218 It is known to be present in over 85% of LSCs, with relatively low expression in HSCs. 216

The humanized anti-CD33 antibody drug-conjugated gemtuzumab ozogamicin is EMA and FDA-approved for first line use in combination with intensive chemotherapy in treatment-naïve AML. 219 – 224 The primary toxicities reported are persistent thrombocytopenia and veno-occlusive disease (VOD). 225 The latter was initially associated with CD33 expression in Kupffer cells within hepatic sinusoids following FDA approval in 2000. 226 Upon reapproval in 2017 for administration in a fractionated dosing schedule, VOD was less frequent and was subsequently reported to be associated with the direct hepatotoxicity of the conjugated drug (calicheamicin). 224

In line with the evidence reported with anti-CD123 unconjugated molecules, mAbs and antibody-drug conjugates directed against CD33 (lintuzumab, 227 – 229 SGN-CD33A, 230 and IMGN779 231 ) have failed to demonstrate relevant antileukemic activity to date. Notably, several CD33 × CD3 BiTEs have shown promising results with an acceptable toxicity profile in clinical trials for R/R AML (AMG 330, 232 , 233 AMG 673, 234 GEM333, JNJ-67571244, and SAR440234) (Fig. 4 ).

CLL-1

CLL-1, also known as CLEC12A, myeloid inhibitory c-type lectin-like receptor, 235 dendritic cell-associated C-type lectin 2 (DCAL-2), 236 or CD371, is a C-type lectin-like type II transmembrane receptor with a role in cell adhesion and cell-to-cell signaling. 237 – 239 It is expressed in over 85% of patients with AML, both in blasts and LSCs. 235 , 240 Furthermore, it is expressed exclusively in myeloid lineage cells 198 and is absent in granulocyte-macrophage progenitors. In addition, CLL-1 does not show relevant expression on HSCs or extra-hematological tissues, 239 , 241 , 242 limiting potential on-target/off-tumor risks and making it an exciting target for investigation. 198

NKG2D

Natural killer group 2 member D (NKG2D) is a highly conserved activating receptor of NK cells and T lymphocytes that plays a pivotal role in immune recognition of tumoral cells through the engagement with a group of ligands, namely MICA, MICB, and the UL16-binding proteins. 243 – 245 NKG2D ligands are induced in response to DNA damage, inflammation, and malignant transformation. 246 – 249 Expression of NKG2D ligands has been documented in different hematologic malignancies, including AML, whereas expression is generally absent in healthy tissues. 250 , 251 Consequently, there is growing interest in NKG2D and NKG2D ligands as potential targets for CAR-T cell therapy. 148

CD7

CD7 is a transmembrane protein essential for T cell and T cell/B cell interactions in early lymphoid development. 252 , 253 It is among the earliest T cell-associated antigens expressed during T-lymphocyte maturation and is aberrantly present in approximately 30-40% of adult AML patients. 254 , 255 An important consideration is that CD7, present on T cells, requires CD7-directed CAR-T cells with CD7 gene-knockout strategies to prevent effector T cell fratricide. 256 – 259 Some strategies have been successful in preliminary studies, mainly for T cell leukemia/lymphoma. 255 , 260 Consequently, CD7 may represent a viable target for CD7 + AML. 253 , 258 , 259

CD38

CD38 is a surface glycoprotein that plays a role in cell adhesion, migration, and intracellular calcium mobilization. 261 – 263 It is known to be expressed in plasma cells but is also expressed heterogeneously in myeloid cells. 264 Combinations of the humanized mAb targeting CD38, daratumumab, with other drugs, have demonstrated efficacy in the treatment of AML and T-ALL in clinical trials ( NCT03067571 and NCT03384654 ), with no significant cytopenia reported. 265 Similarly, another CD38 mAb, isatuximab, 266 , 267 has been employed in a second-stage study ( NCT03860844 ), investigating its use in combination with standard salvage chemotherapy in children with R/R ALL or AML in first or second relapse. No unexpected safety issues were observed, and complete response (or complete response with incomplete peripheral blood count recovery) was observed in 50% of patients in the AML cohort. 268 Then, targeting CD38 presents a promising strategy that may additionally hold potential benefits for a variety of malignancies. 269

CD44v6

CD44, or the receptor for hyaluronic acid, is a cell surface adhesive molecule implicated in the aggregation, migration, activation, and malignant transformation of leukocytes. 270 – 272 It is expressed on multiple tissue types, although some splice isoforms of CD44 are relatively tumor-restricted. For example, the splice site variant CD44v6 is present in over 60% of AML samples and is not shared by non-tumoral cells 273 or HSCs, indicating that this antigen is a promising target. The available data demonstrate promising results in in vitro and in vivo mouse models. 273 – 275

CD70

CD70, or the tumor necrosis factor receptor ligand, is expressed on antigen-presenting cells and is upregulated to promote an effector CD8 + T cell response and downregulate Th17 function. Reports have identified CD70 expression in 45% of AML blasts and in 30% of LSCs, 276 or even lower. 277 Other studies suggest its expression in up to 75% of AML LSCs. 199 The targeting of CD70 with a mAb (cusatuzumab) has been demonstrated to successfully eliminate AML-LSCs when combined with HMAs, making it an exciting target for CAR-T cell therapy. 278 The preclinical evidence for CAR-T cells targeting CD70 is encouraging. 277 , 279

FLT3

FLT3 is a very well-characterized receptor ligand for HSCs maintenance and differentiation. It is implicated in 30% of patients with AML (approximately 24% involving FLT3-ITD and 7-10% involving FLT3-TKD 280 ). Some FLT3 inhibitors have already received FDA approval (midostaurin, gilteritinib) with an acceptable safety profile. 281 Additional FLT3 inhibitors under investigation include quizartinib, 282 sorafenib 283 and crenolanib. 284 To date, most data regarding CAR-T cell therapy is preclinical, 285 – 287 and significant concerns have been raised regarding FLT3 expression in HSCs. In this context, some constructs in development include safety switches (described in the following sections) to reduce myeloablation. 288

Other potential targets currently under investigation include CD19, 289 ADGRE2, 193 , 290 and ILT3. 291 However, there is limited data available regarding their efficacy and safety.

Current strategies implemented in clinical trials

Currently, there are 75 registered clinical trials of CAR-T cell therapy for AML (Table 2), of which 53 (71%) are Phase 1 or early Phase 1 trials, with CD33 and CD123 being the most frequently targeted antigens (Fig. 4 ). Most of these trials recruit patients from China and the US. Past and ongoing clinical trials of CAR-T cells for treating AML are discussed below.

CD123-CAR-T cells in clinical trials

In 2020, a German group testing CAR-T cell therapy directed to CD123 reported the preclinical efficacy of UniCAR-T-CD123, 292 a two-component, rapidly switchable and second-generation CAR-T. The construct carries a CD28 co-stimulatory domain that, by itself, does not recognize any surface antigen apart from a soluble adaptor named targeting module (TM), which is included in the second component. 293 , 294 The TM is administered intravenously and confers specificity against the antigen of choice. In this case, the TM included a scFv directed to the CD123 antigen (Fig. 3 ). Due to the brief half-life of the TM, the interruption of its continuous intravenous administration rapidly deactivates T cell activity, which mitigates the associated toxicities.

This strategy is currently being investigated in a Phase 1a trial in R/R AML ( NCT04230265 ), with early promising results and an acceptable toxicity profile. Indeed, the trial was modified to include a prolonged schedule of TM administration. To date, 19 patients who have undergone extensive prior treatment have received UniCAR-T-CD123, including 12 with previous alloHSCT. CRS was observed in 12 patients, mainly grade 1 or 2. No prolonged myelosuppression was observed, and therefore rescue alloHSCT was not required. The ORR for the R/R AML population was 53%. 295 The same group developed the world’s first CRISPR-engineered switchable allogeneic CAR-T designed to circumvent graft-versus-host disease (GvHD) and cell rejection. The trial is currently in progress and is registered as Phase 1 ( NCT05949125 ). 296

A multicentric clinical trial ( NCT03190278 ) conducted in the US has evaluated the efficacy of universal CD123-directed CAR-T cells. This approach involved gene-editing technology to modify allogeneic T cells to express a second-generation CAR targeting CD123 (comprising CD123 scFv-4-1BB-CD3ζ). 297 The TCR αβ was inactivated by targeting the TRAC gene using TALEN® nucleases, which helps to reduce the risk of GvHD. Furthermore, a “safety switch” was incorporated by including an RQR8 deletion ligand containing epitopes from CD34 and CD20 antigens, thereby conferring susceptibility to rituximab on the modified cells.

The CAR-T cell product demonstrated potent antitumor activity in vitro and long-term disease-free survival in a subset of primary patient-derived BPDCN xenograft (PDX) mouse models. 298 Concerns arose during the transition to the clinic when the first patient treated (UCART123; NCT03203369 ) died after developing severe CRS and pulmonary capillary leak syndrome. 299 The trial was discontinued and later reopened for R/R AML, with the addition of a CD52 knockout, dose reduction, and an upper age limit (AMELI-01; a Phase 1 open-label dose-escalation trial testing UCART123v1.2), which is still recruiting ( NCT03190278 , NCT04106076 ). Preliminary data presented at ASH (American Society of Hematology) 2022 congress indicated that the addition of alemtuzumab to the fludarabine and cyclophosphamide lymphodepletion regimen resulted in more robust and greater UCART123v1.2 expansion, which was an essential concern in an allogeneic context. Moreover, the expansion of UCART123v1.2 correlated with a reduction in tumor burden. 300 CRS occurred in 100% of the cohort, with some cases being severe, and therefore, systematic tocilizumab is planned to be administered for future stages.

Alternative approaches consider CAR-T cell treatment in the context of a bridge to alloHSCT. One example is the CATCHAML trial ( NCT04318678 ) for pediatric R/R AML. This involves a second-generation CD28 co-stimulated CAR that incorporates a CD20 safety switch (Fig. 3 ). To date, preliminary data from 12 patients enrolled in the trial report the absence of grade ≥2 CRS or neurotoxicity despite the heterogeneous nature of the responses observed. A phenotypic analysis conducted by the researchers revealed that CD123-CAR-T cell products were predominantly effector memory cells. Accordingly, the next generation of CD123-CAR T-cell products will be manufactured in the presence of dasatinib, with the objective of limiting T cell differentiation and exhaustion. 301

Several ongoing trials are employing additional approaches targeting CD123. There is compelling preclinical evidence from a soluble tumor-targeting protein (SPRX002) that exclusively binds to AML cells expressing CD123, thereby enabling their destruction by T cells transduced ex vivo. These are known as Antigen Receptor Complex (ARC) T cells. 302 A Phase 1 clinical trial ( NCT05457010 ) is currently enrolling and is projected to conclude in November 2025. A strategy involving the electroporation of anti-CD123-CAR mRNA into “biodegradable” T cells in patients with R/R AML ( NCT02623582 ) was terminated due to an absence of an anti-tumor effect. 303 Finally, a case report from a pivotal trial testing a fourth-generation, apoptosis-inducible lentiviral CAR targeting CD123 has been published, 262 but there is no further evidence of this construct.

More conventional strategies such as CD123CAR (autologous CD123CAR-CD28-CD3ζ-EGFRt) have demonstrated antileukemic efficacy with acceptable toxicities in seven patients with R/R AML who had undergone prior alloHSCT ( NCT02159495 ). 304 , 305

CD33-CAR-T cells in clinical trials

A second-generation CD33-directed CAR construct comprising lintuzumab-CD28/CD3ζ 306 has demonstrated promising outcomes in a Phase 1/2 dose-escalation interim analysis of children, adolescents, and young adults with R/R AML ( NCT03971799 ). This construct includes a combination of a targeting motif derived from lintuzumab (HuM195, SGN-33; an antibody that targets the distal CD33 IgV domain) linked to CD28/CD3. The rationale was based on the observation that the rs12459419 C > T single nucleotide polymorphism, associated with decreased CD33 surface expression, is present in more than 50% of AML patients. 307 – 309 The lintuzumab-enhanced CD33 CAR-T cells are capable of recognizing low-antigen-density AML.

A total of 24 subjects were enrolled in the trial, of whom 12 had undergone prior alloHSCT. CD33-CAR-T products were successfully manufactured for 23 patients and subsequently infused into 19, primarily due to the progression of the disease. Four patients experienced CRS grade 3 or 4, which was successfully managed. Responses were reported in those who achieved the highest dose level. Based on the rapid clinical efficacy observed at dose level 4, enrollment has resumed in Phase 2. 310 The authors highlight that despite the considerable inter-patient heterogeneity of apheresis products, the centralized manufacturing of CD33-CAR-T cells was feasible for the 6 participant centers. 311 Notably, the authors did not report sinusoidal obstruction syndrome, a complication that has been previously associated with gemtuzumab.

A Phase 1 clinical trial conducted at MD Anderson Cancer Center evaluated the efficacy of a 4-1BB and CD3ζ endodomain co-expressed with a truncated human epidermal growth factor receptor but failed to demonstrate an anti-leukemic effect ( NCT03126864 ). The researchers encountered difficulties regarding the efficiency of transduction and the complexity of the clinical setting, given the 2–4 weeks required for production (risk of AML progression and other clinical complications such as infections). As a consequence of this, the trial was closed after the enrollment of 11 patients. 312 The current focus of research is on the development of a platform that will facilitate more rapid production and in vivo expansion of a product referred to as PRGN-3006 or UltraCAR-T. The preliminary responses were encouraging, 313 reason why the product gained the fast-track designation by the FDA. The UltraCAR-T is based on a non-viral Sleeping Beauty system to express the CAR, as well as a membrane-bound IL-15 for stronger in vivo expansion and persistence. Furthermore, the construct contains a safety switch that can conditionally eliminate CAR-T cells, thereby improving the toxicity profile (Fig. 3 ).

The addition of a potentiating molecule linked to human CD33 scFv via a self-cleaving P2A peptide has been reported to functionally enhance CD33-CAR-T cells and render them safe. Furthermore, this approach has demonstrated anti-leukemic efficacy, as revealed in a preliminary report at ASCO 2024 314 ( NCT04835519 ). An intriguing strategy comprising a combination of VCAR33 (allogenic CARs with a lintuzumab-derived binding domain and a CD28 co-stimulatory domain) is currently enrolling patients in a Phase 1/2 study 315 ( NCT04849910 ), with the possibility of subsequent CD33-deleted alloHSCT consolidation.

An additional conceptually appealing approach may be the drug-induced dimerization of split CAR designs, which allow for cycles of tumor killing interspersed with periods of myeloid recovery. These strategies may permit physicians to modulate CAR activity based on clinical needs. In this context, a CD33-targeted dimerizing agent-regulated immunoreceptor complex (DARIC) is currently being evaluated. 275 The platform comprises separate antigen targeting and T cell signaling components, with embedded extracellular rapamycin-dependent heterodimerizing domains (Fig. 3 ). The targeting and signaling components undergo dimerization in the presence of rapamycin, thereby eliciting antigen-responsive T cell activation. Appelbaum et al. reported evidence of in vitro and in vivo antitumor activity against established CD33+ human tumor xenografts in NSG (NOD scid gamma) mouse models. 316 However, the Phase 1, PLAT-08 trial of SC-DARIC33 in pediatric patients with AML was put on hold by the FDA following a severe grade 5 adverse event report.

Finally, an interesting study performed multiplexed base editing to remove TCR, CD52, and the shared AML/T lineage antigen CD7 from T cells, which enabled the generation of universal donor CAR-T cells (BE-CAR33, BE-CAR7) for combinational use. Preclinical data demonstrated the robust activity of BE-CAR33 alone and in combination with BE-CAR7 against human CD7 + CD33 + AML cells in a PDX model from a KIT-mutated AML patient. 317 Preliminary results from other early clinical trials of CAR-T cell strategies targeting CD33 have shown promising results with acceptable safety profiles. 141 , 313 , 318

CLL1-CAR-T cells in clinical trials

A second-generation murine anti-CLL-1 scFv with an intracellular domain of CD28 and OX40 and a PD-1 silencing shRNA sequence, to strengthen CAR-T function, has been tested in a Phase 1 trial. Two patients who had previously undergone anti-CD38 CAR-T cell therapy and experienced treatment failure achieved a complete response, although no further follow-up has been provided. 319 In a similar strategy, the CB-012 platform has been engineered with next-generation Cas12a CRISPR hybrid RNA-DNA (chRDNA) genome-editing technology to target both checkpoint function and immunomodulation, which has the potential to improve antitumor activity (AMpLify Phase 1 clinical trial 320 ) (Fig. 3 ). In other preliminary studies, CAR-T cells directed against the CLL1 antigen have also been reported to be safe and provide a promising response rate in heavily pretreated patients 321 , 322

Other targets in clinical trials

CD38 has been targeted in a Phase 1/2 CD38-CAR-T cell therapy in six patients with R/R AML post-alloHSCT ( NCT04351022 ). CD38-CAR-T cells were manufactured without incident, with four products derived from an autologous source and two from a donor source. Four weeks after the infusion of CD38-CAR-T cells, the ORR was 66.7% (4/6 patients) including one patient who achieved complete remission (CR) and three patients who achieved complete remission with incomplete count recovery (CRi) and full donor chimerism. The 6-month OS and leukemia-free survival rates were both 50%, with a median of 7.9 and 6.4 months, respectively. Toxicities were considered acceptable. 323

Some interesting strategies are being explored that target CD7. A recent study involving seven patients with R/R AML suggested that sequential treatment with CD7-CAR-T cells followed by haploidentical HSCT may be both safe and effective, leading to durable responses. 324 Other strategies include autologous nanobody-derived fratricide-resistant CD7-CAR-T cells. Notably, an off-target CD7 blockade strategy was developed employing a tandem CD7 nanobody VHH6 coupled with an endoplasmic reticulum/Golgi-retention motif peptide, effectively sequestering the CD7 surface marker intracellularly 325 ( Fig. 3 ) .

A Phase 1 dose-escalation study was conducted to evaluate the efficacy of NKG2D-CAR-T cells for R/R AML and high-risk myelodysplastic syndrome without lymphodepletion conditioning ( NCT02203825 ). However, no notable expansion or objective clinical efficacy was observed. The possible explanations for the observed results include the lack of a costimulatory domain in the CAR construct, heterogeneous NKG2D ligand expression in the patients, and the conserved nature of NKG2D, which may be related to the lack of immunogenicity. 326 , 327

Finally, a Phase 1 trial is currently evaluating a bispecific CLL1-CD33-CAR with two complete CAR constructs connected by a P2A cleavable linker ( NCT03795779 ). Nine patients were treated until September 2019; eight treatments were manufactured from autologous cells, while a ninth was derived from an HLA-matched sibling donor. Two patients experienced grade 3 or 4 CRS, four patients experienced immune effector cell-associated neurotoxicity syndrome (in 3 cases, grade 3 or more), and all patients experienced grade four pancytopenia. On disease re-evaluation at four weeks post-CAR-T cell infusion, seven out of nine patients were negative for minimal residual disease by flow cytometry, and two patients had no response. 328

Future directions

Manufacturing

The primary elements of the CAR-T cell manufacturing process have largely been standardized. They can be divided into four main stages: isolation and enrichment of T cells, activation and expansion of T cells, gene transfer of a CAR vector, and ex vivo CAR-T cell expansion and cryopreservation. 329

In the first stage, PBMCs (Peripheral Blood Mononuclear Cells) are isolated from peripheral blood by density gradient centrifugation to remove granulocytes, red blood cells, and platelets. In this initial phase, the patient with R/R AML may experience prolonged cytopenia, which could impede the success of apheresis. Notably, the cellular composition at the outset of production can impact the phenotype of the CAR-T cells. At this stage, it should be considered that patients with R/R AML may present with low numbers of effector T cells, besides an activated circulating cytokine profile, as reported in other hematological cancers at advanced stages. 330

An alternative approach in this context is the selection of CD3 + T cells using magnetic bead-based systems, such as the CliniMACS® system. This enables T cell expansion and administration of the final cell product, ensuring a properly defined CD4:CD8 ratio 331 – 333 (Fig. 5 ). Fig. 5 Automated CAR-T cell manufacturing process including leukapheresis and cryopreservation (1), T-cell activation and transduction (2), modified T-cell expansion (3), and lymphodepleting chemotherapy prior to patient infusion. Potential challenges in the AML context are highlighted in the green boxes. This figure was created with Biorender.com

T cell activation is typically initiated by unconjugated mAbs, most commonly anti-CD3/anti-CD28 antibody-coated magnetic beads. 334 Afterward, the method of delivery of the CAR transgene can significantly impact its expression level. At present, all FDA- and EMA-approved CAR-T cell products employ lentiviral or retroviral transduction to achieve CAR transgene integration. Still, several alternative non-viral gene delivery methods have been investigated, with promising results. 335

It is important to note that production delays may prove fatal for this highly aggressive disease. Using donor-derived CAR-T cells, also known as allogeneic CAR-T, universal CAR-T (UCART), or off-the-shelf CAR-T, 336 , 337 could expand this strategy by being immediately available. Some of the currently engineered CAR-T cells, such as BE-CAR33 or BE-CAR7, are already based on this strategy and have shown efficacy in PDX models and are currently being tested in the CARAML clinical trial ( NCT05942599 ). 317

Furthermore, the optimal lymphodepleting therapy remains to be determined. Some evidence supports the use of HMAs concomitantly with the lymphodepleting regimen, which have been demonstrated to augment CD123 and other antigen expression on AML blast surfaces. Recent findings also suggest that combining CAR-T cells with cytokine signaling inhibitors could enhance immunotherapy efficacy in the specific AML context ( NCT03766126 ). 160

Finally, selecting eligible AML patients may require a more cautious approach than that employed in CAR-T cell therapy for other hematological malignancies. In the event of myeloid aplasia, the patient may require a rescue alloHSCT. Accordingly, a meticulous and multidisciplinary clinical strategy, including the identification of HSCT donors prior to CAR-T infusion, may be considered.

Strategies to circumvent antigen heterogeneity

Given the molecular and cytogenetic heterogeneity of AML, a promising approach for effective CAR-T cell therapy with increased specificity might be to target two different antigens using tandem or bicistronic CARs. These strategies are still in the early stages of clinical development, with limited available information. Related to this, the emergence of antigen-low expression clones evading effector cell-mediated killing may constitute one mechanism of disease escape during AML evolution. 196 In this context, both modifying the binding affinity and avidity of the scFv, and selecting appropriate costimulatory domains, can be used to enhance CAR sensitivity.

The scFv determines the antigen-binding affinity and specificity of CAR-T cells. 338 A high affinity scFv enhances the binding strength to the tumor antigen, improving tumor recognition and cytotoxicity. Additionally, the multivalent nature of CAR constructs facilitates a high-avidity effect, increasing overall binding efficiency and T cell activation, even in the presence of antigen heterogeneity. Optimizing both affinity and avidity can lead to more effective and sensitive CAR-T therapies, enabling better tumor targeting and improved clinical outcomes. However, achieving the right balance of affinity and specificity is complex. The affinity must be strong enough for the CAR-T cells to recognize tumor antigens and induce T cell-mediated destruction, but excessively high affinity may lead to off-target binding to healthy tissues. 339 , 340 Furthermore, high-affinity CAR-T cells may exhibit reduced persistence in vivo due to activation-induced T cell exhaustion and apoptosis. 341

Costimulatory elements may also influence CAR sensitivity. CD28 CARs typically exhibit a reduced requirement for target antigen density, 342 as well as enhanced and accelerated expansion. 343 These features make CD28 an interesting co-stimulator domain for the treatment of AML. Indeed, most strategies currently being tested in early clinical stages (discussed in this review) have selected the CD28 co-stimulator domain. Conversely, 4-1BB CARs typically exhibit more remarkable persistence, in part due to the reduction in T cell exhaustion induced by prolonged CAR signaling. 344 This attribute may be particularly advantageous in contexts where an alloHSCT rescue is not anticipated as a component of the therapeutic strategy.

Additionally, the signaling machinery can be enhanced by modifying the multimeric CD3 complex (CD3 complex-based receptors). This CD3 complex plays a pivotal role in TCR-mediated antigen recognition. 345 , 346 Regarding this, preclinical evidence indicates that the substitution of chimeric V L –Cα and V H –Cβ chains for the endogenous TCR may improve sensitivity. 347 This is the case of HIT receptors, STAR receptors, 348 , 349 TCAR, antibody-TCR (AbTCR), TCR fusion constructs (TRuC), 350 and T cell antigen coupler (TAC) receptors. Specifically, STAR-T cells have demonstrated superior killing in low neoantigen density context and improved tumor control in mouse models in comparison with conventional CAR-T strategies. 351 , 352 However, in contrast to CAR-T cells, most TCR-engineered T cells can only recognize intracellular tumor antigens presented by MHC molecules. 353 , 354 Of note, CAR antigen sensitivity may also be enhanced without a structural modification by amplifying downstream activation signaling. 355

The complexity of AML treatment may necessitate innovative strategies such as epitope-editing (Fig. 6 ). Early efforts in epitope-editing included CRISPR/Cas9-mediated CD33 knock-out in CD33-positive tumor cells and primary HSPCs, demonstrating its feasiblility. 356 – 358 More recent advancements, such as the work led by Casirati et al., successfully performed epitope engineering of donor CD34+ HSPCs to confer resistance to CAR-T cells targeting FLT3, CD123, and KIT antigens. 359 The authors confirmed the resistance of epitope-edited hematopoiesis and the subsequent eradication of PDXs after CAR-T cell treatment. In the case of CD123, these results have been validated by other groups. 360 Similarly, Wellhausen et al. generated CRISPR epitope-edited CD45-CAR-T cells to evade CAR-T cell recognition. These epitope-edited CD45-CAR-T cells exhibited fratricide resistance and efficacy against PDX AML. 361 Thus, ex vivo epitope editing in HSCs and T cells could revolutionize CAR-T cell therapies for AML, offering a promising strategy to enhance treatment effectiveness and durability. Fig. 6 Epitope engineering of Hematopoietic Stem Progenitor Cells (HSPCs) ( a ) to confer resistance to CAR-T cells targeting ( b ). The complexity of AML treatment may require innovative strategies, including recently implemented approaches such as epitope editing through epitope mutagenesis, prime editing, and base editing. LSCs, Leukemia Stem Cells. Figure created with Biorender.com

When considering bispecific and complex editing approaches, it is crucial to control over cell killing to mitigate potential on-target/off-tumor toxicities, particularly in the context of AML (Fig. 7 ). One of the earliest strategies proposed to regulate toxicity is the use of switchable CAR-T cells. This approach involves introducing genes encoding surface proteins, antigens or intracellular effectors into the CAR-T cells. Upon gene expression, CAR-T cells become responsive to specific drugs, enabling the controlled cessation of their activity. 362 , 363 An illustrative example is incorporating a truncated epidermal growth factor receptor (EGFRt) into CAR-T cells. The administration of cetuximab can target EGFRt, which could lead to the elimination of active CAR-T cells through antibody-dependent cellular cytotoxicity. 364 Fig. 7 Bispecific strategies ( a ) and safety modulation approaches ( b ) currently under investigation. Ongoing developments in bispecific strategies include tandem CARs, dual CARs, multispecific CARs, and CAR-T cells engineered to express BiTEs targeting a different antigen through the activation of bystander T cells. Another approach involves CARs that recognize a common adapter molecule, allowing for simultaneous targeting with a single CAR construct. In the AML context, key safety strategies include the implementation of safety switches and the use of gating mechanisms, such as “AND,” “NOT,” and “AND-NOT” gate strategies. Figure created with Biorender.com

A novel strategy recently published by He et al. 224 involves the isolation of multiple nanobodies (heavy-chain-only antibodies with a small single variable domain) that bind to various epitopes. By employing a sequentially tumor-selected antibody and antigen retrieval (STAR) system, the researchers developed a bispecific and split CAR (BissCAR) targeting CD13 and TIM3. The BissCAR-T cells effectively eradicated patient-derived AML in murine and PDX models with limited toxicity to normal HSPCs.

Other relevant platforms currently in development include a split, universal, and programmable (SUPRA) CAR system, which is designed to improve specificity and controllability, 365 and the RevCAR-T platform, which employs an “AND” logic gate to target CD33 and CD123 in a versatile manner. 366 In this context, the incorporation of the “OR” or “AND” logic gate strategies could also prove beneficial in reducing off-tumor side effects, as the tumor with both antigens will be selectively eliminated compared with tumors with a single antigen. 367 – 370

The “OR” logic gate is based on two completely independent CAR molecules able to recognize the presence of a single antigen or both antigens simultaneously. 182 The SUPRA CAR system employs an AND or NOT logic gate design to target CD33 and FLT3. The construct comprises of a universal chimeric receptor expressed on the T cell, zipCAR, coupled to a soluble antigen-binding adapter, zipFv, which contains a leucine zipper and scFv. 370 The “AND” logic gate would only achieve full activation status upon binding their cognate antigens simultaneously. Two distinct CARs are co-expressed on a single T cell, each with complementary signaling domains. However, the CAR-T cell attains full activation only when both of its receptors bind to their respective antigens simultaneously. For example, the use of synthetic Notch (synNotch) receptors in a dual CAR-T system enables synergistic and selective binding, minimizing on-target/off-tumor toxicity. 371 – 374 Upon recognition of the antigen by the first receptor, a transcription factor is activated, which in turn induces the expression of a second CAR. This subsequently binds to the secondary antigen. 338

In addition to these two concepts, “NOT” gates are also noteworthy for their ability to turn off CAR-T cell activity upon encountering unintended target cells. For example, the “NOT”-gate CD93-CAR-T is an inhibitory CAR strategy designed to mitigate endothelial toxicity generated by CD93-CAR-T cells, which eliminates AML but exerts on-target/off-tumor toxicity to endothelial cells. 375 “IF-THEN” gates (which allow spatiotemporal regulation of CAR expression) and “IF-BETTER” gates (in which a CAR-engaging antigen A performs better in the presence of antigen B) are also under investigation. 347

Using different logic gate CAR-T designs could also mitigate AML relapse. 376 Traditional CAR-T therapies can be limited by the heterogeneous nature of AML, where tumor cells may downregulate or lose expression of the targeted antigen, leading to relapse. By employing logic gate circuits, these therapies can be adapted to recognize more complex antigen expression patterns specific to AML. 377 , 378 For example, incorporating “OR”-gate CARs – where two independent antigen recognition domains enable targeting multiple antigens – can enhance tumor recognition and reduce the likelihood of escape. Additionally, integrating a “safety switch” that responds to both tumor-associated markers and inhibitory signals from the TME can improve CAR-T cell persistence while minimizing off-target toxicity issue. 56 Furthermore, optimizing costimulatory domains is essential to ensure adequate CAR-T cell proliferation and persistence, which are strongly correlated with durable leukemia remission. 379 This multi-layered approach holds significant potential for reducing relapse rates and improving long-term outcomes in AML.

New antigens under development

The major challenge encountered in CAR-T cell development for AML has been the inability to identify a specific targetable antigen. Further efforts are needed in whole-genome sequencing, surfaceome profiling of AML LSCs, and proteomic and transcriptomic studies comparing antigen expression in LSCs and healthy stem cells. 17 , 146 , 380 Some antigens that have been the subject of early directed and promising strategies are shown in Fig. 8 . Fig. 8 Folate Receptor (FR), Wilm Tumor 1 (WT1), Leukocytic immunoglobulin-like receptor (LILRB4), CD84, Siglec-6, and T-cell immunoglobulin mucin-3 (TIM-3) are antigens that show promising features for CAR-T cell targeting. Figure created with Biorender.com

In a notable advance, Lynn et al. 381 developed an FRβ-specific CAR construct, supported by compelling preclinical evidence, targeted to a folate receptor (FR). The FR is expressed on approximately 70% of primary AML blasts. 382 FRα and FRβ are cell surface-bound proteins through glycosyl-phosphatidylinositol linkages. This receptor is an attractive target because its expression is limited in normal tissue and can be upregulated by all-trans retinoic acid, 383 a drug approved for acute promyelocytic leukemia.

Additionally, Rafiq et al. 384 successfully developed and tested WT1-CAR-T cells, demonstrating efficacy against cell lines in an in vitro model. Wilms tumor 1 (WT1) is an oncogenic zinc-finger transcription factor with low expression in the BM and notable overexpression in various hematological malignancies (AML and CLL), as well as in several solid tumors (such as glioblastoma, mesothelioma, and ovarian cancer). 385

Moreover, LILRB4, a leukocytic immunoglobulin-like receptor belonging to the LILRB family, 386 – 389 has shown promising results in preclinical studies. 389 The LILRB family is expressed on AML cells and has been reported to be uniquely expressed on normal monocytic cells at the promonocyte stage of development. 390 An interesting first-in-human study presented at the last ASH congress (San Diego, December 2024) demonstrated that LILRB4 STAR-T therapy is a promising approach in LILRB4 -positive R/R AML patients. 391 Further data from the Phase II trial is eagerly awaited. Additionally, exciting findings were reported on a humanized IgG1 monoclonal antibody with high affinity and specificity for LILRB4, tested in combination with azacytidine for CMML. This combination appears to be well tolerated, with preliminary efficacy outcomes showing superiority over azacytidine alone, leading to rapid and sustained responses. 392

Similarly, a potential new target for developing CAR-T cells in AML is CD84, an immunoreceptor belonging to the SLAM family (SLAMF5 393 , 394 ). CD84 is overexpressed on AML cells while displaying comparatively low expression in CD34+ HSCs and absent in other tissues. Perez-Amill et al. 395 developed a CD84-CAR-T therapy with promising in vitro and in vivo results.

Siglec-6 is expressed in primary AML blasts but is absent in normal HSCs. 396 , 397 Building on this finding, Jetani et al. 397 engineered a Siglec-6 CAR-T cell therapy utilizing a targeting domain derived from the mAb JML-1. Subsequent in vitro and in vivo studies demonstrated its remarkable efficacy against AML blasts while preserving regular HSCs activity. A similarly featured antigen is TIM-3 (T-cell immunoglobulin mucin-3), which is expressed in LSCs in almost all types of AML but not in HSCs. 398 – 400 TIM3-CAR-T cells exhibited robust antileukemia activity in xenograft models, accompanied by the production of IFN-γ, granzyme B, and perforin. 224

Furthermore, tumor cells are known to express cancer-specific surface protein conformations that are difficult to detect using standard technologies assessing gene or protein expression. However, these unique conformations can be identified and selectively targeted. In this context, recent studies have applied structural surfaceomics to AML, integrating cross-linking mass spectrometry with glycoprotein surface capture. Although still an emerging field, preliminary findings suggests that AML exhibits a distinct conformational signature involving various proteins, including integrin β2, which has been proposed as a potential target for CAR-T therapy. 401

Another emerging approach that could circumvent the challenges in AML treatment is the combination of antibodies and cell-based therapies, known as STAb (Secreting T-cell-engaging Antibody). This strategy is based on the endogenous secretion of T cell-redirecting bispecific antibodies (bsAbs). 402 STAb immunotherapies involve genetically modifying T cells with nucleic acids or viral vectors to encode bsAbs. This approach not only offers therapeutic potential similar to CAR-T cells but also enables the secreted bispecific antibodies to bind and activate bystander T cells. As a result, all circulating T cells are effectively “converted” into CAR-T-like cells, enhancing overall efficacy. 403 , 404 The ability to recruit and activate bystander T cells amplifies the immune response, making STAbs a promising strategy for targeting cancer and other diseases by broadening immune activation beyond the directly engineered T cells.

This T cells engineered to produce bsAbs have demonstrated antitumor activity in preclinical models. 405 For example, CD1a-, CD19-, and BCMA-STAb T cells have been tested in PDX models of cortical T-ALL, B-ALL and MM, respectively, showing higher efficacy than their respective second-generation CAR-based therapies. 406 Similarly, dual-targeted STAb-T cells secreting BCMA TCE and CD19 TCE have been effectively tested in in vitro models of B-cell malignancies. 407 This platform has also been studied in B-ALL, with promising results. An interesting example is a dual-target strategy based on T cells expressing an anti-CD22-CAR and also secreting an anti-CD19 T-cell engager antibody. This approach was compared with a previously validated anti-CD19/CD22 tandem CAR therapy, demonstrating that STAb-T cells exhibited an enhanced and faster in vitro cytotoxic activity. 408 Given its ability to recruit bystander T cells, this innovative therapy is particularly promising for aggressive diseases prone to relapse with low effector T cells counts, such as AML. Indeed, some preliminary studies in AML have reported encouraging results. 409 , 410

There is mounting interest in gamma-delta (γδ) T cell-based products for adoptive immunotherapy. 411 – 414 Specifically, Delta One T (DOT) cells (Vδ1 + γδ T cells) have been identified as a promising avenue for cancer immunotherapy due to their reduced susceptibility to activation-induced cell death and their capacity to persist as tumor-reactive lymphocytes over extended periods (Fig. 9 ). 415 Preclinical studies have demonstrated the safety and efficacy of this approach, 416 , 417 and it is undergoing testing in a Phase 1 clinical trial ( NCT05015426 ) as a single infusion following alloHSCT. Fig. 9 AML BM niche with intrinsic and extrinsic features ( a ) and future strategies to modulate tumor microenvironment ( b ). Among the promising strategies for modulating the bone marrow microenvironment, TRUCKs (1), the addition of exogenous cytokines to boost ex-vivo expansion (2), the use of gamma-delta T cell-based products (3), and the combination with checkpoint inhibitors (4) are especially noteworthy. Figure created with Biorender.com

Modulating the tumor microenvironment

Given the T cell-inhibiting role of MDSCs, 418 – 421 concomitant administration of CAR-T cells with small molecules capable of depleting the MDSC population may be synergistic. 422 Several strategies that enhance CAR-T cell efficacy in the context of B-cell malignancies may also be relevant in AML. These include the upregulation of IL-15 expression or the IL-18 transgene (TRUCKs) and the addition of exogenous IL-7, IL-15, and/or IL-21 cytokines during the ex vivo expansion of CAR-T cells 423 – 426 (Fig. 9 ).

Because of the low mutational burden of AML and the correspondingly low frequency of AML-reactive T cells, 427 CAR-T cell combinations with checkpoint inhibitors (e.g., anti-PD-1 or anti-CTLA-4 antibodies) might be an interesting future strategy 428 , 429 as it may also overcome T cell exhaustion and enhance CAR-T cell efficacy. This could be achieved either through exogenously administered inhibitors or genetic engineering, enabling the CAR-T cell to synthesize these antibodies. 430 For example, the combination of immune checkpoint inhibitor PD-1/PD-L1 monoclonal antibodies and CAR-T cells has effectively prevented immune suppression and enhanced the anti-tumor activity of CAR-T cells. 431 Similarly, novel strategies have been explored, such as the incorporation a Fc-mutant TIM3 receptor decoy to counteract inhibitory signals originating from the blasts or the TME in R/R B-ALL. 57 In addition to TIM3, other immune checkpoint receptors, such as PD1, CLTA-4 and LAG3, can also be targeted as decoys to further disrupt these inhibitory signaling pathways. The flexibility to choose from a variety of inhibitory pathways to adapt this platform to different diseases offers a promising avenue for improving the overall efficacy and durability of CAR-based therapies.

The combined use of apoptosis-regulating drugs, such as BCL-2 inhibitors, can lower the threshold for CAR-T cells to trigger tumor cell killing through pathways like death receptors. This strategy helps overcome tumor cell resistance to therapy, thereby enhancing the overall effectiveness of the treatment. 432 , 433 Moreover, combination with cytoreductive chemotherapy or epigenetic modulators such as HMA (e.g., azacitidine or decitabine) can reduce the tumor burden and modulate the immune microenvironment. There are several clinical trials ongoing testing the synergistic function of epigenetic drugs and immunotherapy. 434 Indeed, it has been proven that CAR-T cells treated with methylation inhibitors such as low-dose decitabine during CAR T cell manufacturing present stronger antitumour effector function, proliferation, memory phenotype maintenance, cytokine release capacities and a lower exhaustion-associated gene expression under tumor cell stimulation in vivo and in vitro. 435 These epigenetic agents before CAR-T cell infusion may enhance CAR-T efficacy by reducing immunosuppressive cells or increasing antigen expression on AML blasts. 77 , 435 Moreover, some studies have used histone, DNA, and miRNA modifications to downregulate inhibitory molecules such as PD1, CTLA-3, TIM2 and LAG3 resulting in T cell-intrinsic upregulation. 436 – 438 Additionally, the combination with immunomodulators like lenalidomide or TGF-β inhibitors can promote a more favorable microenvironment for CAR-T activity. 439 , 440

Combining CAR-T cells with metabolic modulators also represents a promising strategy, as metabolic pathways are integral to T cells’ function, persistence, and efficacy. CAR-T cells, require robust metabolic activity to support their proliferation, survival, and effector functions. Within the TME, however, metabolic stressors such as hypoxia, nutrient deprivation, and the accumulation of immunosuppressive metabolites can lead to CAR-T cell exhaustion and dysfunction. 441 In this context, there is some preclinical evidence of the combination of metabolic modulators with CAR-T cell therapy. For instance, increasing L-arginine levels (crucial for CAR-T cell proliferation and cytotoxicity) by modulating PRODH2 enzyme seems a preclinical exciting strategy. 442 , 443 A study modified CAR-T cells to overexpress kynureninase, increasing their cytotoxicity in the TME. 444 Further publications combined IDO1 inhibitors (a key enzyme in kynurenine synthesis) with CAR-T cells.

Conclusions and perspectives

Modern CAR-T cell therapy represents the culmination of decades of immunology and genetic engineering research. Foundational discoveries, such as the identification of T cells and the demonstration of immune-mediated cancer eradication, as well as the early efforts led by Dr. Steven Rosenberg highlighting the potential of TILs, paved the way for advancements in adoptive cell therapy.

The first FDA-approved CAR-T therapies, Kymriah® and Yescarta®, revolutionized treatment for B-cell malignancies. Despite these successes, challenges remain, particularly in extending CAR-T therapy to solid tumors and certain hematological malignancies such as AML.

Regarding solid tumors, the tumor microenvironment, antigen heterogeneity, and limited CAR-T cell persistence present significant obstacles. This review describes that while no CAR-T therapy has received FDA approval for solid malignancies, certain strategies such as intracranial IL-13Ra-targeted CAR therapy (multifocal glioblastoma 124 ), and ongoing clinical trials with Claudin18.2 (gastrointestinal tumors 126 ) and GD2 (H3K27M-mutated glioma 125 ; and neuroblastoma 127 ) show promise.

Additionally, other T cell-based approaches, including ongoing trials targeting antigens like bispecific TCE and TCR-T therapies, are being explored in this specific solid tumor setting. For instance, the gp100 peptide-MHC/CD3 bispecific T-cell engager (TCE) tebentafusp, which was approved for uveal melanoma in 2022, 128 is one strategy that holds great promise. In line with this, further approaches described in this review that are being currently tested show strong potential, such an autologous TCR T-cell therapy named afami-cel for synovial sarcoma, 129 and other cellular therapies for HPV-associated cancers. 130 – 132 While significant challenges remain, the evolving landscape of CAR-T cell therapy offers promising avenues for expanding its impact beyond hematologic malignancies.

Furthermore, CAR-T cell therapy holds great promise for the treatment of AML. However, several challenges must be addressed to fully realize its therapeutic potential. AML presents a highly heterogeneous landscape, driven by diverse genetic, cytogenetic, and epigenetic alterations that influence disease presentation, progression, and treatment response. The complexity of AML remains a challenge, particularly due to the presence of LSCs and clonal evolution mechanisms that contribute to therapy resistance and relapse.

Additionally, as exposed in this work, the AML bone marrow microenvironment further exacerbates these challenges by fostering immune evasion, metabolic suppression, and a highly immunosuppressive setting that impairs immune-based therapies. The BM microenvironment in AML is characterized by metabolic byproducts such as lactate, adenosine, and kynurenine, which inhibit T cell function and drive immune exhaustion. Furthermore, the presence of myeloid-derived suppressor cells (MDSCs), T regulatory cells (Tregs), and inhibitory checkpoints, such as PD-1, TIM-3, and LAG-3, contributes to T cell dysfunction. These immunosuppressive factors not only hinder the effectiveness of conventional therapies but also pose significant obstacles to CAR-T cell therapy, which has demonstrated limited success in AML compared to its applications in B-cell malignancies.

Moreover, a major limitation described in this review still to be faced in the development of CAR-T cell therapies for AML is the lack of an optimal target antigen. An ideal target should be highly expressed on AML blasts and LSCs while being absent in normal hematopoietic and extra-hematopoietic tissues to minimize on-target/off-tumor toxicity. Current CAR-T cell targets under investigation include CD123, CD33, CLL-1, NKG2D, CD7, CD38, CD44v6, CD70, and FLT3. Each of these antigens presents unique advantages and challenges, including concerns related to myeloablation, endothelial toxicity, and antigen escape mechanisms. Among these targets, CD123 and CD33 have been extensively studied, with various CAR-T cell constructs in preclinical and early clinical phases. However, toxicity concerns, particularly myelosuppression, remain a significant challenge. Emerging targets such as CLL-1 and NKG2D offer promising avenues due to their selective expression in AML while sparing normal HSCs. Additionally, strategies such as bispecific CARs, safety switches, and combinatorial approaches with immune checkpoint inhibitors or metabolic modulators are being explored to enhance CAR-T cell efficacy and safety.

Overall, while significant progress has been made in understanding AML heterogeneity and immune evasion, further research is required to optimize CAR-T cell strategies and overcome the inherent challenges of AML treatment. The integration of multi-targeting approaches, improved manufacturing techniques, and a deeper understanding of the BM microenvironment may ultimately enhance the therapeutic potential of CAR-T cells in AML.

Additionally, certain concerns regarding CAR-T cell therapy must be carefully evaluated in the context of AML. For instance, reports have highlighted potential long-term side effects, including the incidence of secondary myeloid neoplasms following CD19-CAR-T cell therapy. 445 , 446 Studies estimate the incidence to range from 1% to 10%, 427 – 429 which is comparable to the risk of therapy-related myeloid neoplasms observed after chemotherapy or autologous HSCT in patients with NHL. Furthermore, the FDA had raised concerns following the diagnosis of 22 cases of T cell malignancies within two years of CAR-T infusion. 447 While these findings warrant attention, further studies and long-term follow-up are necessary to draw definitive conclusions regarding the risks associated with CAR-T cell therapy. 448

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Acknowledgements

Research in P.M.’s laboratory is supported by CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support; the European Research Council grants (ERC-PoC-957466 IT4B-TALL, ERC-PoC-101100665 BiTE-CAR); H2020 (101057250-CANCERNA), the MINECO (PID2022-142966OB-I00/ MCIN/AEI/10.13039/501100011033 and Feder Funds), MINECO/European Union NextGenerationEU (CPP2021-008508, CPP2021-008676, CPP2022-009759); the Deutsche José Carreras Leukämie-Siftung (DJCLS15R/2021), the Spanish Association Against Cancer (AECC, PRYGN234975MENE), and the ISCIII-RICORS within the Next Generation EU program (plan de Recuperación, Transformación y Resilencia). K.F. is supported by Marie-Sklodowska Curie-Postdoctoral fellowship (101153028).

Author contributions

I.Z. conceptualization, reading, literature search and writing the original draft. L.E., V.M-A., M.D-B., T.V-H., K.F., M.J., A.U., J.E., P.M. contribution to methodology, writing, review and editing. P.M. contribution to supervision. All authors have read and approved the article.

Funding

This research received no external funding.

Competing interests

P.M. is a cofounder of OneChain Immunotherapeutics, a spin-off company from the Josep Carreras Leukemia Research Institute. The remaining authors report no conflicts of interest in this work.

References

1. DiNardo CD Erba HP Freeman SD Wei AH Acute myeloid leukaemia Lancet 2023 401 2073 2086 10.1016/S0140-6736(23)00108-3 37068505 DiNardo, C. D., Erba, H. P., Freeman, S. D. & Wei, A. H. Acute myeloid leukaemia. Lancet 401 , 2073–2086 (2023). 37068505 10.1016/S0140-6736(23)00108-3

2. Kantarjian H Acute myeloid leukemia: current progress and future directions Blood Cancer J. 2021 11 41 10.1038/s41408-021-00425-3 33619261 PMC7900255 Kantarjian, H. et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 11 , 41 (2021). 33619261 10.1038/s41408-021-00425-3 PMC7900255

3. van Galen P Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity Cell 2019 176 1265 1281.e24 10.1016/j.cell.2019.01.031 30827681 PMC6515904 van Galen, P. et al. Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity. Cell 176 , 1265–1281.e24 (2019). 30827681 10.1016/j.cell.2019.01.031 PMC6515904

4. Zeng AGX A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia Nat. Med. 2022 28 1212 1223 10.1038/s41591-022-01819-x 35618837 Zeng, A. G. X. et al. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nat. Med. 28 , 1212–1223 (2022). 35618837 10.1038/s41591-022-01819-x

5. Kayser S Levis MJ The clinical impact of the molecular landscape of acute myeloid leukemia Haematologica 2023 108 308 320 10.3324/haematol.2022.280801 36722402 PMC9890016 Kayser, S. & Levis, M. J. The clinical impact of the molecular landscape of acute myeloid leukemia. Haematologica 108 , 308–320 (2023). 36722402 10.3324/haematol.2022.280801 PMC9890016

6. DiNardo CD Azacitidine and venetoclax in previously untreated acute myeloid leukemia N. Engl. J. Med. 2020 383 617 629 10.1056/NEJMoa2012971 32786187 DiNardo, C. D. et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl. J. Med. 383 , 617–629 (2020). 32786187 10.1056/NEJMoa2012971

7. Pratz KW Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia Am. J. Hematol. 2024 99 615 624 10.1002/ajh.27246 38343151 Pratz, K. W. et al. Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am. J. Hematol. 99 , 615–624 (2024). 38343151 10.1002/ajh.27246

8. Kadia TM Phase II study of venetoclax added to cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia. J. Clin. Oncol. 2022 40 3848 3857 10.1200/JCO.21.02823 35704787 PMC9671758 Kadia, T. M. et al. Phase II study of venetoclax added to cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia. J. Clin. Oncol. 40 , 3848–3857 (2022). 35704787 10.1200/JCO.21.02823 PMC9671758

9. Wei AH Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial Blood 2020 135 2137 2145 10.1182/blood.2020004856 32219442 PMC7290090 Wei, A. H. et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 135 , 2137–2145 (2020). 32219442 10.1182/blood.2020004856 PMC7290090

10. Perl AE Gilteritinib or chemotherapy for relapsed or refractory FLT3 -mutated AML N. Engl. J. Med. 2019 381 1728 1740 10.1056/NEJMoa1902688 31665578 Perl, A. E. et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3 -mutated AML. N. Engl. J. Med. 381 , 1728–1740 (2019). 31665578 10.1056/NEJMoa1902688

11. Perl AE Follow-up of patients with R/R FLT3- mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial Blood 2022 139 3366 3375 10.1182/blood.2021011583 35081255 PMC9197557 Perl, A. E. et al. Follow-up of patients with R/R FLT3- mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood 139 , 3366–3375 (2022). 35081255 10.1182/blood.2021011583 PMC9197557

12. Montesinos P Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia N. Engl. J. Med. 2022 386 1519 1531 10.1056/NEJMoa2117344 35443108 Montesinos, P. et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N. Engl. J. Med. 386 , 1519–1531 (2022). 35443108 10.1056/NEJMoa2117344

13. Perl AE The role of targeted therapy in the management of patients with AML Blood Adv. 2017 1 2281 2294 10.1182/bloodadvances.2017009829 29296877 PMC5737125 Perl, A. E. The role of targeted therapy in the management of patients with AML. Blood Adv. 1 , 2281–2294 (2017). 29296877 10.1182/bloodadvances.2017009829 PMC5737125

14. Döhner H Weisdorf DJ Bloomfield CD Acute myeloid leukemia N. Engl. J. Med. 2015 373 1136 1152 10.1056/NEJMra1406184 26376137 Döhner, H., Weisdorf, D. J. & Bloomfield, C. D. Acute myeloid leukemia. N. Engl. J. Med. 373 , 1136–1152 (2015). 26376137 10.1056/NEJMra1406184

15. Jen W Combination therapy with novel agents for acute myeloid leukaemia: insights into treatment of a heterogenous disease Br. J. Haematol. 2024 205 30 47 10.1111/bjh.19519 38724457 PMC12068000 Jen, W. et al. Combination therapy with novel agents for acute myeloid leukaemia: insights into treatment of a heterogenous disease. Br. J. Haematol. 205 , 30–47 (2024). 38724457 10.1111/bjh.19519 PMC12068000

16. Löwenberg B High-dose daunorubicin in older patients with acute myeloid leukemia N. Engl. J. Med. 2009 361 1235 1248 10.1056/NEJMoa0901409 19776405 Löwenberg, B. et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N. Engl. J. Med. 361 , 1235–1248 (2009). 19776405 10.1056/NEJMoa0901409

17. Shlush LI Tracing the origins of relapse in acute myeloid leukaemia to stem cells Nature 2017 547 104 108 10.1038/nature22993 28658204 Shlush, L. I. et al. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature 547 , 104–108 (2017). 28658204 10.1038/nature22993

18. Ganzel C Very poor long-term survival in past and more recent studies for relapsed AML patients: the ECOG-ACRIN experience Am. J. Hematol. 2018 93 1074 1081 10.1002/ajh.25162 29905379 PMC6699929 Ganzel, C. et al. Very poor long-term survival in past and more recent studies for relapsed AML patients: the ECOG-ACRIN experience. Am. J. Hematol. 93 , 1074–1081 (2018). 29905379 10.1002/ajh.25162 PMC6699929

19. Witkowski MT Lasry A Carroll WL Aifantis I Immune-based therapies in acute leukemia Trends Cancer 2019 5 604 618 10.1016/j.trecan.2019.07.009 31706508 PMC6859901 Witkowski, M. T., Lasry, A., Carroll, W. L. & Aifantis, I. Immune-based therapies in acute leukemia. Trends Cancer 5 , 604–618 (2019). 31706508 10.1016/j.trecan.2019.07.009 PMC6859901

20. De Kouchkovsky I Abdul-Hay M Acute myeloid leukemia: a comprehensive review and 2016 update’ Blood Cancer J. 2016 6 e441 e441 10.1038/bcj.2016.50 27367478 PMC5030376 De Kouchkovsky, I. & Abdul-Hay, M. Acute myeloid leukemia: a comprehensive review and 2016 update’. Blood Cancer J. 6 , e441–e441 (2016). 27367478 10.1038/bcj.2016.50 PMC5030376

21. Zeidan AM Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial Lancet Haematol. 2024 11 e38 e50 10.1016/S2352-3026(23)00333-2 38065203 Zeidan, A. M. et al. Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 11 , e38–e50 (2024). 38065203 10.1016/S2352-3026(23)00333-2

22. Daver N Alotaibi AS Bücklein V Subklewe M T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments Leukemia 2021 35 1843 1863 10.1038/s41375-021-01253-x 33953290 PMC8257483 Daver, N., Alotaibi, A. S., Bücklein, V. & Subklewe, M. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia 35 , 1843–1863 (2021). 33953290 10.1038/s41375-021-01253-x PMC8257483

23. Lane AA Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia Blood Adv. 2024 8 591 602 10.1182/bloodadvances.2023011721 38052038 PMC10837492 Lane, A. A. et al. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Adv. 8 , 591–602 (2024). 38052038 10.1182/bloodadvances.2023011721 PMC10837492

24. Ranieri R Current status and future perspectives in targeted therapy of NPM1-mutated AML Leukemia 2022 36 2351 2367 10.1038/s41375-022-01666-2 36008542 PMC9522592 Ranieri, R. et al. Current status and future perspectives in targeted therapy of NPM1-mutated AML. Leukemia 36 , 2351–2367 (2022). 36008542 10.1038/s41375-022-01666-2 PMC9522592

25. Issa GC Therapeutic implications of menin inhibition in acute leukemias Leukemia 2021 35 2482 2495 10.1038/s41375-021-01309-y 34131281 Issa, G. C. et al. Therapeutic implications of menin inhibition in acute leukemias. Leukemia 35 , 2482–2495 (2021). 34131281 10.1038/s41375-021-01309-y

26. June CH Sadelain M Chimeric antigen receptor therapy. N. Engl. J. Med. 2018 379 64 73 10.1056/NEJMra1706169 29972754 PMC7433347 June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379 , 64–73 (2018). 29972754 10.1056/NEJMra1706169 PMC7433347

27. June CH Blazar BR Riley JL Engineering lymphocyte subsets: tools, trials and tribulations Nat. Rev. Immunol. 2009 9 704 716 10.1038/nri2635 19859065 PMC3412112 June, C. H., Blazar, B. R. & Riley, J. L. Engineering lymphocyte subsets: tools, trials and tribulations. Nat. Rev. Immunol. 9 , 704–716 (2009). 19859065 10.1038/nri2635 PMC3412112

28. Sadelain M Rivière I Riddell S Therapeutic T cell engineering Nature 2017 545 423 431 10.1038/nature22395 28541315 PMC5632949 Sadelain, M., Rivière, I. & Riddell, S. Therapeutic T cell engineering. Nature 545 , 423–431 (2017). 28541315 10.1038/nature22395 PMC5632949

29. Uslu U Castelli S June CH CAR T cell combination therapies to treat cancer Cancer Cell 2024 42 1319 1325 10.1016/j.ccell.2024.07.002 39059390 Uslu, U., Castelli, S. & June, C. H. CAR T cell combination therapies to treat cancer. Cancer Cell 42 , 1319–1325 (2024). 39059390 10.1016/j.ccell.2024.07.002

30. Hudecek M The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity Cancer Immunol. Res. 2015 3 125 135 10.1158/2326-6066.CIR-14-0127 25212991 PMC4692801 Hudecek, M. et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol. Res. 3 , 125–135 (2015). 25212991 10.1158/2326-6066.CIR-14-0127 PMC4692801

31. Maus MV Grupp SA Porter DL June CH Antibody derivatives as new therapeutics for hematologic antibody-modified T cells: CARs take the front seat for matologic malignancies Blood 2014 123 2625 2635 10.1182/blood-2013-11-492231 24578504 PMC3999751 Maus, M. V., Grupp, S. A., Porter, D. L. & June, C. H. Antibody derivatives as new therapeutics for hematologic antibody-modified T cells: CARs take the front seat for matologic malignancies. Blood 123 , 2625–2635 (2014). 24578504 10.1182/blood-2013-11-492231 PMC3999751

32. Barrett DM Grupp SA June CH Chimeric antigen receptor- and TCR-modified T cells enter main street and wall street J. Immunol. 2015 195 755 761 10.4049/jimmunol.1500751 26188068 PMC4507286 Barrett, D. M., Grupp, S. A. & June, C. H. Chimeric antigen receptor- and TCR-modified T cells enter main street and wall street. J. Immunol. 195 , 755–761 (2015). 26188068 10.4049/jimmunol.1500751 PMC4507286

33. June CH O’Connor RS Kawalekar OU Ghassemi S Milone MC CAR T cell immunotherapy for human cancer Science 2018 359 1361 1365 10.1126/science.aar6711 29567707 June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359 , 1361–1365 (2018). 29567707 10.1126/science.aar6711

34. Guedan S Ruella M June CH Emerging cellular therapies for cancer Annu. Rev. Immunol. 2019 37 145 171 10.1146/annurev-immunol-042718-041407 30526160 PMC7399614 Guedan, S., Ruella, M. & June, C. H. Emerging cellular therapies for cancer. Annu. Rev. Immunol. 37 , 145–171 (2019). 30526160 10.1146/annurev-immunol-042718-041407 PMC7399614

35. Marvin-Peek J Savani BN Olalekan OO Dholaria B Challenges and advances in chimeric antigen receptor therapy for acute myeloid leukemia Cancers 2022 14 497 10.3390/cancers14030497 35158765 PMC8833567 Marvin-Peek, J., Savani, B. N., Olalekan, O. O. & Dholaria, B. Challenges and advances in chimeric antigen receptor therapy for acute myeloid leukemia. Cancers 14 , 497 (2022). 35158765 10.3390/cancers14030497 PMC8833567

36. Chang ZL Hou AJ Chen YY Engineering primary T cells with chimeric antigen receptors for rewired responses to soluble ligands Nat. Protoc. 2020 15 1507 1524 10.1038/s41596-020-0294-8 32103205 PMC7430204 Chang, Z. L., Hou, A. J. & Chen, Y. Y. Engineering primary T cells with chimeric antigen receptors for rewired responses to soluble ligands. Nat. Protoc. 15 , 1507–1524 (2020). 32103205 10.1038/s41596-020-0294-8 PMC7430204

37. Sterner RC Sterner RM CAR-T cell therapy: current limitations and potential strategies Blood Cancer J. 2021 11 69 10.1038/s41408-021-00459-7 33824268 PMC8024391 Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11 , 69 (2021). 33824268 10.1038/s41408-021-00459-7 PMC8024391

38. Irving BA Weiss A The cytoplasmic domain of the T cell receptor chain is sufficient to couple to receptor-associated signal transduction pathways Cell 1991 64 891 901 10.1016/0092-8674(91)90314-O 1705867 Irving, B. A. & Weiss, A. The cytoplasmic domain of the T cell receptor chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 64 , 891–901 (1991). 1705867 10.1016/0092-8674(91)90314-o

39. Sadelain M Rivière I Brentjens R Targeting tumours with genetically enhanced T lymphocytes Nat. Rev. Cancer 2003 3 35 45 10.1038/nrc971 12509765 Sadelain, M., Rivière, I. & Brentjens, R. Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer 3 , 35–45 (2003). 12509765 10.1038/nrc971

40. Brocker T Chimeric Fv-ζ or Fv-ε receptors are not sufficient to induce activation or cytokine production in peripheral T cells Blood 2000 96 1999 2001 10.1182/blood.V96.5.1999 10961908 Brocker, T. Chimeric Fv-ζ or Fv-ε receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood 96 , 1999–2001 (2000). 10961908

41. Lamers CHJ Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience J. Clin. Oncol. 2006 24 e20 e22 10.1200/JCO.2006.05.9964 16648493 Lamers, C. H. J. et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24 , e20–e22 (2006). 16648493 10.1200/JCO.2006.05.9964

42. Stancovski I Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors J. Immunol. 1993 151 6577 6582 10.4049/jimmunol.151.11.6577 7902379 Stancovski, I. et al. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J. Immunol. 151 , 6577–6582 (1993). 7902379

43. Moritz D Wels W Mattern J Groner B Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells Proc. Natl. Acad. Sci. USA 1994 91 4318 4322 10.1073/pnas.91.10.4318 7910405 PMC43776 Moritz, D., Wels, W., Mattern, J. & Groner, B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc. Natl. Acad. Sci. USA 91 , 4318–4322 (1994). 7910405 10.1073/pnas.91.10.4318 PMC43776

44. Kershaw MH A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer Clin. Cancer Res. 2006 12 6106 6115 10.1158/1078-0432.CCR-06-1183 17062687 PMC2154351 Kershaw, M. H. et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12 , 6106–6115 (2006). 17062687 10.1158/1078-0432.CCR-06-1183 PMC2154351

45. Eshhar Z Waks T Gross G Schindler DG Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors Proc. Natl. Acad. Sci. USA 1993 90 720 724 10.1073/pnas.90.2.720 8421711 PMC45737 Eshhar, Z., Waks, T., Gross, G. & Schindler, D. G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA 90 , 720–724 (1993). 8421711 10.1073/pnas.90.2.720 PMC45737

46. Sadelain M Brentjens R Rivière I The basic principles of chimeric antigen receptor design Cancer Discov. 2013 3 388 398 10.1158/2159-8290.CD-12-0548 23550147 PMC3667586 Sadelain, M., Brentjens, R. & Rivière, I. The basic principles of chimeric antigen receptor design. Cancer Discov. 3 , 388–398 (2013). 23550147 10.1158/2159-8290.CD-12-0548 PMC3667586

47. Chen L Flies DB Molecular mechanisms of T cell co-stimulation and co-inhibition Nat. Rev. Immunol. 2013 13 227 242 10.1038/nri3405 23470321 PMC3786574 Chen, L. & Flies, D. B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13 , 227–242 (2013). 23470321 10.1038/nri3405 PMC3786574

48. Haynes NM Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors Blood 2002 100 3155 3163 10.1182/blood-2002-04-1041 12384413 Haynes, N. M. et al. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 100 , 3155–3163 (2002). 12384413 10.1182/blood-2002-04-1041

49. Imai C Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia Leukemia 2004 18 676 684 10.1038/sj.leu.2403302 14961035 Imai, C. et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18 , 676–684 (2004). 14961035 10.1038/sj.leu.2403302

50. Guedan, S. et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight 3 , e96976 (2018). 10.1172/jci.insight.96976 PMC5821198 29321369

51. Hombach AA Heiders J Foppe M Chmielewski M Abken H OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4 + T cells Oncoimmunology 2012 1 458 466 10.4161/onci.19855 22754764 PMC3382912 Hombach, A. A., Heiders, J., Foppe, M., Chmielewski, M. & Abken, H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4 + T cells. Oncoimmunology 1 , 458–466 (2012). 22754764 10.4161/onci.19855 PMC3382912

52. Collinson-Pautz MR Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies Leukemia 2019 33 2195 2207 10.1038/s41375-019-0417-9 30816327 PMC6756044 Collinson-Pautz, M. R. et al. Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies. Leukemia 33 , 2195–2207 (2019). 30816327 10.1038/s41375-019-0417-9 PMC6756044

53. Chmielewski M Abken H TRUCKs: the fourth generation of CARs Expert Opin. Biol. Ther. 2015 15 1145 1154 10.1517/14712598.2015.1046430 25985798 Chmielewski, M. & Abken, H. TRUCKs: the fourth generation of CARs. Expert Opin. Biol. Ther. 15 , 1145–1154 (2015). 25985798 10.1517/14712598.2015.1046430

54. Chang ZL Chen YY CARs: synthetic immunoreceptors for cancer therapy and beyond Trends Mol. Med. 2017 23 430 450 10.1016/j.molmed.2017.03.002 28416139 PMC5423782 Chang, Z. L. & Chen, Y. Y. CARs: synthetic immunoreceptors for cancer therapy and beyond. Trends Mol. Med. 23 , 430–450 (2017). 28416139 10.1016/j.molmed.2017.03.002 PMC5423782

55. Cappell, K.M. & Kochenderfer, J.N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20 , 359–371 (2023). 10.1038/s41571-023-00754-1 PMC10100620 37055515

56. Lim WA June CH The principles of engineering immune cells to treat cancer Cell 2017 168 724 740 10.1016/j.cell.2017.01.016 28187291 PMC5553442 Lim, W. A. & June, C. H. The principles of engineering immune cells to treat cancer. Cell 168 , 724–740 (2017). 28187291 10.1016/j.cell.2017.01.016 PMC5553442

57. Falgàs, A. et al. A TIM-3-Fc decoy secreted by engineered T cells improves CD19 CAR-T cell therapy in B cell acute lymphoblastic leukemia. [Manuscript submitted for publication]. Blood (2025). 10.1182/blood.2024025440 40090006

58. Hong M Clubb JD Chen YY Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell 2020 38 473 488 10.1016/j.ccell.2020.07.005 32735779 Hong, M., Clubb, J. D. & Chen, Y. Y. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell 38 , 473–488 (2020). 32735779 10.1016/j.ccell.2020.07.005

59. Asmamaw Dejenie, T. et al. Current updates on generations, approvals, and clinical trials of CAR T-cell therapy. Hum. Vaccin. Immunother. 18 , 2036528 (2022). 10.1080/21645515.2022.2114254 PMC9746433 36094837

60. Tokarew N Ogonek J Endres S von Bergwelt-Baildon M Kobold S Teaching an old dog new tricks: next-generation CAR T cells Br. J. Cancer 2019 120 26 37 10.1038/s41416-018-0325-1 30413825 PMC6325111 Tokarew, N., Ogonek, J., Endres, S., von Bergwelt-Baildon, M. & Kobold, S. Teaching an old dog new tricks: next-generation CAR T cells. Br. J. Cancer 120 , 26–37 (2019). 30413825 10.1038/s41416-018-0325-1 PMC6325111

61. Kagoya Y A novel chimeric antigen receptor containing a JAK–STAT signaling domain mediates superior antitumor effects Nat. Med. 2018 24 352 359 10.1038/nm.4478 29400710 PMC5839992 Kagoya, Y. et al. A novel chimeric antigen receptor containing a JAK–STAT signaling domain mediates superior antitumor effects. Nat. Med. 24 , 352–359 (2018). 29400710 10.1038/nm.4478 PMC5839992

62. Li D Genetically engineered T cells for cancer immunotherapy Signal Transduct. Target Ther. 2019 4 35 10.1038/s41392-019-0070-9 31637014 PMC6799837 Li, D. et al. Genetically engineered T cells for cancer immunotherapy. Signal Transduct. Target Ther. 4 , 35 (2019). 31637014 10.1038/s41392-019-0070-9 PMC6799837

63. Zhang J Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL Nature 2022 609 369 374 10.1038/s41586-022-05140-y 36045296 PMC9452296 Zhang, J. et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature 609 , 369–374 (2022). 36045296 10.1038/s41586-022-05140-y PMC9452296

64. Rupp LJ CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells Sci. Rep. 2017 7 737 10.1038/s41598-017-00462-8 28389661 PMC5428439 Rupp, L. J. et al. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci. Rep. 7 , 737 (2017). 28389661 10.1038/s41598-017-00462-8 PMC5428439

65. Jacobson CA Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial Lancet Oncol. 2022 23 91 103 10.1016/S1470-2045(21)00591-X 34895487 Jacobson, C. A. et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 23 , 91–103 (2022). 34895487 10.1016/S1470-2045(21)00591-X

66. San-Miguel J Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl. J. Med. 2023 389 335 347 10.1056/NEJMoa2303379 37272512 San-Miguel, J. et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl. J. Med. 389 , 335–347 (2023). 37272512 10.1056/NEJMoa2303379

67. Rafiq S Hackett CS Brentjens RJ Engineering strategies to overcome the current roadblocks in CAR T cell therapy Nat. Rev. Clin. Oncol. 2020 17 147 167 10.1038/s41571-019-0297-y 31848460 PMC7223338 Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat. Rev. Clin. Oncol. 17 , 147–167 (2020). 31848460 10.1038/s41571-019-0297-y PMC7223338

68. Labanieh L Majzner RG Mackall CL Programming CAR-T cells to kill cancer Nat. Biomed. Eng. 2018 2 377 391 10.1038/s41551-018-0235-9 31011197 Labanieh, L., Majzner, R. G. & Mackall, C. L. Programming CAR-T cells to kill cancer. Nat. Biomed. Eng. 2 , 377–391 (2018). 31011197 10.1038/s41551-018-0235-9

69. Miller JF Immunological function of the thymus Lancet 1961 2 748 749 10.1016/S0140-6736(61)90693-6 14474038 Miller, J. F. Immunological function of the thymus. Lancet 2 , 748–749 (1961). 14474038 10.1016/s0140-6736(61)90693-6

70. Miller JF Analysis of the thymus influence in leukaemogenesis Nature 1961 191 248 249 10.1038/191248a0 13770811 Miller, J. F. Analysis of the thymus influence in leukaemogenesis. Nature 191 , 248–249 (1961). 13770811 10.1038/191248a0

71. Finn OJ Human tumor antigens yesterday, today, and tomorrow Cancer Immunol. Res 2017 5 347 354 10.1158/2326-6066.CIR-17-0112 28465452 PMC5490447 Finn, O. J. Human tumor antigens yesterday, today, and tomorrow. Cancer Immunol. Res 5 , 347–354 (2017). 28465452 10.1158/2326-6066.CIR-17-0112 PMC5490447

72. Rosenberg SA Spiess P Lafreniere R A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes Science 1986 233 1318 1321 10.1126/science.3489291 3489291 Rosenberg, S. A., Spiess, P. & Lafreniere, R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233 , 1318–1321 (1986). 3489291 10.1126/science.3489291

73. Rosenberg SA Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report N. Engl. J. Med. 1988 319 1676 1680 10.1056/NEJM198812223192527 3264384 Rosenberg, S. A. et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319 , 1676–1680 (1988). 3264384 10.1056/NEJM198812223192527

74. Rosenberg SA Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2 J. Natl Cancer Inst. 1994 86 1159 1166 10.1093/jnci/86.15.1159 8028037 Rosenberg, S. A. et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl Cancer Inst. 86 , 1159–1166 (1994). 8028037 10.1093/jnci/86.15.1159

75. Kuwana Y Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions Biochem. Biophys. Res Commun. 1987 149 960 968 10.1016/0006-291X(87)90502-X 3122749 Kuwana, Y. et al. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem. Biophys. Res Commun. 149 , 960–968 (1987). 3122749 10.1016/0006-291x(87)90502-x

76. Gross G Waks T Eshhar Z Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity Proc. Natl. Acad. Sci. USA 1989 86 10024 10028 10.1073/pnas.86.24.10024 2513569 PMC298636 Gross, G., Waks, T. & Eshhar, Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl. Acad. Sci. USA 86 , 10024–10028 (1989). 2513569 10.1073/pnas.86.24.10024 PMC298636

77. El Khawanky N Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia Nat. Commun. 2021 12 6436 10.1038/s41467-021-26683-0 34750374 PMC8575966 El Khawanky, N. et al. Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. Nat. Commun. 12 , 6436 (2021). 34750374 10.1038/s41467-021-26683-0 PMC8575966

78. Hege KM Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer J. Immunother. Cancer 2017 5 22 10.1186/s40425-017-0222-9 28344808 PMC5360066 Hege, K. M. et al. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J. Immunother. Cancer 5 , 22 (2017). 28344808 10.1186/s40425-017-0222-9 PMC5360066

79. Gallardo HF Tan C Ory D Sadelain M Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes Blood 1997 90 952 957 10.1182/blood.V90.3.952 9242523 Gallardo, H. F., Tan, C., Ory, D. & Sadelain, M. Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes. Blood 90 , 952–957 (1997). 9242523

80. Krause A Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes J. Exp. Med 1998 188 619 626 10.1084/jem.188.4.619 9705944 PMC2213361 Krause, A. et al. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J. Exp. Med 188 , 619–626 (1998). 9705944 10.1084/jem.188.4.619 PMC2213361

81. Thompson CB CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines Proc. Natl. Acad. Sci. USA 1989 86 1333 1337 10.1073/pnas.86.4.1333 2465550 PMC286684 Thompson, C. B. et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc. Natl. Acad. Sci. USA 86 , 1333–1337 (1989). 2465550 10.1073/pnas.86.4.1333 PMC286684

82. Maher J Brentjens RJ Gunset G Rivière I Sadelain M Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor Nat. Biotechnol. 2002 20 70 75 10.1038/nbt0102-70 11753365 Maher, J., Brentjens, R. J., Gunset, G., Rivière, I. & Sadelain, M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat. Biotechnol. 20 , 70–75 (2002). 11753365 10.1038/nbt0102-70

83. Finney HM Lawson AD Bebbington CR Weir AN Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product J. Immunol. 1998 161 2791 2797 10.4049/jimmunol.161.6.2791 9743337 Finney, H. M., Lawson, A. D., Bebbington, C. R. & Weir, A. N. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol. 161 , 2791–2797 (1998). 9743337

84. Brentjens RJ Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 Nat. Med 2003 9 279 286 10.1038/nm827 12579196 Brentjens, R. J. et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med 9 , 279–286 (2003). 12579196 10.1038/nm827

85. Hoyos V Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety Leukemia 2010 24 1160 1170 10.1038/leu.2010.75 20428207 PMC2888148 Hoyos, V. et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 24 , 1160–1170 (2010). 20428207 10.1038/leu.2010.75 PMC2888148

86. Kochenderfer JN Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor J. Immunother. 2009 32 689 702 10.1097/CJI.0b013e3181ac6138 19561539 PMC2747302 Kochenderfer, J. N. et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J. Immunother. 32 , 689–702 (2009). 19561539 10.1097/CJI.0b013e3181ac6138 PMC2747302

87. Milone MC Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo Mol. Ther. 2009 17 1453 1464 10.1038/mt.2009.83 19384291 PMC2805264 Milone, M. C. et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17 , 1453–1464 (2009). 19384291 10.1038/mt.2009.83 PMC2805264

88. Hollyman D Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy J. Immunother. 2009 32 169 180 10.1097/CJI.0b013e318194a6e8 19238016 PMC2683970 Hollyman, D. et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J. Immunother. 32 , 169–180 (2009). 19238016 10.1097/CJI.0b013e318194a6e8 PMC2683970

89. Kohn DB CARs on track in the clinic Mol. Ther. 2011 19 432 438 10.1038/mt.2011.1 21358705 PMC3048197 Kohn, D. B. et al. CARs on track in the clinic. Mol. Ther. 19 , 432–438 (2011). 21358705 10.1038/mt.2011.1 PMC3048197

90. Kochenderfer JN Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 Blood 2010 116 4099 4102 10.1182/blood-2010-04-281931 20668228 PMC2993617 Kochenderfer, J. N. et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116 , 4099–4102 (2010). 20668228 10.1182/blood-2010-04-281931 PMC2993617

91. Kalos M T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia Sci. Transl. Med 2011 3 95ra73 10.1126/scitranslmed.3002842 21832238 PMC3393096 Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med 3 , 95ra73 (2011). 21832238 10.1126/scitranslmed.3002842 PMC3393096

92. Porter DL Levine BL Kalos M Bagg A June CH Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia N. Engl. J. Med 2011 365 725 733 10.1056/NEJMoa1103849 21830940 PMC3387277 Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med 365 , 725–733 (2011). 21830940 10.1056/NEJMoa1103849 PMC3387277

93. Brentjens RJ Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias Blood 2011 118 4817 4828 10.1182/blood-2011-04-348540 21849486 PMC3208293 Brentjens, R. J. et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118 , 4817–4828 (2011). 21849486 10.1182/blood-2011-04-348540 PMC3208293

94. Brentjens RJ CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia Sci. Transl. Med. 2013 5 177ra38 10.1126/scitranslmed.3005930 23515080 PMC3742551 Brentjens, R. J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5 , 177ra38 (2013). 23515080 10.1126/scitranslmed.3005930 PMC3742551

95. Grupp SA Chimeric antigen receptor-modified T cells for acute lymphoid leukemia N. Engl. J. Med 2013 368 1509 1518 10.1056/NEJMoa1215134 23527958 PMC4058440 Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med 368 , 1509–1518 (2013). 23527958 10.1056/NEJMoa1215134 PMC4058440

96. Schneider, M. Carl June, first year Emily Whitehead reflect on experiences with Penn-pioneered cancer treatment. The Daily Pennsylvanian (2024).

97. Jain MD Smith M Shah NN How I treat refractory CRS and ICANS after CAR T-cell therapy Blood 2023 141 2430 2442 36989488 10.1182/blood.2022017414 PMC10329191 Jain, M. D., Smith, M. & Shah, N. N. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood 141 , 2430–2442 (2023). 36989488 10.1182/blood.2022017414 PMC10329191

98. Kotch C Barrett D Teachey DT Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome Expert Rev. Clin. Immunol. 2019 15 813 822 10.1080/1744666X.2019.1629904 31219357 PMC7936577 Kotch, C., Barrett, D. & Teachey, D. T. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev. Clin. Immunol. 15 , 813–822 (2019). 31219357 10.1080/1744666X.2019.1629904 PMC7936577

99. Romano J Wilsterman E Toal M Joyce C Cytokine Release Syndrome in the Pediatric Population and Implications for Intensive Care Management Crit. Care Clin. 2023 39 277 285 10.1016/j.ccc.2022.09.004 36898773 Romano, J., Wilsterman, E., Toal, M. & Joyce, C. Cytokine Release Syndrome in the Pediatric Population and Implications for Intensive Care Management. Crit. Care Clin. 39 , 277–285 (2023). 36898773 10.1016/j.ccc.2022.09.004

100. McNerney KO INSPIRED symposium part 3: prevention and management of pediatric chimeric antigen receptor T Cell-associated emergent toxicities Transpl. Cell Ther. 2024 30 38 55 10.1016/j.jtct.2023.10.006 PMC10842156 37821079 McNerney, K. O. et al. INSPIRED symposium part 3: prevention and management of pediatric chimeric antigen receptor T Cell-associated emergent toxicities. Transpl. Cell Ther. 30 , 38–55 (2024). 10.1016/j.jtct.2023.10.006 PMC10842156 37821079

101. Maude SL Chimeric antigen receptor T cells for sustained remissions in leukemia N. Engl. J. Med 2014 371 1507 1517 10.1056/NEJMoa1407222 25317870 PMC4267531 Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med 371 , 1507–1517 (2014). 25317870 10.1056/NEJMoa1407222 PMC4267531

102. Park JH Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia N. Engl. J. Med. 2018 378 449 459 10.1056/NEJMoa1709919 29385376 PMC6637939 Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378 , 449–459 (2018). 29385376 10.1056/NEJMoa1709919 PMC6637939

103. Kochenderfer JN B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells Blood 2012 119 2709 2720 10.1182/blood-2011-10-384388 22160384 PMC3327450 Kochenderfer, J. N. et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119 , 2709–2720 (2012). 22160384 10.1182/blood-2011-10-384388 PMC3327450

104. Porter DL Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia Sci. Transl. Med. 2015 7 303ra139 10.1126/scitranslmed.aac5415 26333935 PMC5909068 Porter, D. L. et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7 , 303ra139 (2015). 26333935 10.1126/scitranslmed.aac5415 PMC5909068

105. University of Pennsylvania. University of Pennsylvania and Novartis Form Alliance to Expand Use of Personalized T Cell Therapy for Cancer Patients. University of Pennsylvania and Penn Medicine announce breakthrough in the treatment of a rare genetic disease. Penn Medicine https://www.pennmedicine.org/news/news-releases/2012/august/university-of-pennsylvania-and (2012).

106. Costandi M Kite and NCI partner on T cells Nat. Biotechnol. 2013 31 10 10 10.1038/nbt0113-10a Costandi, M. Kite and NCI partner on T cells. Nat. Biotechnol. 31 , 10–10 (2013).23302918

107. Memorial Sloan Kettering Cancer Center. New biotech startup will pit immune system against cancer with cutting-edge gene therapy. Memorial Sloan Kettering Cancer Center https://www.mskcc.org/news/new-biotech-startup-will-pit-immune-system-against (2020).

108. Braendstrup P Levine BL Ruella M The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19 Cytotherapy 2020 22 57 69 10.1016/j.jcyt.2019.12.004 32014447 PMC7036015 Braendstrup, P., Levine, B. L. & Ruella, M. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. Cytotherapy 22 , 57–69 (2020). 32014447 10.1016/j.jcyt.2019.12.004 PMC7036015

109. Maude SL Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia N. Engl. J. Med. 2018 378 439 448 10.1056/NEJMoa1709866 29385370 PMC5996391 Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378 , 439–448 (2018). 29385370 10.1056/NEJMoa1709866 PMC5996391

110. Neelapu SS Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma N. Engl. J. Med. 2017 377 2531 2544 10.1056/NEJMoa1707447 29226797 PMC5882485 Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377 , 2531–2544 (2017). 29226797 10.1056/NEJMoa1707447 PMC5882485

111. Fowler NH Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial Nat. Med. 2022 28 325 332 10.1038/s41591-021-01622-0 34921238 Fowler, N. H. et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat. Med. 28 , 325–332 (2022). 34921238 10.1038/s41591-021-01622-0

112. Schuster SJ Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma N. Engl. J. Med. 2019 380 45 56 10.1056/NEJMoa1804980 30501490 Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380 , 45–56 (2019). 30501490 10.1056/NEJMoa1804980

113. Locke FL Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial Lancet Oncol. 2019 20 31 42 10.1016/S1470-2045(18)30864-7 30518502 PMC6733402 Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 20 , 31–42 (2019). 30518502 10.1016/S1470-2045(18)30864-7 PMC6733402

114. Frey NV Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia Blood 2022 140 11 15 10.1182/blood.2021014892 35507688 Frey, N. V. Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia. Blood 140 , 11–15 (2022). 35507688 10.1182/blood.2021014892

115. Bouchkouj N FDA approval summary: brexucabtagene autoleucel for treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia Oncologist 2022 27 892 899 10.1093/oncolo/oyac163 35983953 PMC9526496 Bouchkouj, N. et al. FDA approval summary: brexucabtagene autoleucel for treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Oncologist 27 , 892–899 (2022). 35983953 10.1093/oncolo/oyac163 PMC9526496

116. Sehgal AR Lisocabtagene maraleucel (liso-cel) for treatment of second-line (2L) transplant noneligible (TNE) relapsed/refractory (R/R) aggressive large B-cell non-Hodgkin lymphoma (NHL): Updated results from the PILOT study J. Clin. Oncol. 2020 38 8040 8040 10.1200/JCO.2020.38.15_suppl.8040 Sehgal, A. R. et al. Lisocabtagene maraleucel (liso-cel) for treatment of second-line (2L) transplant noneligible (TNE) relapsed/refractory (R/R) aggressive large B-cell non-Hodgkin lymphoma (NHL): Updated results from the PILOT study. J. Clin. Oncol. 38 , 8040–8040 (2020).

117. Abramson JS Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study Lancet 2020 396 839 852 10.1016/S0140-6736(20)31366-0 32888407 Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396 , 839–852 (2020). 32888407 10.1016/S0140-6736(20)31366-0

118. Munshi NC Idecabtagene vicleucel in relapsed and refractory multiple myeloma N. Engl. J. Med. 2021 384 705 716 10.1056/NEJMoa2024850 33626253 Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384 , 705–716 (2021). 33626253 10.1056/NEJMoa2024850

119. Chekol Abebe, E., Yibeltal Shiferaw, M., Tadele Admasu, F. & Asmamaw Dejenie, T. Ciltacabtagene autoleucel: the second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. Front. Immunol. 13 , 1007515 (2022). 10.3389/fimmu.2022.991092 PMC9479060 36119032

120. Martin T Ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up J. Clin. Oncol. 2022 41 1265 1274 10.1200/JCO.22.00842 35658469 PMC9937098 Martin, T. et al. Ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J. Clin. Oncol. 41 , 1265–1274 (2022). 35658469 10.1200/JCO.22.00842 PMC9937098

121. Narayan V PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial Nat. Med. 2022 28 724 734 10.1038/s41591-022-01726-1 35314843 PMC10308799 Narayan, V. et al. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat. Med. 28 , 724–734 (2022). 35314843 10.1038/s41591-022-01726-1 PMC10308799

122. Haas AR Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers Mol. Ther. 2019 27 1919 1929 10.1016/j.ymthe.2019.07.015 31420241 PMC6838875 Haas, A. R. et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. Mol. Ther. 27 , 1919–1929 (2019). 31420241 10.1016/j.ymthe.2019.07.015 PMC6838875

123. O’Rourke, D. M. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. 9 , eaag3518 (2017). 10.1126/scitranslmed.aaa0984 PMC5762203 28724573

124. Brown CE Regression of glioblastoma after chimeric antigen receptor T-cell therapy N. Engl. J. Med. 2016 375 2561 2569 10.1056/NEJMoa1610497 28029927 PMC5390684 Brown, C. E. et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 375 , 2561–2569 (2016). 28029927 10.1056/NEJMoa1610497 PMC5390684

125. Majzner RG GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas Nature 2022 603 934 941 10.1038/s41586-022-04489-4 35130560 PMC8967714 Majzner, R. G. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603 , 934–941 (2022). 35130560 10.1038/s41586-022-04489-4 PMC8967714

126. Qi C Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results Nat. Med. 2022 28 1189 1198 10.1038/s41591-022-01800-8 35534566 PMC9205778 Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat. Med. 28 , 1189–1198 (2022). 35534566 10.1038/s41591-022-01800-8 PMC9205778

127. Del Bufalo F GD2-CART01 for relapsed or refractory high-risk neuroblastoma N. Engl. J. Med. 2023 388 1284 1295 10.1056/NEJMoa2210859 37018492 Del Bufalo, F. et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N. Engl. J. Med. 388 , 1284–1295 (2023). 37018492 10.1056/NEJMoa2210859

128. Brudno JN Maus MV Hinrichs CS CAR T-cells and T-cell therapies for cancer: a translational science review JAMA 2024 332 1924 1935 10.1001/jama.2024.19462 39495525 PMC11808657 Brudno, J. N., Maus, M. V. & Hinrichs, C. S. CAR T-cells and T-cell therapies for cancer: a translational science review. JAMA 332 , 1924–1935 (2024). 39495525 10.1001/jama.2024.19462 PMC11808657

129. D’Angelo SP Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial Lancet 2024 403 1460 1471 10.1016/S0140-6736(24)00319-2 38554725 PMC11419333 D’Angelo, S. P. et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet 403 , 1460–1471 (2024). 38554725 10.1016/S0140-6736(24)00319-2 PMC11419333

130. Norberg SM Hinrichs CS Engineered T cell therapy for viral and non-viral epithelial cancers Cancer Cell 2023 41 58 69 10.1016/j.ccell.2022.10.016 36400016 PMC9839504 Norberg, S. M. & Hinrichs, C. S. Engineered T cell therapy for viral and non-viral epithelial cancers. Cancer Cell 41 , 58–69 (2023). 36400016 10.1016/j.ccell.2022.10.016 PMC9839504

131. Nagarsheth NB TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers Nat. Med. 2021 27 419 425 10.1038/s41591-020-01225-1 33558725 PMC9620481 Nagarsheth, N. B. et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat. Med. 27 , 419–425 (2021). 33558725 10.1038/s41591-020-01225-1 PMC9620481

132. Doran SL T-cell receptor gene therapy for human papillomavirus–associated epithelial cancers: a first-in-human, phase I/II study J. Clin. Oncol. 2019 37 2759 2768 10.1200/JCO.18.02424 31408414 PMC6800280 Doran, S. L. et al. T-cell receptor gene therapy for human papillomavirus–associated epithelial cancers: a first-in-human, phase I/II study. J. Clin. Oncol. 37 , 2759–2768 (2019). 31408414 10.1200/JCO.18.02424 PMC6800280

133. Diaz de la Guardia R Detailed characterization of mesenchymal stem/stromal cells from a large cohort of aml patients demonstrates a definitive link to treatment outcomes Stem Cell Rep. 2017 8 1573 1586 10.1016/j.stemcr.2017.04.019 PMC5470078 28528702 Diaz de la Guardia, R. et al. Detailed characterization of mesenchymal stem/stromal cells from a large cohort of aml patients demonstrates a definitive link to treatment outcomes. Stem Cell Rep. 8 , 1573–1586 (2017). 10.1016/j.stemcr.2017.04.019 PMC5470078 28528702

134. Vanhooren J CAR-T in the treatment of acute myeloid leukemia: barriers and how to overcome them Hemasphere 2023 7 e937 10.1097/HS9.0000000000000937 37674860 PMC10479376 Vanhooren, J. et al. CAR-T in the treatment of acute myeloid leukemia: barriers and how to overcome them. Hemasphere 7 , e937 (2023). 37674860 10.1097/HS9.0000000000000937 PMC10479376

135. Estey E Döhner H Acute myeloid leukaemia Lancet 2006 368 1894 1907 10.1016/S0140-6736(06)69780-8 17126723 Estey, E. & Döhner, H. Acute myeloid leukaemia. Lancet 368 , 1894–1907 (2006). 17126723 10.1016/S0140-6736(06)69780-8

136. Padmakumar D A concise review on the molecular genetics of acute myeloid leukemia Leuk. Res 2021 111 106727 10.1016/j.leukres.2021.106727 34700049 Padmakumar, D. et al. A concise review on the molecular genetics of acute myeloid leukemia. Leuk. Res 111 , 106727 (2021). 34700049 10.1016/j.leukres.2021.106727

137. Ediriwickrema A Gentles AJ Majeti R Single-cell genomics in AML: extending the frontiers of AML research Blood 2023 141 345 355 10.1182/blood.2021014670 35926108 PMC10082362 Ediriwickrema, A., Gentles, A. J. & Majeti, R. Single-cell genomics in AML: extending the frontiers of AML research. Blood 141 , 345–355 (2023). 35926108 10.1182/blood.2021014670 PMC10082362

138. Khoury JD The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms Leukemia 2022 36 1703 1719 10.1038/s41375-022-01613-1 35732831 PMC9252913 Khoury, J. D. et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia 36 , 1703–1719 (2022). 35732831 10.1038/s41375-022-01613-1 PMC9252913

139. Döhner H Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN Blood 2022 140 1345 1377 10.1182/blood.2022016867 35797463 Döhner, H. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140 , 1345–1377 (2022). 35797463 10.1182/blood.2022016867

140. Arber DA International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data Blood 2022 140 1200 1228 10.1182/blood.2022015850 35767897 PMC9479031 Arber, D. A. et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140 , 1200–1228 (2022). 35767897 10.1182/blood.2022015850 PMC9479031

141. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368 , 2059–2074 (2013). 10.1056/NEJMoa1301689 PMC3767041 23634996

142. Bonnet D Dick JE Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell Nat. Med. 1997 3 730 737 10.1038/nm0797-730 9212098 Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3 , 730–737 (1997). 9212098 10.1038/nm0797-730

143. Gentles AJ Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia JAMA 2010 304 2706 10.1001/jama.2010.1862 21177505 PMC4089862 Gentles, A. J. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA 304 , 2706 (2010). 21177505 10.1001/jama.2010.1862 PMC4089862

144. Thomas D Majeti R Biology and relevance of human acute myeloid leukemia stem cells Blood 2017 129 1577 1585 10.1182/blood-2016-10-696054 28159741 PMC5364335 Thomas, D. & Majeti, R. Biology and relevance of human acute myeloid leukemia stem cells. Blood 129 , 1577–1585 (2017). 28159741 10.1182/blood-2016-10-696054 PMC5364335

145. Morita K Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics Nat. Commun. 2020 11 5327 10.1038/s41467-020-19119-8 33087716 PMC7577981 Morita, K. et al. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat. Commun. 11 , 5327 (2020). 33087716 10.1038/s41467-020-19119-8 PMC7577981

146. Eppert K Stem cell gene expression programs influence clinical outcome in human leukemia Nat. Med. 2011 17 1086 1093 10.1038/nm.2415 21873988 Eppert, K. et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 17 , 1086–1093 (2011). 21873988 10.1038/nm.2415

147. Jiang L Multidimensional study of the heterogeneity of leukemia cells in t(8;21) acute myelogenous leukemia identifies the subtype with poor outcome Proc. Natl. Acad. Sci. USA 2020 117 20117 20126 10.1073/pnas.2003900117 32747558 PMC7443908 Jiang, L. et al. Multidimensional study of the heterogeneity of leukemia cells in t(8;21) acute myelogenous leukemia identifies the subtype with poor outcome. Proc. Natl. Acad. Sci. USA 117 , 20117–20126 (2020). 32747558 10.1073/pnas.2003900117 PMC7443908

148. Paczulla AM Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion Nature 2019 572 254 259 10.1038/s41586-019-1410-1 31316209 PMC6934414 Paczulla, A. M. et al. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature 572 , 254–259 (2019). 31316209 10.1038/s41586-019-1410-1 PMC6934414

149. Rickmann M Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication Ann. Hematol. 2011 90 1047 1058 10.1007/s00277-011-1231-2 21520003 PMC3150660 Rickmann, M. et al. Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication. Ann. Hematol. 90 , 1047–1058 (2011). 21520003 10.1007/s00277-011-1231-2 PMC3150660

150. Chen J-Y The oncometabolite R-2-hydroxyglutarate activates NF-κB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells Sci. Rep. 2016 6 32428 10.1038/srep32428 27577048 PMC5006242 Chen, J.-Y. et al. The oncometabolite R-2-hydroxyglutarate activates NF-κB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells. Sci. Rep. 6 , 32428 (2016). 27577048 10.1038/srep32428 PMC5006242

151. Sasaki M IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics Nature 2012 488 656 659 10.1038/nature11323 22763442 PMC4005896 Sasaki, M. et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 488 , 656–659 (2012). 22763442 10.1038/nature11323 PMC4005896

152. Brummer T Zeiser R The role of the MDM2/p53 axis in antitumor immune responses Blood 2024 143 2701 2709 10.1182/blood.2023020731 37467495 PMC11251213 Brummer, T. & Zeiser, R. The role of the MDM2/p53 axis in antitumor immune responses. Blood 143 , 2701–2709 (2024). 37467495 10.1182/blood.2023020731 PMC11251213

153. Daver NG TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions Cancer Discov. 2022 12 2516 2529 10.1158/2159-8290.CD-22-0332 36218325 PMC9627130 Daver, N. G. et al. TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions. Cancer Discov. 12 , 2516–2529 (2022). 36218325 10.1158/2159-8290.CD-22-0332 PMC9627130

154. Voskarides K Giannopoulou N The role of TP53 in adaptation and evolution Cells 2023 12 512 10.3390/cells12030512 36766853 PMC9914165 Voskarides, K. & Giannopoulou, N. The role of TP53 in adaptation and evolution. Cells 12 , 512 (2023). 36766853 10.3390/cells12030512 PMC9914165

155. McCurdy SR Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclophosphamide Leukemia 2016 30 2102 2106 10.1038/leu.2016.144 27211264 PMC5053847 McCurdy, S. R. et al. Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclophosphamide. Leukemia 30 , 2102–2106 (2016). 27211264 10.1038/leu.2016.144 PMC5053847

156. Crucitti L Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation Leukemia 2015 29 1143 1152 10.1038/leu.2014.314 25371177 Crucitti, L. et al. Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation. Leukemia 29 , 1143–1152 (2015). 25371177 10.1038/leu.2014.314

157. Vago L Loss of mismatched HLA in Leukemia after stem-cell transplantation N. Engl. J. Med. 2009 361 478 488 10.1056/NEJMoa0811036 19641204 Vago, L. et al. Loss of mismatched HLA in Leukemia after stem-cell transplantation. N. Engl. J. Med. 361 , 478–488 (2009). 19641204 10.1056/NEJMoa0811036

158. Binder S Luciano M Horejs-Hoeck J The cytokine network in acute myeloid leukemia (AML): a focus on pro- and anti-inflammatory mediators Cytokine Growth Factor Rev. 2018 43 8 15 10.1016/j.cytogfr.2018.08.004 30181021 Binder, S., Luciano, M. & Horejs-Hoeck, J. The cytokine network in acute myeloid leukemia (AML): a focus on pro- and anti-inflammatory mediators. Cytokine Growth Factor Rev. 43 , 8–15 (2018). 30181021 10.1016/j.cytogfr.2018.08.004

159. Wu Y Chen P Huang H-F Huang M-J Chen Y-Z Reduction of transforming growth factor-β1 expression in leukemia and its possible role in leukemia development Leuk. Lymphoma 2012 53 145 151 10.3109/10428194.2011.603446 21740305 Wu, Y., Chen, P., Huang, H.-F., Huang, M.-J. & Chen, Y.-Z. Reduction of transforming growth factor-β1 expression in leukemia and its possible role in leukemia development. Leuk. Lymphoma 53 , 145–151 (2012). 21740305 10.3109/10428194.2011.603446

160. Bhagwat AS Cytokine-mediated CAR T therapy resistance in AML Nat. Med. 2024 30 3697 3708 10.1038/s41591-024-03271-5 39333315 PMC12118809 Bhagwat, A. S. et al. Cytokine-mediated CAR T therapy resistance in AML. Nat. Med. 30 , 3697–3708 (2024). 39333315 10.1038/s41591-024-03271-5 PMC12118809

161. Vander Heiden MG Cantley LC Thompson CB Understanding the warburg effect: the metabolic requirements of cell proliferation Science 2009 324 1029 1033 10.1126/science.1160809 19460998 PMC2849637 Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the warburg effect: the metabolic requirements of cell proliferation. Science 324 , 1029–1033 (2009). 19460998 10.1126/science.1160809 PMC2849637

162. Mussai F Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment Blood 2013 122 749 758 10.1182/blood-2013-01-480129 23733335 PMC3731930 Mussai, F. et al. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood 122 , 749–758 (2013). 23733335 10.1182/blood-2013-01-480129 PMC3731930

163. Tettamanti S Pievani A Biondi A Dotti G Serafini M Catch me if you can: how AML and its niche escape immunotherapy Leukemia 2022 36 13 22 10.1038/s41375-021-01350-x 34302116 PMC8727297 Tettamanti, S., Pievani, A., Biondi, A., Dotti, G. & Serafini, M. Catch me if you can: how AML and its niche escape immunotherapy. Leukemia 36 , 13–22 (2022). 34302116 10.1038/s41375-021-01350-x PMC8727297

164. Mishra SK Millman SE Zhang L Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets Blood 2023 141 1119 1135 10.1182/blood.2022018092 36548959 PMC10375271 Mishra, S. K., Millman, S. E. & Zhang, L. Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets. Blood 141 , 1119–1135 (2023). 36548959 10.1182/blood.2022018092 PMC10375271

165. van Vlerken-Ysla L Tyurina YY Kagan VE Gabrilovich DI Functional states of myeloid cells in cancer Cancer Cell 2023 41 490 504 10.1016/j.ccell.2023.02.009 36868224 PMC10023509 van Vlerken-Ysla, L., Tyurina, Y. Y., Kagan, V. E. & Gabrilovich, D. I. Functional states of myeloid cells in cancer. Cancer Cell 41 , 490–504 (2023). 36868224 10.1016/j.ccell.2023.02.009 PMC10023509

166. Gabrilovich DI Myeloid-derived suppressor cells Cancer Immunol. Res. 2017 5 3 8 10.1158/2326-6066.CIR-16-0297 28052991 PMC5426480 Gabrilovich, D. I. Myeloid-derived suppressor cells. Cancer Immunol. Res. 5 , 3–8 (2017). 28052991 10.1158/2326-6066.CIR-16-0297 PMC5426480

167. Veglia F Sanseviero E Gabrilovich DI Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity Nat. Rev. Immunol. 2021 21 485 498 10.1038/s41577-020-00490-y 33526920 PMC7849958 Veglia, F., Sanseviero, E. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat. Rev. Immunol. 21 , 485–498 (2021). 33526920 10.1038/s41577-020-00490-y PMC7849958

168. Guo, M. et al. Core binding factor fusion downregulation of ADAR2 RNA editing contributes to AML leukemogenesis. Blood 10.1182/blood.2022015830 (2023). 10.1182/blood.2022015830 36796022

169. Cheng Y N6-methyladenosine on mRNA facilitates a phase-separated nuclear body that suppresses myeloid leukemic differentiation Cancer Cell 2021 39 958 972.e8 10.1016/j.ccell.2021.04.017 34048709 PMC8282764 Cheng, Y. et al. N6-methyladenosine on mRNA facilitates a phase-separated nuclear body that suppresses myeloid leukemic differentiation. Cancer Cell 39 , 958–972.e8 (2021). 34048709 10.1016/j.ccell.2021.04.017 PMC8282764

170. Mabuchi R High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia Leuk. Lymphoma 2016 57 92 98 10.3109/10428194.2015.1041388 25907424 Mabuchi, R. et al. High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia. Leuk. Lymphoma 57 , 92–98 (2016). 25907424 10.3109/10428194.2015.1041388

171. Ghobrial IM Detappe A Anderson KC Steensma DP The bone-marrow niche in MDS and MGUS: implications for AML and MM Nat. Rev. Clin. Oncol. 2018 15 219 233 10.1038/nrclinonc.2017.197 29311715 Ghobrial, I. M., Detappe, A., Anderson, K. C. & Steensma, D. P. The bone-marrow niche in MDS and MGUS: implications for AML and MM. Nat. Rev. Clin. Oncol. 15 , 219–233 (2018). 29311715 10.1038/nrclinonc.2017.197

172. Hao F Sholy C Wang C Cao M Kang X The role of t cell immunotherapy in acute myeloid leukemia Cells 2021 10 3376 10.3390/cells10123376 34943884 PMC8699747 Hao, F., Sholy, C., Wang, C., Cao, M. & Kang, X. The role of t cell immunotherapy in acute myeloid leukemia. Cells 10 , 3376 (2021). 34943884 10.3390/cells10123376 PMC8699747

173. Zhang Z Single-cell RNA-seq reveals a microenvironment and an exhaustion state of T/NK cells in acute myeloid leukemia Cancer Sci. 2023 114 3873 3883 10.1111/cas.15932 37591615 PMC10551605 Zhang, Z. et al. Single-cell RNA-seq reveals a microenvironment and an exhaustion state of T/NK cells in acute myeloid leukemia. Cancer Sci. 114 , 3873–3883 (2023). 37591615 10.1111/cas.15932 PMC10551605

174. Vadakekolathu J Rutella S Escape from T-cell–targeting immunotherapies in acute myeloid leukemia Blood 2024 143 2689 2700 10.1182/blood.2023019961 37467496 PMC11251208 Vadakekolathu, J. & Rutella, S. Escape from T-cell–targeting immunotherapies in acute myeloid leukemia. Blood 143 , 2689–2700 (2024). 37467496 10.1182/blood.2023019961 PMC11251208

175. Noviello M Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT Nat. Commun. 2019 10 1065 10.1038/s41467-019-08871-1 30911002 PMC6434052 Noviello, M. et al. Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. Nat. Commun. 10 , 1065 (2019). 30911002 10.1038/s41467-019-08871-1 PMC6434052

176. Haroun F Solola SA Nassereddine S Tabbara I PD-1 signaling and inhibition in AML and MDS Ann. Hematol. 2017 96 1441 1448 10.1007/s00277-017-3051-5 28643044 Haroun, F., Solola, S. A., Nassereddine, S. & Tabbara, I. PD-1 signaling and inhibition in AML and MDS. Ann. Hematol. 96 , 1441–1448 (2017). 28643044 10.1007/s00277-017-3051-5

177. Abbas HA Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy Nat. Commun. 2021 12 6071 10.1038/s41467-021-26282-z 34663807 PMC8524723 Abbas, H. A. et al. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat. Commun. 12 , 6071 (2021). 34663807 10.1038/s41467-021-26282-z PMC8524723

178. Nuebling T The immune checkpoint modulator OX40 and its ligand OX40L in NK-cell immunosurveillance and acute myeloid leukemia Cancer Immunol. Res. 2018 6 209 221 10.1158/2326-6066.CIR-17-0212 29321210 Nuebling, T. et al. The immune checkpoint modulator OX40 and its ligand OX40L in NK-cell immunosurveillance and acute myeloid leukemia. Cancer Immunol. Res. 6 , 209–221 (2018). 29321210 10.1158/2326-6066.CIR-17-0212

179. Atilla E Benabdellah K The black hole: CAR T cell therapy in AML Cancers 2023 15 2713 10.3390/cancers15102713 37345050 PMC10216020 Atilla, E. & Benabdellah, K. The black hole: CAR T cell therapy in AML. Cancers 15 , 2713 (2023). 37345050 10.3390/cancers15102713 PMC10216020

180. Tikhonova AN The bone marrow microenvironment at single-cell resolution Nature 2019 569 222 228 10.1038/s41586-019-1104-8 30971824 PMC6607432 Tikhonova, A. N. et al. The bone marrow microenvironment at single-cell resolution. Nature 569 , 222–228 (2019). 30971824 10.1038/s41586-019-1104-8 PMC6607432

181. Finney OC CD19 CAR T cell product and disease attributes predict leukemia remission durability J. Clin. Investig. 2019 129 2123 2132 10.1172/JCI125423 30860496 PMC6486329 Finney, O. C. et al. CD19 CAR T cell product and disease attributes predict leukemia remission durability. J. Clin. Investig. 129 , 2123–2132 (2019). 30860496 10.1172/JCI125423 PMC6486329

182. Labanieh L Mackall CL CAR immune cells: design principles, resistance and the next generation Nature 2023 614 635 648 10.1038/s41586-023-05707-3 36813894 Labanieh, L. & Mackall, C. L. CAR immune cells: design principles, resistance and the next generation. Nature 614 , 635–648 (2023). 36813894 10.1038/s41586-023-05707-3

183. Krönig H Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment Eur. J. Haematol. 2014 92 195 203 10.1111/ejh.12228 24175978 Krönig, H. et al. Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment. Eur. J. Haematol. 92 , 195–203 (2014). 24175978 10.1111/ejh.12228

184. Good CR An NK-like CAR T cell transition in CAR T cell dysfunction Cell 2021 184 6081 6100.e26 10.1016/j.cell.2021.11.016 34861191 PMC8827167 Good, C. R. et al. An NK-like CAR T cell transition in CAR T cell dysfunction. Cell 184 , 6081–6100.e26 (2021). 34861191 10.1016/j.cell.2021.11.016 PMC8827167

185. Lynn RC c-Jun overexpression in CAR T cells induces exhaustion resistance Nature 2019 576 293 300 10.1038/s41586-019-1805-z 31802004 PMC6944329 Lynn, R. C. et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576 , 293–300 (2019). 31802004 10.1038/s41586-019-1805-z PMC6944329

186. Al-Matary YS Acute myeloid leukemia cells polarize macrophages towards a leukemia supporting state in a Growth factor independence 1 dependent manner Haematologica 2016 101 1216 1227 10.3324/haematol.2016.143180 27390361 PMC5046651 Al-Matary, Y. S. et al. Acute myeloid leukemia cells polarize macrophages towards a leukemia supporting state in a Growth factor independence 1 dependent manner. Haematologica 101 , 1216–1227 (2016). 27390361 10.3324/haematol.2016.143180 PMC5046651

187. Toffalori C Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation Nat. Med. 2019 25 603 611 10.1038/s41591-019-0400-z 30911134 Toffalori, C. et al. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat. Med. 25 , 603–611 (2019). 30911134 10.1038/s41591-019-0400-z

188. Jia B Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients Blood Cancer J. 2018 8 34 10.1038/s41408-018-0069-4 29563517 PMC5862839 Jia, B. et al. Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients. Blood Cancer J. 8 , 34 (2018). 29563517 10.1038/s41408-018-0069-4 PMC5862839

189. Le Dieu R Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts Blood 2009 114 3909 3916 10.1182/blood-2009-02-206946 19710498 PMC2773481 Le Dieu, R. et al. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood 114 , 3909–3916 (2009). 19710498 10.1182/blood-2009-02-206946 PMC2773481

190. Behl D Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia Leukemia 2006 20 29 34 10.1038/sj.leu.2404032 16281063 Behl, D. et al. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 20 , 29–34 (2006). 16281063 10.1038/sj.leu.2404032

191. Restelli C Recent advances in immune-based therapies for acute myeloid leukemia Blood Cancer Discov. 2024 5 234 248 10.1158/2643-3230.BCD-23-0202 38904305 PMC11215380 Restelli, C. et al. Recent advances in immune-based therapies for acute myeloid leukemia. Blood Cancer Discov. 5 , 234–248 (2024). 38904305 10.1158/2643-3230.BCD-23-0202 PMC11215380

192. Baryawno N A cellular taxonomy of the bone marrow stroma in homeostasis and leukemia Cell 2019 177 1915 1932.e16 10.1016/j.cell.2019.04.040 31130381 PMC6570562 Baryawno, N. et al. A cellular taxonomy of the bone marrow stroma in homeostasis and leukemia. Cell 177 , 1915–1932.e16 (2019). 31130381 10.1016/j.cell.2019.04.040 PMC6570562

193. Haubner S Cooperative CAR targeting to selectively eliminate AML and minimize escape Cancer Cell 2023 41 1871 1891.e6 10.1016/j.ccell.2023.09.010 37802054 PMC11006543 Haubner, S. et al. Cooperative CAR targeting to selectively eliminate AML and minimize escape. Cancer Cell 41 , 1871–1891.e6 (2023). 37802054 10.1016/j.ccell.2023.09.010 PMC11006543

194. Alexandrov LB Signatures of mutational processes in human cancer Nature 2013 500 415 421 10.1038/nature12477 23945592 PMC3776390 Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500 , 415–421 (2013). 23945592 10.1038/nature12477 PMC3776390

195. Ritchie DS Persistence and efficacy of second generation CAR T cell against the ley antigen in acute myeloid leukemia Mol. Ther. 2013 21 2122 2129 10.1038/mt.2013.154 23831595 PMC3831035 Ritchie, D. S. et al. Persistence and efficacy of second generation CAR T cell against the ley antigen in acute myeloid leukemia. Mol. Ther. 21 , 2122–2129 (2013). 23831595 10.1038/mt.2013.154 PMC3831035

196. Majzner RG Mackall CL Clinical lessons learned from the first leg of the CAR T cell journey Nat. Med. 2019 25 1341 1355 10.1038/s41591-019-0564-6 31501612 Majzner, R. G. & Mackall, C. L. Clinical lessons learned from the first leg of the CAR T cell journey. Nat. Med. 25 , 1341–1355 (2019). 31501612 10.1038/s41591-019-0564-6

197. Jordan C The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells Leukemia 2000 14 1777 1784 10.1038/sj.leu.2401903 11021753 Jordan, C. et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14 , 1777–1784 (2000). 11021753 10.1038/sj.leu.2401903

198. Haubner S Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML Leukemia 2019 33 64 74 10.1038/s41375-018-0180-3 29946192 PMC6326956 Haubner, S. et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia 33 , 64–74 (2019). 29946192 10.1038/s41375-018-0180-3 PMC6326956

199. Schorr, C. & Perna, F. Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia. Front. Immunol. 13 , 1085978 (2022). 10.3389/fimmu.2022.1085978 PMC9809466 36605213

200. Munoz L Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies Haematologica 2001 86 1261 1269 11726317 Munoz, L. et al. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica 86 , 1261–1269 (2001). 11726317

201. Pelosi E Castelli G Testa U CD123 a therapeutic target for acute myeloid leukemia and blastic plasmocytoid dendritic neoplasm Int. J. Mol. Sci. 2023 24 2718 10.3390/ijms24032718 36769040 PMC9917129 Pelosi, E., Castelli, G. & Testa, U. CD123 a therapeutic target for acute myeloid leukemia and blastic plasmocytoid dendritic neoplasm. Int. J. Mol. Sci. 24 , 2718 (2023). 36769040 10.3390/ijms24032718 PMC9917129

202. Baroni ML 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo J. Immunother. Cancer 2020 8 e000845 10.1136/jitc-2020-000845 32527933 PMC7292050 Baroni, M. L. et al. 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo. J. Immunother. Cancer 8 , e000845 (2020). 32527933 10.1136/jitc-2020-000845 PMC7292050

203. Frankel AE Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients Blood 2014 124 385 392 10.1182/blood-2014-04-566737 24859366 PMC4260361 Frankel, A. E. et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood 124 , 385–392 (2014). 24859366 10.1182/blood-2014-04-566737 PMC4260361

204. Frankel A Liu J-S Rizzieri D Hogge D Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia Leuk. Lymphoma 2008 49 543 553 10.1080/10428190701799035 18297533 Frankel, A., Liu, J.-S., Rizzieri, D. & Hogge, D. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk. Lymphoma 49 , 543–553 (2008). 18297533 10.1080/10428190701799035

205. He SZ A phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia Leuk. Lymphoma 2015 56 1406 1415 10.3109/10428194.2014.956316 25248882 He, S. Z. et al. A phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. Leuk. Lymphoma 56 , 1406–1415 (2015). 25248882 10.3109/10428194.2014.956316

206. Montesinos P Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study Leukemia 2021 35 62 74 10.1038/s41375-020-0773-5 32203138 PMC7787975 Montesinos, P. et al. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. Leukemia 35 , 62–74 (2021). 32203138 10.1038/s41375-020-0773-5 PMC7787975

207. Naveen P Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm N. Engl. J. Med. 2019 380 1628 1637 10.1056/NEJMoa1815105 31018069 Naveen, P. et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N. Engl. J. Med. 380 , 1628–1637 (2019). 31018069 10.1056/NEJMoa1815105

208. Lane AA Safety and efficacy of combining tagraxofusp (SL-401) with azacitidine or azacitidine and venetoclax in a phase 1b study for CD123 positive AML, MDS, or BPDCN Blood 2021 138 2346 2346 10.1182/blood-2021-147486 Lane, A. A. et al. Safety and efficacy of combining tagraxofusp (SL-401) with azacitidine or azacitidine and venetoclax in a phase 1b study for CD123 positive AML, MDS, or BPDCN. Blood 138 , 2346–2346 (2021).

209. Daver NG Clinical profile of IMGN632, a novel CD123-targeting antibody-drug conjugate (ADC), in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN) Blood 2019 134 734 734 10.1182/blood-2019-128648 Daver, N. G. et al. Clinical profile of IMGN632, a novel CD123-targeting antibody-drug conjugate (ADC), in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood 134 , 734–734 (2019).

210. Daver N Broad activity for the pivekimab sunirine (PVEK, IMGN632), azacitidine, and venetoclax triplet in high-risk patients with relapsed/refractory acute myeloid leukemia (AML) Blood 2022 140 145 149 10.1182/blood-2022-158030 Daver, N. et al. Broad activity for the pivekimab sunirine (PVEK, IMGN632), azacitidine, and venetoclax triplet in high-risk patients with relapsed/refractory acute myeloid leukemia (AML). Blood 140 , 145–149 (2022).

211. Ravandi F Complete responses in relapsed/refractory acute myeloid leukemia (AML) patients on a weekly dosing schedule of vibecotamab (XmAb14045), a CD123 x CD3 T cell-engaging bispecific antibody; initial results of a phase 1 study Blood 2020 136 4 5 10.1182/blood-2020-134746 Ravandi, F. et al. Complete responses in relapsed/refractory acute myeloid leukemia (AML) patients on a weekly dosing schedule of vibecotamab (XmAb14045), a CD123 x CD3 T cell-engaging bispecific antibody; initial results of a phase 1 study. Blood 136 , 4–5 (2020).32614961

212. Godwin JE Flotetuzumab (FLZ), an investigational CD123 x CD3 bispecific dart® protein-induced clustering of CD3+ T cells and CD123+ AML cells in bone marrow biopsies is associated with response to treatment in primary refractory AML patients Blood 2019 134 1410 10.1182/blood-2019-128485 Godwin, J. E. et al. Flotetuzumab (FLZ), an investigational CD123 x CD3 bispecific dart® protein-induced clustering of CD3+ T cells and CD123+ AML cells in bone marrow biopsies is associated with response to treatment in primary refractory AML patients. Blood 134 , 1410 (2019).

213. Uy GL Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia Blood 2021 137 751 762 10.1182/blood.2020007732 32929488 PMC7885824 Uy, G. L. et al. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood 137 , 751–762 (2021). 32929488 10.1182/blood.2020007732 PMC7885824

214. Winer ES A phase 1, first-in-human, dose-escalation study of MGD024, a CD123 x CD3 bispecific dart® molecule, in patients with relapsed or refractory CD123-positive (+) hematologic malignancies Blood 2022 140 11753 11754 10.1182/blood-2022-159524 Winer, E. S. et al. A phase 1, first-in-human, dose-escalation study of MGD024, a CD123 x CD3 bispecific dart® molecule, in patients with relapsed or refractory CD123-positive (+) hematologic malignancies. Blood 140 , 11753–11754 (2022).

215. Stein C Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells Br. J. Haematol. 2010 148 879 889 10.1111/j.1365-2141.2009.08033.x 20064159 Stein, C. et al. Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells. Br. J. Haematol. 148 , 879–889 (2010). 20064159 10.1111/j.1365-2141.2009.08033.x

216. Ehninger A Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia Blood Cancer J. 2014 4 e218 e218 10.1038/bcj.2014.39 24927407 PMC4080210 Ehninger, A. et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 4 , e218–e218 (2014). 24927407 10.1038/bcj.2014.39 PMC4080210

217. Dinndorf P Expression of normal myeloid-associated antigens by acute leukemia cells Blood 1986 67 1048 1053 10.1182/blood.V67.4.1048.1048 2937468 Dinndorf, P. et al. Expression of normal myeloid-associated antigens by acute leukemia cells. Blood 67 , 1048–1053 (1986). 2937468

218. Walter RB Appelbaum FR Estey EH Bernstein ID Acute myeloid leukemia stem cells and CD33-targeted immunotherapy Blood 2012 119 6198 6208 10.1182/blood-2011-11-325050 22286199 PMC3383202 Walter, R. B., Appelbaum, F. R., Estey, E. H. & Bernstein, I. D. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 119 , 6198–6208 (2012). 22286199 10.1182/blood-2011-11-325050 PMC3383202

219. Castaigne S Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study Lancet 2012 379 1508 1516 10.1016/S0140-6736(12)60485-1 22482940 Castaigne, S. et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 379 , 1508–1516 (2012). 22482940 10.1016/S0140-6736(12)60485-1

220. Burnett AK Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial J. Clin. Oncol. 2011 29 369 377 10.1200/JCO.2010.31.4310 21172891 Burnett, A. K. et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J. Clin. Oncol. 29 , 369–377 (2011). 21172891 10.1200/JCO.2010.31.4310

221. FDA. MYLOTARGTM (Gemtuzumab Ozogamicin) for Injection. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761060lbl.pdf (accessed on 1 Sep 2024).

222. EMA. EPAR—Summary for Mylotarg—Epar Product Information Public. Available online: https://www.ema.europa.eu/en/documents/product-information/mylotarg-epar-product-information_en.pdf (accessed on 1 Sep 2024).

223. Norsworthy KJ FDA approval summary: mylotarg for treatment of patients with relapsed or refractory CD33-positive acute myeloid leukemia Oncologist 2018 23 1103 1108 10.1634/theoncologist.2017-0604 29650683 PMC6192608 Norsworthy, K. J. et al. FDA approval summary: mylotarg for treatment of patients with relapsed or refractory CD33-positive acute myeloid leukemia. Oncologist 23 , 1103–1108 (2018). 29650683 10.1634/theoncologist.2017-0604 PMC6192608

224. He X Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia Blood 2020 135 713 723 10.1182/blood.2019002779 31951650 PMC7059518 He, X. et al. Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. Blood 135 , 713–723 (2020). 31951650 10.1182/blood.2019002779 PMC7059518

225. Godwin CD McDonald GB Walter RB Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia Blood 2017 129 2330 2332 10.1182/blood-2017-01-762419 28153826 PMC5399486 Godwin, C. D., McDonald, G. B. & Walter, R. B. Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia. Blood 129 , 2330–2332 (2017). 28153826 10.1182/blood-2017-01-762419 PMC5399486

226. Rajvanshi P Shulman HM Sievers EL McDonald GB Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (mylotarg) therapy Blood 2002 99 2310 2314 10.1182/blood.V99.7.2310 11895761 Rajvanshi, P., Shulman, H. M., Sievers, E. L. & McDonald, G. B. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (mylotarg) therapy. Blood 99 , 2310–2314 (2002). 11895761 10.1182/blood.v99.7.2310

227. Schiller GJ Early clinical evaluation of potential synergy of targeted radiotherapy with lintuzumab-Ac225 and venetoclax in relapsed/refractory AML Blood 2022 140 3336 3337 10.1182/blood-2022-157588 Schiller, G. J. et al. Early clinical evaluation of potential synergy of targeted radiotherapy with lintuzumab-Ac225 and venetoclax in relapsed/refractory AML. Blood 140 , 3336–3337 (2022).

228. Abedin S Lintuzumab-Ac225 with combination with intensive chemotherapy yields high response rate and MRD negativity in R/R AML with adverse features Blood 2022 140 157 158 10.1182/blood-2022-157827 Abedin, S. et al. Lintuzumab-Ac225 with combination with intensive chemotherapy yields high response rate and MRD negativity in R/R AML with adverse features. Blood 140 , 157–158 (2022).

229. Feldman EJ Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia J. Clin. Oncol. 2005 23 4110 4116 10.1200/JCO.2005.09.133 15961759 Feldman, E. J. et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J. Clin. Oncol. 23 , 4110–4116 (2005). 15961759 10.1200/JCO.2005.09.133

230. Stein EM A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia Blood 2018 131 387 396 10.1182/blood-2017-06-789800 29196412 PMC5813721 Stein, E. M. et al. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood 131 , 387–396 (2018). 29196412 10.1182/blood-2017-06-789800 PMC5813721

231. Cortes JE Maturing clinical profile of IMGN779, a next-generation CD33-targeting antibody-drug conjugate, in patients with relapsed or refractory acute myeloid leukemia Blood 2018 132 26 10.1182/blood-2018-99-112891 Cortes, J. E. et al. Maturing clinical profile of IMGN779, a next-generation CD33-targeting antibody-drug conjugate, in patients with relapsed or refractory acute myeloid leukemia. Blood 132 , 26 (2018).

232. Ravandi F Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML) J. Clin. Oncol. 2020 38 7508 7508 10.1200/JCO.2020.38.15_suppl.7508 Ravandi, F. et al. Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML). J. Clin. Oncol. 38 , 7508–7508 (2020).

233. Krupka C CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330 Blood 2014 123 356 365 10.1182/blood-2013-08-523548 24300852 Krupka, C. et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330. Blood 123 , 356–365 (2014). 24300852 10.1182/blood-2013-08-523548

234. Subklewe M Preliminary results from a phase 1 first-in-human study of AMG 673, a novel half-life extended (HLE) anti-CD33/CD3 BiTE® (bispecific T-cell engager) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) Blood 2019 134 833 833 10.1182/blood-2019-127977 Subklewe, M. et al. Preliminary results from a phase 1 first-in-human study of AMG 673, a novel half-life extended (HLE) anti-CD33/CD3 BiTE® (bispecific T-cell engager) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). Blood 134 , 833–833 (2019).

235. Marshall ASJ Human MICL (CLEC12A) is differentially glycosylated and is down-regulated following cellular activation Eur. J. Immunol. 2006 36 2159 2169 10.1002/eji.200535628 16838277 Marshall, A. S. J. et al. Human MICL (CLEC12A) is differentially glycosylated and is down-regulated following cellular activation. Eur. J. Immunol. 36 , 2159–2169 (2006). 16838277 10.1002/eji.200535628

236. Chen C-H Dendritic-cell-associated C-type lectin 2 (DCAL-2) alters dendritic-cell maturation and cytokine production Blood 2006 107 1459 1467 10.1182/blood-2005-08-3264 16239426 PMC1895401 Chen, C.-H. et al. Dendritic-cell-associated C-type lectin 2 (DCAL-2) alters dendritic-cell maturation and cytokine production. Blood 107 , 1459–1467 (2006). 16239426 10.1182/blood-2005-08-3264 PMC1895401

237. Ngai LL Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients Eur. J. Haematol. 2021 107 343 353 10.1111/ejh.13672 34053123 PMC8457079 Ngai, L. L. et al. Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients. Eur. J. Haematol. 107 , 343–353 (2021). 34053123 10.1111/ejh.13672 PMC8457079

238. Zhao X Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia Haematologica 2010 95 71 78 10.3324/haematol.2009.009811 19648166 PMC2805740 Zhao, X. et al. Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia. Haematologica 95 , 71–78 (2010). 19648166 10.3324/haematol.2009.009811 PMC2805740

239. Bakker ABH C-Type lectin-like molecule-1 Cancer Res. 2004 64 8443 8450 10.1158/0008-5472.CAN-04-1659 15548716 Bakker, A. B. H. et al. C-Type lectin-like molecule-1. Cancer Res. 64 , 8443–8450 (2004). 15548716 10.1158/0008-5472.CAN-04-1659

240. Hutten TJA CLEC12A-mediated antigen uptake and cross-presentation by human dendritic cell subsets efficiently boost tumor-reactive t cell responses J. Immunol. 2016 197 2715 2725 10.4049/jimmunol.1600011 27566820 Hutten, T. J. A. et al. CLEC12A-mediated antigen uptake and cross-presentation by human dendritic cell subsets efficiently boost tumor-reactive t cell responses. J. Immunol. 197 , 2715–2725 (2016). 27566820 10.4049/jimmunol.1600011

241. Toft-Petersen M The CLEC12A receptor marks human basophils: potential implications for minimal residual disease detection in acute myeloid leukemia Cytom. B. Clin. Cytom. 2018 94 520 526 10.1002/cyto.b.21540 28718199 Toft-Petersen, M. et al. The CLEC12A receptor marks human basophils: potential implications for minimal residual disease detection in acute myeloid leukemia. Cytom. B. Clin. Cytom. 94 , 520–526 (2018). 10.1002/cyto.b.21540 28718199

242. Bill M Mapping the CLEC12A expression on myeloid progenitors in normal bone marrow; implications for understanding CLEC12A-related cancer stem cell biology J. Cell Mol. Med. 2018 22 2311 2318 10.1111/jcmm.13519 29411522 PMC5867061 Bill, M. et al. Mapping the CLEC12A expression on myeloid progenitors in normal bone marrow; implications for understanding CLEC12A-related cancer stem cell biology. J. Cell Mol. Med. 22 , 2311–2318 (2018). 29411522 10.1111/jcmm.13519 PMC5867061

243. Zloza A NKG2D signaling on CD8+ T cells represses T-bet and rescues CD4-unhelped CD8+ T cell memory recall but not effector responses Nat. Med. 2012 18 422 428 10.1038/nm.2683 22366950 PMC3436127 Zloza, A. et al. NKG2D signaling on CD8+ T cells represses T-bet and rescues CD4-unhelped CD8+ T cell memory recall but not effector responses. Nat. Med. 18 , 422–428 (2012). 22366950 10.1038/nm.2683 PMC3436127

244. Sheppard S The immunoreceptor NKG2D promotes tumour growth in a model of hepatocellular carcinoma Nat. Commun. 2017 8 13930 10.1038/ncomms13930 28128200 PMC5290164 Sheppard, S. et al. The immunoreceptor NKG2D promotes tumour growth in a model of hepatocellular carcinoma. Nat. Commun. 8 , 13930 (2017). 28128200 10.1038/ncomms13930 PMC5290164

245. Bauer S Activation of NK Cells and T Cells by NKG2D, a receptor for stress-inducible MICA Science 1999 285 727 729 10.1126/science.285.5428.727 29555676 Bauer, S. et al. Activation of NK Cells and T Cells by NKG2D, a receptor for stress-inducible MICA. Science . 285 , 727–729 (1999). 29555676

246. Mastaglio S Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy Blood Adv. 2018 2 335 346 10.1182/bloodadvances.2017015230 29449224 PMC5858482 Mastaglio, S. et al. Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy. Blood Adv. 2 , 335–346 (2018). 29449224 10.1182/bloodadvances.2017015230 PMC5858482

247. Salih HR Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia Blood 2003 102 1389 1396 10.1182/blood-2003-01-0019 12714493 Salih, H. R. et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102 , 1389–1396 (2003). 12714493 10.1182/blood-2003-01-0019

248. Zhang T Lemoi BA Sentman CL Chimeric NK-receptor–bearing T cells mediate antitumor immunotherapy Blood 2005 106 1544 1551 10.1182/blood-2004-11-4365 15890688 PMC1895219 Zhang, T., Lemoi, B. A. & Sentman, C. L. Chimeric NK-receptor–bearing T cells mediate antitumor immunotherapy. Blood 106 , 1544–1551 (2005). 15890688 10.1182/blood-2004-11-4365 PMC1895219

249. Lanier LL NKG2D Receptor and its ligands in host defense Cancer Immunol. Res. 2015 3 575 582 10.1158/2326-6066.CIR-15-0098 26041808 PMC4457299 Lanier, L. L. NKG2D Receptor and its ligands in host defense. Cancer Immunol. Res. 3 , 575–582 (2015). 26041808 10.1158/2326-6066.CIR-15-0098 PMC4457299

250. Rohner A Langenkamp U Siegler U Kalberer CP Wodnar-Filipowicz A Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis Leuk. Res. 2007 31 1393 1402 10.1016/j.leukres.2007.02.020 17391757 Rohner, A., Langenkamp, U., Siegler, U., Kalberer, C. P. & Wodnar-Filipowicz, A. Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis. Leuk. Res. 31 , 1393–1402 (2007). 17391757 10.1016/j.leukres.2007.02.020

251. Diermayr S NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities Blood 2008 111 1428 1436 10.1182/blood-2007-07-101311 17993609 Diermayr, S. et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 111 , 1428–1436 (2008). 17993609 10.1182/blood-2007-07-101311

252. Themeli M Selecting CD7− T cells for CAR T-cell therapy Blood 2022 140 2652 2653 10.1182/blood.2022017935 36548020 PMC9665220 Themeli, M. Selecting CD7− T cells for CAR T-cell therapy. Blood 140 , 2652–2653 (2022). 36548020 10.1182/blood-2022-162206 PMC9665220

253. Watanabe N Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies Mol. Ther. 2023 31 24 34 10.1016/j.ymthe.2022.09.003 36086817 PMC9840107 Watanabe, N. et al. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies. Mol. Ther. 31 , 24–34 (2023). 36086817 10.1016/j.ymthe.2022.09.003 PMC9840107

254. Tan Y Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia J. Hematol. Oncol. 2023 16 34 10.1186/s13045-023-01427-3 37020231 PMC10074659 Tan, Y. et al. Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia. J. Hematol. Oncol. 16 , 34 (2023). 37020231 10.1186/s13045-023-01427-3 PMC10074659

255. Hu Y Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study Cell Res. 2022 32 995 1007 10.1038/s41422-022-00721-y 36151216 PMC9652391 Hu, Y. et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 32 , 995–1007 (2022). 36151216 10.1038/s41422-022-00721-y PMC9652391

256. Georgiadis C Base-edited CAR T cells for combinational therapy against T cell malignancies Leukemia 2021 35 3466 3481 10.1038/s41375-021-01282-6 34035409 PMC8632682 Georgiadis, C. et al. Base-edited CAR T cells for combinational therapy against T cell malignancies. Leukemia 35 , 3466–3481 (2021). 34035409 10.1038/s41375-021-01282-6 PMC8632682

257. Png YT Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies Blood Adv. 2017 1 2348 2360 10.1182/bloodadvances.2017009928 29296885 PMC5729624 Png, Y. T. et al. Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies. Blood Adv. 1 , 2348–2360 (2017). 29296885 10.1182/bloodadvances.2017009928 PMC5729624

258. Lu, P. et al. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase i clinical trial. Blood , 140 , 321–334 (2022). 10.1182/blood.2021014498 35500125

259. Gomes-Silva D CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies Blood 2017 130 285 296 10.1182/blood-2017-01-761320 28539325 PMC5520470 Gomes-Silva, D. et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood 130 , 285–296 (2017). 28539325 10.1182/blood-2017-01-761320 PMC5520470

260. Cao X CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia Exp. Hematol. Oncol. 2022 11 67 10.1186/s40164-022-00318-6 36175988 PMC9523980 Cao, X. et al. CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia. Exp. Hematol. Oncol. 11 , 67 (2022). 36175988 10.1186/s40164-022-00318-6 PMC9523980

261. Muñoz P Antigen-induced clustering of surface CD38 and recruitment of intracellular CD38 to the immunologic synapse Blood 2008 111 3653 3664 10.1182/blood-2007-07-101600 18212246 Muñoz, P. et al. Antigen-induced clustering of surface CD38 and recruitment of intracellular CD38 to the immunologic synapse. Blood 111 , 3653–3664 (2008). 18212246 10.1182/blood-2007-07-101600

262. Deterre, P. et al. CD38 in T- and B-cell functions. in Human CD38 and Related Molecules 146–168 (KARGER, 2000). 10.1159/000058767 10851783

263. Terhorst C Biochemical studies of the human thymocyte cell-surface antigens T6, T9 and T10 Cell 1981 23 771 780 10.1016/0092-8674(81)90441-4 7013988 Terhorst, C. et al. Biochemical studies of the human thymocyte cell-surface antigens T6, T9 and T10. Cell 23 , 771–780 (1981). 7013988 10.1016/0092-8674(81)90441-4

264. Keyhani A Increased CD38 expression is associated with favorable prognosis in adult acute leukemia Leuk. Res. 2000 24 153 159 10.1016/S0145-2126(99)00147-2 10654451 Keyhani, A. et al. Increased CD38 expression is associated with favorable prognosis in adult acute leukemia. Leuk. Res. 24 , 153–159 (2000). 10654451 10.1016/s0145-2126(99)00147-2

265. Glisovic-Aplenc T CD38 as a pan-hematologic target for chimeric antigen receptor T cells Blood Adv. 2023 7 4418 4430 10.1182/bloodadvances.2022007059 37171449 PMC10440474 Glisovic-Aplenc, T. et al. CD38 as a pan-hematologic target for chimeric antigen receptor T cells. Blood Adv. 7 , 4418–4430 (2023). 37171449 10.1182/bloodadvances.2022007059 PMC10440474

266. Facon, T. et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med . 391 , 1597–1609 (2024) 10.1056/NEJMoa2400712 38832972

267. Attal M Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study Lancet 2019 394 2096 2107 10.1016/S0140-6736(19)32556-5 31735560 Attal, M. et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet 394 , 2096–2107 (2019). 31735560 10.1016/S0140-6736(19)32556-5

268. Baruchel A P501: Isatuximab plus chemotherapy for pediatric relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia (isakids): interim efficacy analysis Hemasphere 2023 7 e121813e 10.1097/01.HS9.0000968912.12181.3e PMC12572944 41180900 Baruchel, A. et al. P501: Isatuximab plus chemotherapy for pediatric relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia (isakids): interim efficacy analysis. Hemasphere 7 , e121813e (2023). 10.1002/hem3.70245 PMC12572944 41180900

269. Naik J CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia Haematologica 2019 104 e100 e103 10.3324/haematol.2018.192757 30190344 PMC6395314 Naik, J. et al. CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia. Haematologica 104 , e100–e103 (2019). 30190344 10.3324/haematol.2018.192757 PMC6395314

270. Van Driel M CD44 variant isoforms are involved in plasma cell adhesion to bone marrow stromal cells Leukemia 2002 16 135 143 10.1038/sj.leu.2402336 11840273 Van Driel, M. et al. CD44 variant isoforms are involved in plasma cell adhesion to bone marrow stromal cells. Leukemia 16 , 135–143 (2002). 11840273 10.1038/sj.leu.2402336

271. Heider K-H Kuthan H Stehle G Munzert G CD44v6: a target for antibody-based cancer therapy Cancer Immunol. Immunother. 2004 53 567 579 10.1007/s00262-003-0494-4 14762695 PMC11032850 Heider, K.-H., Kuthan, H., Stehle, G. & Munzert, G. CD44v6: a target for antibody-based cancer therapy. Cancer Immunol. Immunother. 53 , 567–579 (2004). 14762695 10.1007/s00262-003-0494-4 PMC11032850

272. Wang, Z., Zhao, K., Hackert, T. & Zöller, M. CD44/CD44v6 a reliable companion in cancer-initiating cell maintenance and tumor progression. Front. Cell Dev. Biol. 6 , (2018). 10.3389/fcell.2018.00097 PMC6122270 30211160

273. Casucci M CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma Blood 2013 122 3461 3472 10.1182/blood-2013-04-493361 24016461 Casucci, M. et al. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood 122 , 3461–3472 (2013). 24016461 10.1182/blood-2013-04-493361

274. Tang, L. et al. CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations. Clin. Transl. Med. 12 , e1007 (2022). 10.1002/ctm2.1043 PMC9513046 36163632

275. Stornaiuolo A Characterization and functional analysis of cd44v6.car t cells endowed with a new low-affinity nerve growth factor receptor-based spacer Hum. Gene Ther. 2021 32 744 760 10.1089/hum.2020.216 33554732 PMC8312023 Stornaiuolo, A. et al. Characterization and functional analysis of cd44v6.car t cells endowed with a new low-affinity nerve growth factor receptor-based spacer. Hum. Gene Ther. 32 , 744–760 (2021). 33554732 10.1089/hum.2020.216 PMC8312023

276. Wu, G. et al. Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia. Front. Immunol. 14 , 1093750 (2023). 10.3389/fimmu.2023.1093750 PMC9950117 36845088

277. Sauer T CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity Blood 2021 138 318 330 10.1182/blood.2020008221 34323938 PMC8323977 Sauer, T. et al. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood 138 , 318–330 (2021). 34323938 10.1182/blood.2020008221 PMC8323977

278. Riether C Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents Nat. Med. 2020 26 1459 1467 10.1038/s41591-020-0910-8 32601337 Riether, C. et al. Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat. Med. 26 , 1459–1467 (2020). 32601337 10.1038/s41591-020-0910-8

279. Mirazee J Shah NN CD70 CAR T cells in AML: form follows function Cell Rep. Med. 2022 3 100639 10.1016/j.xcrm.2022.100639 35584621 PMC9133448 Mirazee, J. & Shah, N. N. CD70 CAR T cells in AML: form follows function. Cell Rep. Med. 3 , 100639 (2022). 35584621 10.1016/j.xcrm.2022.100639 PMC9133448

280. Daver N Schlenk RF Russell NH Levis MJ Targeting FLT3 mutations in AML: review of current knowledge and evidence Leukemia 2019 33 299 312 10.1038/s41375-018-0357-9 30651634 PMC6365380 Daver, N., Schlenk, R. F., Russell, N. H. & Levis, M. J. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia 33 , 299–312 (2019). 30651634 10.1038/s41375-018-0357-9 PMC6365380

281. Short NJ Kantarjian H Ravandi F Daver N Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia Ther. Adv. Hematol. 2019 10 204062071982731 10.1177/2040620719827310 PMC6378516 30800259 Short, N. J., Kantarjian, H., Ravandi, F. & Daver, N. Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. Ther. Adv. Hematol. 10 , 204062071982731 (2019). 10.1177/2040620719827310 PMC6378516 30800259

282. Erba HP Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet 2023 401 1571 1583 10.1016/S0140-6736(23)00464-6 37116523 Erba, H. P. et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401 , 1571–1583 (2023). 37116523 10.1016/S0140-6736(23)00464-6

283. Wang ES Crenolanib and intensive chemotherapy in adults with newly diagnosed FLT3-mutated AML J. Clin. Oncol. 2024 42 1776 1787 10.1200/JCO.23.01061 38324741 PMC11107896 Wang, E. S. et al. Crenolanib and intensive chemotherapy in adults with newly diagnosed FLT3-mutated AML. J. Clin. Oncol. 42 , 1776–1787 (2024). 38324741 10.1200/JCO.23.01061 PMC11107896

284. Loo S Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG Blood 2023 142 1960 1971 10.1182/blood.2023020301 37647654 PMC10733823 Loo, S. et al. Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG. Blood 142 , 1960–1971 (2023). 37647654 10.1182/blood.2023020301 PMC10733823

285. Chien CD Preclinical development of FLT3-Redirected chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia Blood 2016 128 1072 10.1182/blood.V128.22.1072.1072 Chien, C. D. et al. Preclinical development of FLT3-Redirected chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia. Blood 128 , 1072 (2016).

286. Jetani H CAR T-cells targeting FLT3 have potent activity against FLT3−ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib Leukemia 2018 32 1168 1179 10.1038/s41375-018-0009-0 29472720 Jetani, H. et al. CAR T-cells targeting FLT3 have potent activity against FLT3−ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib. Leukemia 32 , 1168–1179 (2018). 29472720 10.1038/s41375-018-0009-0

287. Sleiman S Anti-FLT3 CAR T cells in acute myeloid leukemia Blood 2021 138 1703 10.1182/blood-2021-151196 Sleiman, S. et al. Anti-FLT3 CAR T cells in acute myeloid leukemia. Blood 138 , 1703 (2021).

288. Sommer C Allogeneic FLT3 CAR T cells with an off-switch exhibit potent activity against AML and can be depleted to expedite bone marrow recovery Mol. Ther. 2020 28 2237 2251 10.1016/j.ymthe.2020.06.022 32592688 PMC7544976 Sommer, C. et al. Allogeneic FLT3 CAR T cells with an off-switch exhibit potent activity against AML and can be depleted to expedite bone marrow recovery. Mol. Ther. 28 , 2237–2251 (2020). 32592688 10.1016/j.ymthe.2020.06.022 PMC7544976

289. Barneh, F. et al. Repurposing CD19-directed immunotherapies for pediatric t(8;21) acute myeloid leukemia. Haematologica 109 , 4131–4136 (2024) 10.3324/haematol.2024.285707 PMC11609786 39113654

290. Perna F Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML Cancer Cell 2017 32 506 519.e5 10.1016/j.ccell.2017.09.004 29017060 PMC7025434 Perna, F. et al. Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML. Cancer Cell 32 , 506–519.e5 (2017). 29017060 10.1016/j.ccell.2017.09.004 PMC7025434

291. Dobrowolska H Expression of immune inhibitory receptor ILT3 in acute myeloid leukemia with monocytic differentiation Cytom. B. Clin. Cytom. 2013 84B 21 29 10.1002/cyto.b.21050 23027709 Dobrowolska, H. et al. Expression of immune inhibitory receptor ILT3 in acute myeloid leukemia with monocytic differentiation. Cytom. B. Clin. Cytom. 84B , 21–29 (2013). 10.1002/cyto.b.21050 23027709

292. Loff S Rapidly switchable universal car-t cells for treatment of CD123-positive leukemia Mol. Ther. Oncol. 2020 17 408 420 10.1016/j.omto.2020.04.009 PMC7240059 32462078 Loff, S. et al. Rapidly switchable universal car-t cells for treatment of CD123-positive leukemia. Mol. Ther. Oncol. 17 , 408–420 (2020). 10.1016/j.omto.2020.04.009 PMC7240059 32462078

293. Cartellieri M Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts Blood Cancer J. 2016 6 e458 e458 10.1038/bcj.2016.61 27518241 PMC5022178 Cartellieri, M. et al. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. Blood Cancer J. 6 , e458–e458 (2016). 27518241 10.1038/bcj.2016.61 PMC5022178

294. Bachmann M The UniCAR system: a modular CAR T cell approach to improve the safety of CAR T cells Immunol. Lett. 2019 211 13 22 10.1016/j.imlet.2019.05.003 31091431 Bachmann, M. The UniCAR system: a modular CAR T cell approach to improve the safety of CAR T cells. Immunol. Lett. 211 , 13–22 (2019). 31091431 10.1016/j.imlet.2019.05.003

295. Wermke M Updated results from a phase i dose escalation study of the rapidly-switchable universal CAR-T Therapy UniCAR-T-CD123 in relapsed/refractory AML Blood 2023 142 3465 10.1182/blood-2023-177867 PMC8176767 33624009 Wermke, M. et al. Updated results from a phase i dose escalation study of the rapidly-switchable universal CAR-T Therapy UniCAR-T-CD123 in relapsed/refractory AML. Blood 142 , 3465 (2023). 10.1182/blood.2020009759 PMC8176767 33624009

296. ClinicalTrials.gov. Available online: https://clinicaltrials.gov/study/NCT05949125 .

297. Sugita M Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia Nat. Commun. 2022 13 2227 10.1038/s41467-022-29668-9 35484102 PMC9050731 Sugita, M. et al. Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia. Nat. Commun. 13 , 2227 (2022). 35484102 10.1038/s41467-022-29668-9 PMC9050731

298. Cai T Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells Nat. Commun. 2022 13 2228 10.1038/s41467-022-29669-8 35484100 PMC9051102 Cai, T. et al. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. Nat. Commun. 13 , 2228 (2022). 35484100 10.1038/s41467-022-29669-8 PMC9051102

299. Pemmaraju N CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): clinicopathological insights Leuk. Res. 2022 121 106928 10.1016/j.leukres.2022.106928 35963025 Pemmaraju, N. et al. CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): clinicopathological insights. Leuk. Res. 121 , 106928 (2022). 35963025 10.1016/j.leukres.2022.106928

300. Sallman DA Ameli-01: A phase I trial of UCART123v1.2, an anti-CD123 allogeneic CAR-T cell product, in adult patients with relapsed or refractory (R/R) CD123+ acute myeloid leukemia (AML) Blood 2022 140 2371 2373 10.1182/blood-2022-169928 Sallman, D. A. et al. Ameli-01: A phase I trial of UCART123v1.2, an anti-CD123 allogeneic CAR-T cell product, in adult patients with relapsed or refractory (R/R) CD123+ acute myeloid leukemia (AML). Blood 140 , 2371–2373 (2022).36054916

301. Naik S Safety and anti-leukemic activity of CD123-CAR T cells in pediatric patients with AML: preliminary results from a phase 1 trial Blood 2022 140 4584 4585 10.1182/blood-2022-170201 Naik, S. et al. Safety and anti-leukemic activity of CD123-CAR T cells in pediatric patients with AML: preliminary results from a phase 1 trial. Blood 140 , 4584–4585 (2022).

302. Edwards JP Abstract 587: ACLX-002, a novel CD123-targeted universal CAR-T cell therapy for relapsed or refractory acute myeloid leukemia that can be activated and silenced in vivo with soluble protein adapters in a dose dependent manner Cancer Res. 2022 82 587 10.1158/1538-7445.AM2022-587 Edwards, J. P. et al. Abstract 587: ACLX-002, a novel CD123-targeted universal CAR-T cell therapy for relapsed or refractory acute myeloid leukemia that can be activated and silenced in vivo with soluble protein adapters in a dose dependent manner. Cancer Res. 82 , 587 (2022).

303. Cummins KD Treating relapsed / refractory (RR) AML with biodegradable anti-CD123 CAR modified T cells Blood 2017 130 1359 Cummins, K. D. et al. Treating relapsed / refractory (RR) AML with biodegradable anti-CD123 CAR modified T cells. Blood 130 , 1359 (2017).

304. Budde LE Abstract PR14: CD123CAR displays clinical activity in relapsed/refractory (R/R) acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN): Safety and efficacy results from a phase 1 study Cancer Immunol. Res. 2020 8 PR14 PR14 10.1158/2326-6074.TUMIMM18-PR14 Budde, L. E. et al. Abstract PR14: CD123CAR displays clinical activity in relapsed/refractory (R/R) acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN): Safety and efficacy results from a phase 1 study. Cancer Immunol. Res. 8 , PR14–PR14 (2020).

305. Budde L Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-specific CAR T cells: a first-in-human clinical trial Blood 2017 130 811 811 10.1182/blood.V130.Suppl_1.811.811 Budde, L. et al. Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-specific CAR T cells: a first-in-human clinical trial. Blood 130 , 811–811 (2017).

306. Qin H Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design J. Immunother. Cancer 2021 9 e003149 10.1136/jitc-2021-003149 34531250 PMC8449984 Qin, H. et al. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design. J. Immunother. Cancer 9 , e003149 (2021). 34531250 10.1136/jitc-2021-003149 PMC8449984

307. Lamba JK CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients Leuk. Lymphoma 2018 59 2250 2253 10.1080/10428194.2017.1421756 29320902 PMC7199442 Lamba, J. K. et al. CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients. Leuk. Lymphoma 59 , 2250–2253 (2018). 29320902 10.1080/10428194.2017.1421756 PMC7199442

308. Mortland L Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin–containing chemotherapy Clin. Cancer Res. 2013 19 1620 1627 10.1158/1078-0432.CCR-12-3115 23444229 PMC3602123 Mortland, L. et al. Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin–containing chemotherapy. Clin. Cancer Res. 19 , 1620–1627 (2013). 23444229 10.1158/1078-0432.CCR-12-3115 PMC3602123

309. Godwin CD The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemia Leukemia 2020 34 2479 2483 10.1038/s41375-020-0755-7 32071429 PMC7431376 Godwin, C. D. et al. The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemia. Leukemia 34 , 2479–2483 (2020). 32071429 10.1038/s41375-020-0755-7 PMC7431376

310. Shah NN CD33 CAR T-cells (CD33CART) for children and young adults with relapsed/refractory AML: dose-escalation results from a phase I/II multicenter trial Blood 2023 142 771 771 10.1182/blood-2023-179667 Shah, N. N. et al. CD33 CAR T-cells (CD33CART) for children and young adults with relapsed/refractory AML: dose-escalation results from a phase I/II multicenter trial. Blood 142 , 771–771 (2023).

311. Bowser B Success of centralized manufacturing of CD33 CAR T-cells (CD33CART) for children and young adults with relapsed/refractory AML Transplant. Cell. Ther. 2024 30 S153 S154 10.1016/j.jtct.2023.12.195 Bowser, B. et al. Success of centralized manufacturing of CD33 CAR T-cells (CD33CART) for children and young adults with relapsed/refractory AML. Transplant. Cell. Ther. 30 , S153–S154 (2024).

312. Tambaro FP Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia Leukemia 2021 35 3282 3286 10.1038/s41375-021-01232-2 33833386 PMC8550958 Tambaro, F. P. et al. Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia 35 , 3282–3286 (2021). 33833386 10.1038/s41375-021-01232-2 PMC8550958

313. Sallman DA Phase 1/1b safety study of prgn-3006 ultracar-T in patients with relapsed or refractory CD33-positive acute myeloid leukemia and higher risk myelodysplastic syndromes Blood 2022 140 10313 10315 10.1182/blood-2022-169142 Sallman, D. A. et al. Phase 1/1b safety study of prgn-3006 ultracar-T in patients with relapsed or refractory CD33-positive acute myeloid leukemia and higher risk myelodysplastic syndromes. Blood 140 , 10313–10315 (2022).

314. Pan J Phase I study of functionally enhanced CD33 CAR T cells in patients with relapsed or refractory acute myeloid leukemia J. Clin. Oncol. 2024 42 6518 6518 10.1200/JCO.2024.42.16_suppl.6518 Pan, J. et al. Phase I study of functionally enhanced CD33 CAR T cells in patients with relapsed or refractory acute myeloid leukemia. J. Clin. Oncol. 42 , 6518–6518 (2024).

315. Shah NN Phase 1/2 Study of donor-derived anti-CD33 chimeric antigen receptor expressing T cells (VCAR33) in patients with relapsed or refractory acute myeloid leukemia after allogeneic hematopoietic cell transplantation Blood 2023 142 4862 10.1182/blood-2023-180990 Shah, N. N. et al. Phase 1/2 Study of donor-derived anti-CD33 chimeric antigen receptor expressing T cells (VCAR33) in patients with relapsed or refractory acute myeloid leukemia after allogeneic hematopoietic cell transplantation. Blood 142 , 4862 (2023).

316. Appelbaum, J. et al. Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing. J. Clin. Investig. 134, e169155 (2024). 10.1172/JCI162593 PMC11060733 38502193

317. Liu, J. et al. Targeted CD7 CAR T-cells for treatment of T-lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances. Front. Immunol. 14 , 1108959 (2023). 10.3389/fimmu.2023.1170968 PMC10196106 37215124

318. O'Hear C, et al. Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia. Haematologica 100 , 336–344 (2015). 10.3324/haematol.2014.112748 PMC4349272 25480499

319. Ma, Y.-J. et al. CAR-T therapy in two AML patients with post-transplant relapse and failure of anti-CD38 CAR-T cell treatment. Am. J. Cancer Res. 12, 1454–1463 (2022). PMC8899985 35261791

320. Wainberg ZA AMPLIFY-7P: Phase 1 and randomized phase 2 study of amphiphile immunotherapy ELI-002 7P as adjuvant treatment for subjects with G12D, G12R, G12V, G12C, G12A, G12S and G13D Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma J. Clin. Oncol. 2024 42 TPS720 TPS720 10.1200/JCO.2024.42.3_suppl.TPS720 Wainberg, Z. A. et al. AMPLIFY-7P: Phase 1 and randomized phase 2 study of amphiphile immunotherapy ELI-002 7P as adjuvant treatment for subjects with G12D, G12R, G12V, G12C, G12A, G12S and G13D Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma. J. Clin. Oncol. 42 , TPS720–TPS720 (2024).

321. Jin X First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia J. Hematol. Oncol. 2022 15 88 10.1186/s13045-022-01308-1 35799191 PMC9264641 Jin, X. et al. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia. J. Hematol. Oncol. 15 , 88 (2022). 35799191 10.1186/s13045-022-01308-1 PMC9264641

322. Francica B Abstract 6323: Preclinical evaluation of CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy, that exhibits specific and potent toxicity in acute myeloid leukemia (AML) xenograft models Cancer Res. 2024 84 6323 6323 10.1158/1538-7445.AM2024-6323 Francica, B. et al. Abstract 6323: Preclinical evaluation of CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy, that exhibits specific and potent toxicity in acute myeloid leukemia (AML) xenograft models. Cancer Res. 84 , 6323–6323 (2024).

323. Cui, Q. et al. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. J. Hematol. Oncol . 14 , 153 (2021). 10.1186/s13045-021-01092-4 PMC8152118 34034795

324. Hu Y Sequential CD7 CAR T-Cell therapy and allogeneic HSCT without GVHD prophylaxis N. Engl. J. Med. 2024 390 1467 1480 10.1056/NEJMoa2313812 38657244 Hu, Y. et al. Sequential CD7 CAR T-Cell therapy and allogeneic HSCT without GVHD prophylaxis. N. Engl. J. Med. 390 , 1467–1480 (2024). 38657244 10.1056/NEJMoa2313812

325. Zhang M Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia/lymphoma Clin. Cancer Res. 2022 28 2830 2843 10.1158/1078-0432.CCR-21-4097 35435984 Zhang, M. et al. Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia/lymphoma. Clin. Cancer Res. 28 , 2830–2843 (2022). 35435984 10.1158/1078-0432.CCR-21-4097

326. Baumeister SH Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML/MDS and multiple myeloma Cancer Immunol. Res. 2019 7 100 112 10.1158/2326-6066.CIR-18-0307 30396908 PMC7814996 Baumeister, S. H. et al. Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML/MDS and multiple myeloma. Cancer Immunol. Res. 7 , 100–112 (2019). 30396908 10.1158/2326-6066.CIR-18-0307 PMC7814996

327. Nikiforow S A first-in-human phase I trial of NKG2D chimeric antigen receptor-T cells in AML/MDS and multiple myeloma J. Clin. Oncol. 2016 34 TPS3102 TPS3102 10.1200/JCO.2016.34.15_suppl.TPS3102 Nikiforow, S. et al. A first-in-human phase I trial of NKG2D chimeric antigen receptor-T cells in AML/MDS and multiple myeloma. J. Clin. Oncol. 34 , TPS3102–TPS3102 (2016).

328. Liu, F. et al. First-in-human CLL1-CD33 compound CAR (cCAR) T cell therapy in relapsed and refractory acute myeloid leukemia. EHA Library Abstract S149 (2020).

329. Levine BL Miskin J Wonnacott K Keir C Global manufacturing of CAR T cell therapy Mol. Ther. Methods Clin. Dev. 2017 4 92 101 10.1016/j.omtm.2016.12.006 28344995 PMC5363291 Levine, B. L., Miskin, J., Wonnacott, K. & Keir, C. Global manufacturing of CAR T cell therapy. Mol. Ther. Methods Clin. Dev. 4 , 92–101 (2017). 28344995 10.1016/j.omtm.2016.12.006 PMC5363291

330. Stock S Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients Int. J. Cancer 2019 145 1312 1324 10.1002/ijc.32201 30737788 Stock, S. et al. Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients. Int. J. Cancer 145 , 1312–1324 (2019). 30737788 10.1002/ijc.32201

331. Casati A Clinical-scale selection and viral transduction of human naïve and central memory CD8+ T cells for adoptive cell therapy of cancer patients Cancer Immunol. Immunother. 2013 62 1563 1573 10.1007/s00262-013-1459-x 23903715 PMC6348480 Casati, A. et al. Clinical-scale selection and viral transduction of human naïve and central memory CD8+ T cells for adoptive cell therapy of cancer patients. Cancer Immunol. Immunother. 62 , 1563–1573 (2013). 23903715 10.1007/s00262-013-1459-x PMC6348480

332. Wang X Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory t cells manufactured at clinical scale J. Immunother. 2012 35 689 701 10.1097/CJI.0b013e318270dec7 23090078 PMC3525345 Wang, X. et al. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory t cells manufactured at clinical scale. J. Immunother. 35 , 689–701 (2012). 23090078 10.1097/CJI.0b013e318270dec7 PMC3525345

333. Schmueck-Henneresse M Comprehensive approach for identifying the T cell subset origin of CD3 and CD28 antibody–activated chimeric antigen receptor-modified T cells J. Immunother. 2017 199 348 362 10.4049/jimmunol.1601494 PMC5536854 28550199 Schmueck-Henneresse, M. et al. Comprehensive approach for identifying the T cell subset origin of CD3 and CD28 antibody–activated chimeric antigen receptor-modified T cells. J. Immunother. 199 , 348–362 (2017). 10.4049/jimmunol.1601494 PMC5536854 28550199

334. Ayala Ceja, M., Khericha, M., Harris, C. M., Puig-Saus, C. & Chen, Y. Y. CAR-T cell manufacturing: major process parameters and next-generation strategies. J. Exp. Med . 221 , e20230903 (2024). 10.1084/jem.20230903 PMC10791545 38226974

335. Roth TL Reprogramming human T cell function and specificity with non-viral genome targeting Nature 2018 559 405 409 10.1038/s41586-018-0326-5 29995861 PMC6239417 Roth, T. L. et al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature 559 , 405–409 (2018). 29995861 10.1038/s41586-018-0326-5 PMC6239417

336. Depil S Duchateau P Grupp SA Mufti G Poirot L “Off-the-shelf”allogeneic CAR T cells: development and challenges Nat. Rev. Drug. Discov. 2020 19 185 199 10.1038/s41573-019-0051-2 31900462 Depil, S., Duchateau, P., Grupp, S. A., Mufti, G. & Poirot, L. “Off-the-shelf”allogeneic CAR T cells: development and challenges. Nat. Rev. Drug. Discov. 19 , 185–199 (2020). 31900462 10.1038/s41573-019-0051-2

337. Poirot L Multiplex genome-edited T-cell manufacturing platform for “off-the-shelf” adoptive T-cell immunotherapies Cancer Res. 2015 75 3853 3864 10.1158/0008-5472.CAN-14-3321 26183927 Poirot, L. et al. Multiplex genome-edited T-cell manufacturing platform for “off-the-shelf” adoptive T-cell immunotherapies. Cancer Res. 75 , 3853–3864 (2015). 26183927 10.1158/0008-5472.CAN-14-3321

338. Vishwasrao P Li G Boucher JC Smith DL Hui SK Emerging CAR T cell strategies for the treatment of AML Cancers 2022 14 1241 10.3390/cancers14051241 35267549 PMC8909045 Vishwasrao, P., Li, G., Boucher, J. C., Smith, D. L. & Hui, S. K. Emerging CAR T cell strategies for the treatment of AML. Cancers 14 , 1241 (2022). 35267549 10.3390/cancers14051241 PMC8909045

339. Ghorashian S Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR Nat. Med. 2019 25 1408 1414 10.1038/s41591-019-0549-5 31477906 Ghorashian, S. et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat. Med. 25 , 1408–1414 (2019). 31477906 10.1038/s41591-019-0549-5

340. Watanabe, K., Kuramitsu, S., Posey, A. D. & June, C. H. Expanding the therapeutic window for CAR T cell therapy in solid tumors: the knowns and unknowns of CAR T cell biology. Front. Immunol. 9 2486 (2018). 10.3389/fimmu.2018.02486 PMC6212550 30416506

341. Mao, R., Kong, W. & He, Y. The affinity of antigen-binding domain on the antitumor efficacy of CAR T cells: moderate is better. Front. Immunol. 13 , 900241 (2022). 10.3389/fimmu.2022.1032403 PMC9618871 36325345

342. Mansilla-Soto J HLA-independent T cell receptors for targeting tumors with low antigen density Nat. Med. 2022 28 345 352 10.1038/s41591-021-01621-1 35027758 PMC9469647 Mansilla-Soto, J. et al. HLA-independent T cell receptors for targeting tumors with low antigen density. Nat. Med. 28 , 345–352 (2022). 35027758 10.1038/s41591-021-01621-1 PMC9469647

343. Zhao Z Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells Cancer Cell 2015 28 415 428 10.1016/j.ccell.2015.09.004 26461090 PMC5003056 Zhao, Z. et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28 , 415–428 (2015). 26461090 10.1016/j.ccell.2015.09.004 PMC5003056

344. Long AH 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors Nat. Med. 2015 21 581 590 10.1038/nm.3838 25939063 PMC4458184 Long, A. H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21 , 581–590 (2015). 25939063 10.1038/nm.3838 PMC4458184

345. Hwang MS Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens Nat. Commun. 2021 12 5271 10.1038/s41467-021-25605-4 34489470 PMC8421441 Hwang, M. S. et al. Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens. Nat. Commun. 12 , 5271 (2021). 34489470 10.1038/s41467-021-25605-4 PMC8421441

346. MacKay M The therapeutic landscape for cells engineered with chimeric antigen receptors Nat. Biotechnol. 2020 38 233 244 10.1038/s41587-019-0329-2 31907405 MacKay, M. et al. The therapeutic landscape for cells engineered with chimeric antigen receptors. Nat. Biotechnol. 38 , 233–244 (2020). 31907405 10.1038/s41587-019-0329-2

347. Hamieh M Mansilla-Soto J Rivière I Sadelain M Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating Cancer Discov. 2023 13 829 843 10.1158/2159-8290.CD-23-0101 36961206 PMC10068450 Hamieh, M., Mansilla-Soto, J., Rivière, I. & Sadelain, M. Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating. Cancer Discov. 13 , 829–843 (2023). 36961206 10.1158/2159-8290.CD-23-0101 PMC10068450

348. Mog, B. J. et al. Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities. Sci. Transl. Med. 16 , eadh1696 (2024). 10.1126/scitranslmed.adg7123 PMC12226805 38985855

349. Liu, Y. et al. Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors. Sci. Transl. Med. 13 , eabd8636 (2021). 10.1126/scitranslmed.abb5191 33762437

350. Baeuerle PA Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response Nat. Commun. 2019 10 2087 10.1038/s41467-019-10097-0 31064990 PMC6504948 Baeuerle, P. A. et al. Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response. Nat. Commun. 10 , 2087 (2019). 31064990 10.1038/s41467-019-10097-0 PMC6504948

351. Yu, L. et al. Converting TCR-based chimeric antigen receptor STAR into dual-specific targeting receptor for cancer immunotherapy. Mol. Ther . 10.1016/j.ymthe.2025.02.001 (2025). 10.1016/j.ymthe.2025.02.001 PMC11997479 39916328

352. Huang D TCR-mimicking STAR conveys superior sensitivity over CAR in targeting tumors with low-density neoantigens Cell Rep. 2024 43 114949 10.1016/j.celrep.2024.114949 39520682 Huang, D. et al. TCR-mimicking STAR conveys superior sensitivity over CAR in targeting tumors with low-density neoantigens. Cell Rep. 43 , 114949 (2024). 39520682 10.1016/j.celrep.2024.114949

353. Rosenberg SA Restifo NP Adoptive cell transfer as personalized immunotherapy for human cancer Science 2015 348 62 68 10.1126/science.aaa4967 25838374 PMC6295668 Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348 , 62–68 (2015). 25838374 10.1126/science.aaa4967 PMC6295668

354. Weber EW Maus MV Mackall CL The emerging landscape of immune cell therapies Cell 2020 181 46 62 10.1016/j.cell.2020.03.001 32243795 PMC8900215 Weber, E. W., Maus, M. V. & Mackall, C. L. The emerging landscape of immune cell therapies. Cell 181 , 46–62 (2020). 32243795 10.1016/j.cell.2020.03.001 PMC8900215

355. Carnevale J RASA2 ablation in T cells boosts antigen sensitivity and long-term function Nature 2022 609 174 182 10.1038/s41586-022-05126-w 36002574 PMC9433322 Carnevale, J. et al. RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature 609 , 174–182 (2022). 36002574 10.1038/s41586-022-05126-w PMC9433322

356. Borot F Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies Proc. Natl. Acad. Sci. USA 2019 116 11978 11987 10.1073/pnas.1819992116 31138698 PMC6575599 Borot, F. et al. Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies. Proc. Natl. Acad. Sci. USA 116 , 11978–11987 (2019). 31138698 10.1073/pnas.1819992116 PMC6575599

357. Kim MY Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia Cell 2018 173 1439 1453.e19 10.1016/j.cell.2018.05.013 29856956 PMC6003425 Kim, M. Y. et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell 173 , 1439–1453.e19 (2018). 29856956 10.1016/j.cell.2018.05.013 PMC6003425

358. Liu Y CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells Int. J. Cancer 2022 150 1141 1155 10.1002/ijc.33865 34766343 Liu, Y. et al. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells. Int. J. Cancer 150 , 1141–1155 (2022). 34766343 10.1002/ijc.33865

359. Casirati G Epitope editing enables targeted immunotherapy of acute myeloid leukaemia Nature 2023 621 404 414 10.1038/s41586-023-06496-5 37648862 PMC10499609 Casirati, G. et al. Epitope editing enables targeted immunotherapy of acute myeloid leukaemia. Nature 621 , 404–414 (2023). 37648862 10.1038/s41586-023-06496-5 PMC10499609

360. Ji R-J Epitope prime editing shields hematopoietic cells from CD123 immunotherapy for acute myeloid leukemia Cell Stem Cell 2024 31 1650 1666.e8 10.1016/j.stem.2024.09.003 39353428 Ji, R.-J. et al. Epitope prime editing shields hematopoietic cells from CD123 immunotherapy for acute myeloid leukemia. Cell Stem Cell 31 , 1650–1666.e8 (2024). 39353428 10.1016/j.stem.2024.09.003

361. Wellhausen, N. et al. Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy. Sci. Transl. Med. 15 , eabm2443 (2023). 10.1126/scitranslmed.adi1145 PMC10682510 37651540

362. Liu D Zhao J Song Y Engineering switchable and programmable universal CARs for CAR T therapy J. Hematol. Oncol. 2019 12 69 10.1186/s13045-019-0763-0 31272471 PMC6610960 Liu, D., Zhao, J. & Song, Y. Engineering switchable and programmable universal CARs for CAR T therapy. J. Hematol. Oncol. 12 , 69 (2019). 31272471 10.1186/s13045-019-0763-0 PMC6610960

363. Cui Y T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activity Cell Rep. 2023 42 112797 10.1016/j.celrep.2023.112797 37436890 Cui, Y. et al. T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activity. Cell Rep. 42 , 112797 (2023). 37436890 10.1016/j.celrep.2023.112797

364. Zarychta J Kowalczyk A Krawczyk M Lejman M Zawitkowska J CAR-T cells immunotherapies for the treatment of acute myeloid leukemia-recent advances Cancers 2023 15 2944 10.3390/cancers15112944 37296906 PMC10252035 Zarychta, J., Kowalczyk, A., Krawczyk, M., Lejman, M. & Zawitkowska, J. CAR-T cells immunotherapies for the treatment of acute myeloid leukemia-recent advances. Cancers 15 , 2944 (2023). 37296906 10.3390/cancers15112944 PMC10252035

365. Cho JH Engineering advanced logic and distributed computing in human CAR immune cells Nat. Commun. 2021 12 792 10.1038/s41467-021-21078-7 33542232 PMC7862674 Cho, J. H. et al. Engineering advanced logic and distributed computing in human CAR immune cells. Nat. Commun. 12 , 792 (2021). 33542232 10.1038/s41467-021-21078-7 PMC7862674

366. Kittel-Boselli E Targeting acute myeloid leukemia using the revCAR platform: a programmable, switchable and combinatorial strategy Cancers 2021 13 4785 10.3390/cancers13194785 34638268 PMC8508561 Kittel-Boselli, E. et al. Targeting acute myeloid leukemia using the revCAR platform: a programmable, switchable and combinatorial strategy. Cancers 13 , 4785 (2021). 34638268 10.3390/cancers13194785 PMC8508561

367. Lajoie MJ Designed protein logic to target cells with precise combinations of surface antigens Science 2020 369 1637 1643 10.1126/science.aba6527 32820060 PMC8085813 Lajoie, M. J. et al. Designed protein logic to target cells with precise combinations of surface antigens. Science 369 , 1637–1643 (2020). 32820060 10.1126/science.aba6527 PMC8085813

368. Roybal KT Precision tumor recognition by T cells with combinatorial antigen-sensing circuits Cell 2016 164 770 779 10.1016/j.cell.2016.01.011 26830879 PMC4752902 Roybal, K. T. et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 164 , 770–779 (2016). 26830879 10.1016/j.cell.2016.01.011 PMC4752902

369. Tousley AM Co-opting signalling molecules enables logic-gated control of CAR T cells Nature 2023 615 507 516 10.1038/s41586-023-05778-2 36890224 PMC10564584 Tousley, A. M. et al. Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature 615 , 507–516 (2023). 36890224 10.1038/s41586-023-05778-2 PMC10564584

370. Cho JH Collins JJ Wong WW Universal chimeric antigen receptors for multiplexed and logical control of T cell responses Cell 2018 173 1426 1438.e11 10.1016/j.cell.2018.03.038 29706540 PMC5984158 Cho, J. H., Collins, J. J. & Wong, W. W. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell 173 , 1426–1438.e11 (2018). 29706540 10.1016/j.cell.2018.03.038 PMC5984158

371. Allen, G. M. et al. Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science 378 (2022). 10.1126/science.aba1624 PMC9970000 36520915

372. Zhu I Modular design of synthetic receptors for programmed gene regulation in cell therapies Cell 2022 185 1431 1443.e16 10.1016/j.cell.2022.03.023 35427499 PMC9108009 Zhu, I. et al. Modular design of synthetic receptors for programmed gene regulation in cell therapies. Cell 185 , 1431–1443.e16 (2022). 35427499 10.1016/j.cell.2022.03.023 PMC9108009

373. Roybal KT Engineering T cells with customized therapeutic response programs using synthetic notch receptors Cell 2016 167 419 432.e16 10.1016/j.cell.2016.09.011 27693353 PMC5072533 Roybal, K. T. et al. Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell 167 , 419–432.e16 (2016). 27693353 10.1016/j.cell.2016.09.011 PMC5072533

374. Morsut L Engineering customized cell sensing and response behaviors using synthetic notch receptors Cell 2016 164 780 791 10.1016/j.cell.2016.01.012 26830878 PMC4752866 Morsut, L. et al. Engineering customized cell sensing and response behaviors using synthetic notch receptors. Cell 164 , 780–791 (2016). 26830878 10.1016/j.cell.2016.01.012 PMC4752866

375. Richards RM NOT-gated CD93 CAR T cells effectively target AML with minimized endothelial cross-reactivity Blood Cancer Discov. 2021 2 648 665 10.1158/2643-3230.BCD-20-0208 34778803 PMC8580619 Richards, R. M. et al. NOT-gated CD93 CAR T cells effectively target AML with minimized endothelial cross-reactivity. Blood Cancer Discov. 2 , 648–665 (2021). 34778803 10.1158/2643-3230.BCD-20-0208 PMC8580619

376. Simon S Bugos G Salter AI Riddell SR Synthetic receptors for logic gated T cell recognition and function Curr. Opin. Immunol. 2022 74 9 17 10.1016/j.coi.2021.09.003 34571290 PMC8901444 Simon, S., Bugos, G., Salter, A. I. & Riddell, S. R. Synthetic receptors for logic gated T cell recognition and function. Curr. Opin. Immunol. 74 , 9–17 (2022). 34571290 10.1016/j.coi.2021.09.003 PMC8901444

377. Zah E Lin M-Y Silva-Benedict A Jensen MC Chen YY T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells Cancer Immunol. Res. 2016 4 498 508 10.1158/2326-6066.CIR-15-0231 27059623 PMC4933590 Zah, E., Lin, M.-Y., Silva-Benedict, A., Jensen, M. C. & Chen, Y. Y. T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol. Res. 4 , 498–508 (2016). 27059623 10.1158/2326-6066.CIR-15-0231 PMC4933590

378. Grada Z TanCAR: A novel bispecific chimeric antigen receptor for cancer immunotherapy Mol. Ther. Nucleic Acids 2013 2 e105 10.1038/mtna.2013.32 23839099 PMC3731887 Grada, Z. et al. TanCAR: A novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol. Ther. Nucleic Acids 2 , e105 (2013). 23839099 10.1038/mtna.2013.32 PMC3731887

379. Wang, J.-Y. & Wang, L. CAR T cell therapy: where are we now, and where are we heading? Blood sci. 5 , 237–248 (2023). 10.1097/BS9.0000000000000173 PMC10629745 37941917

380. Nelde A Immune surveillance of acute myeloid leukemia is mediated by HLA-presented antigens on leukemia progenitor cells Blood Cancer Discov. 2023 4 468 489 10.1158/2643-3230.BCD-23-0020 37847741 PMC10618727 Nelde, A. et al. Immune surveillance of acute myeloid leukemia is mediated by HLA-presented antigens on leukemia progenitor cells. Blood Cancer Discov. 4 , 468–489 (2023). 37847741 10.1158/2643-3230.BCD-23-0020 PMC10618727

381. Lynn RC Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor–expressing T cells Blood 2015 125 3466 3476 10.1182/blood-2014-11-612721 25887778 PMC4447861 Lynn, R. C. et al. Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor–expressing T cells. Blood 125 , 3466–3476 (2015). 25887778 10.1182/blood-2014-11-612721 PMC4447861

382. Ross JF Chaudhuri PK Ratnam M Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications Cancer 1994 73 2432 2443 10.1002/1097-0142(19940501)73:9<2432::AID-CNCR2820730929>3.0.CO;2-S 7513252 Ross, J. F., Chaudhuri, P. K. & Ratnam, M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 73 , 2432–2443 (1994). 7513252 10.1002/1097-0142(19940501)73:9<2432::aid-cncr2820730929>3.0.co;2-s

383. Wang H Zheng X Behm FG Ratnam M Differentiation-independent retinoid induction of folate receptor type β, a potential tumor target in myeloid leukemia Blood 2000 96 3529 3536 10.1182/blood.V96.10.3529 11071651 Wang, H., Zheng, X., Behm, F. G. & Ratnam, M. Differentiation-independent retinoid induction of folate receptor type β, a potential tumor target in myeloid leukemia. Blood 96 , 3529–3536 (2000). 11071651

384. Rafiq S Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen Leukemia 2017 31 1788 1797 10.1038/leu.2016.373 27924074 PMC5495623 Rafiq, S. et al. Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen. Leukemia 31 , 1788–1797 (2017). 27924074 10.1038/leu.2016.373 PMC5495623

385. Di Stasi, A., Jimenez, A. M., Minagawa, K., Al-Obaidi, M. & Rezvani, K. Review of the results of WT1 peptide vaccination strategies for myelodysplastic syndromes and acute myeloid leukemia from nine different studies. Front. Immunol. 6 , 236 (2015). 10.3389/fimmu.2015.00036 PMC4316779 25699052

386. Li Z LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells Cell Mol. Immunol. 2020 17 272 282 10.1038/s41423-019-0321-2 31700117 PMC7052276 Li, Z. et al. LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells. Cell Mol. Immunol. 17 , 272–282 (2020). 31700117 10.1038/s41423-019-0321-2 PMC7052276

387. Deng M LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration Nature 2018 562 605 609 10.1038/s41586-018-0615-z 30333625 PMC6296374 Deng, M. et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature 562 , 605–609 (2018). 30333625 10.1038/s41586-018-0615-z PMC6296374

388. Yang T LILRB4, an immune checkpoint on myeloid cells Blood Sci. 2022 4 49 56 10.1097/BS9.0000000000000109 35957669 PMC9362873 Yang, T. et al. LILRB4, an immune checkpoint on myeloid cells. Blood Sci. 4 , 49–56 (2022). 35957669 10.1097/BS9.0000000000000109 PMC9362873

389. John S A novel anti-LILRB4 CAR-T Cell for the treatment of monocytic AML Mol. Ther. 2018 26 2487 2495 10.1016/j.ymthe.2018.08.001 30131301 PMC6171100 John, S. et al. A novel anti-LILRB4 CAR-T Cell for the treatment of monocytic AML. Mol. Ther. 26 , 2487–2495 (2018). 30131301 10.1016/j.ymthe.2018.08.001 PMC6171100

390. Kang X Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors Cell Cycle 2016 15 25 40 10.1080/15384101.2015.1121324 26636629 PMC4825776 Kang, X. et al. Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors. Cell Cycle 15 , 25–40 (2016). 26636629 10.1080/15384101.2015.1121324 PMC4825776

391. Zhao X LILRB4 synthetic T-cell receptor and antigen receptor-T (STAR-T) for refractory/relapsed acute myeloid leukemia: first-in-human phase I clinical trial Blood 2024 144 4831 4831 10.1182/blood-2024-207297 Zhao, X. et al. LILRB4 synthetic T-cell receptor and antigen receptor-T (STAR-T) for refractory/relapsed acute myeloid leukemia: first-in-human phase I clinical trial. Blood 144 , 4831–4831 (2024).

392. Mannis GN IO-202, a Novel Anti-LILRB4 antibody, with azacitidine for hypomethylating agent-naive chronic myelomonocytic leukemia: phase 1b expansion cohort results Blood 2024 144 1008 1008 10.1182/blood-2024-206538 Mannis, G. N. et al. IO-202, a Novel Anti-LILRB4 antibody, with azacitidine for hypomethylating agent-naive chronic myelomonocytic leukemia: phase 1b expansion cohort results. Blood 144 , 1008–1008 (2024).

393. Wang Y Quan Y He J Chen S Dong Z SLAM-family receptors promote resolution of ILC2-mediated inflammation Nat. Commun. 2024 15 5056 10.1038/s41467-024-49466-9 38871792 PMC11176369 Wang, Y., Quan, Y., He, J., Chen, S. & Dong, Z. SLAM-family receptors promote resolution of ILC2-mediated inflammation. Nat. Commun. 15 , 5056 (2024). 38871792 10.1038/s41467-024-49466-9 PMC11176369

394. Radomir L The survival and function of IL-10-producing regulatory B cells are negatively controlled by SLAMF5 Nat. Commun. 2021 12 1893 10.1038/s41467-021-22230-z 33767202 PMC7994628 Radomir, L. et al. The survival and function of IL-10-producing regulatory B cells are negatively controlled by SLAMF5. Nat. Commun. 12 , 1893 (2021). 33767202 10.1038/s41467-021-22230-z PMC7994628

395. Pérez-Amill L CD84: a novel target for CAR T-cell therapy for acute myeloid leukemia Blood 2022 140 7379 7381 10.1182/blood-2022-165339 Pérez-Amill, L. et al. CD84: a novel target for CAR T-cell therapy for acute myeloid leukemia. Blood 140 , 7379–7381 (2022).

396. Ghorashian S Pule M Siglec-6 CAR T: magic bullet for a moving target Blood 2021 138 1786 1787 10.1182/blood.2021013184 34762132 PMC9642788 Ghorashian, S. & Pule, M. Siglec-6 CAR T: magic bullet for a moving target. Blood 138 , 1786–1787 (2021). 34762132 10.1182/blood.2021013184 PMC9642788

397. Jetani H Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia Blood 2021 138 1830 1842 10.1182/blood.2020009192 34289026 PMC9642786 Jetani, H. et al. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia. Blood 138 , 1830–1842 (2021). 34289026 10.1182/blood.2020009192 PMC9642786

398. Klaihmon P Luanpitpong S Kang X Issaragrisil S Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells Cancer Cell. Int. 2023 23 297 10.1186/s12935-023-03153-9 38012684 PMC10680184 Klaihmon, P., Luanpitpong, S., Kang, X. & Issaragrisil, S. Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells. Cancer Cell. Int. 23 , 297 (2023). 38012684 10.1186/s12935-023-03153-9 PMC10680184

399. Wolf Y Anderson AC Kuchroo VK TIM3 comes of age as an inhibitory receptor Nat. Rev. Immunol. 2020 20 173 185 10.1038/s41577-019-0224-6 31676858 PMC7327798 Wolf, Y., Anderson, A. C. & Kuchroo, V. K. TIM3 comes of age as an inhibitory receptor. Nat. Rev. Immunol. 20 , 173–185 (2020). 31676858 10.1038/s41577-019-0224-6 PMC7327798

400. Sabatos CA Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance Nat. Immunol. 2003 4 1102 1110 10.1038/ni988 14556006 Sabatos, C. A. et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat. Immunol. 4 , 1102–1110 (2003). 14556006 10.1038/ni988

401. Mandal K Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy target Nat. Cancer 2023 4 1592 1609 10.1038/s43018-023-00652-6 37904046 PMC10663162 Mandal, K. et al. Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy target. Nat. Cancer 4 , 1592–1609 (2023). 37904046 10.1038/s43018-023-00652-6 PMC10663162

402. Blanco B Compte M Lykkemark S Sanz L Alvarez-Vallina L T Cell-redirecting strategies to ‘STAb’ tumors: beyond CARs and bispecific antibodies Trends Immunol. 2019 40 243 257 10.1016/j.it.2019.01.008 30827461 Blanco, B., Compte, M., Lykkemark, S., Sanz, L. & Alvarez-Vallina, L. T Cell-redirecting strategies to ‘STAb’ tumors: beyond CARs and bispecific antibodies. Trends Immunol. 40 , 243–257 (2019). 30827461 10.1016/j.it.2019.01.008

403. Huehls AM Coupet TA Sentman CL Bispecific T-cell engagers for cancer immunotherapy Immunol. Cell Biol. 2015 93 290 296 10.1038/icb.2014.93 25367186 PMC4445461 Huehls, A. M., Coupet, T. A. & Sentman, C. L. Bispecific T-cell engagers for cancer immunotherapy. Immunol. Cell Biol. 93 , 290–296 (2015). 25367186 10.1038/icb.2014.93 PMC4445461

404. Dunn GP Bruce AT Ikeda H Old LJ Schreiber RD Cancer immunoediting: from immunosurveillance to tumor escape Nat. Immunol. 2002 3 991 998 10.1038/ni1102-991 12407406 Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3 , 991–998 (2002). 12407406 10.1038/ni1102-991

405. Liu X Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice Blood Cancer J. 2016 6 e430 e430 10.1038/bcj.2016.38 27258611 PMC5141353 Liu, X. et al. Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice. Blood Cancer J. 6 , e430–e430 (2016). 27258611 10.1038/bcj.2016.38 PMC5141353

406. Jiménez-Reinoso, A. et al. Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers. J. Immunother. Cancer 10 , e004042 (2022). 10.1136/jitc-2022-005333 PMC9791403 36564128

407. Velasco-Sidro M Arroyo-Ródenas J Díez-Alonso L Ramírez-Fernández Á Álvarez-Vallina L Dual-targeted STAb-T cells secreting BCMA and CD19 T cell engagers for improved control of haematological cancers Oncoimmunology 2025 14 2444701 10.1080/2162402X.2024.2444701 39723764 PMC12952728 Velasco-Sidro, M., Arroyo-Ródenas, J., Díez-Alonso, L., Ramírez-Fernández, Á & Álvarez-Vallina, L. Dual-targeted STAb-T cells secreting BCMA and CD19 T cell engagers for improved control of haematological cancers. Oncoimmunology 14 , 2444701 (2025). 39723764 10.1080/2162402X.2024.2444701 PMC12952728

408. Arroyo-Rodenas J Effect of CD22-directed CAR-T cells secreting anti-CD19 T cell engagers on control of leukemia progression compared to tandem anti-CD19/CD22 CAR-T cells J. Clin. Oncol. 2024 42 2550 2550 10.1200/JCO.2024.42.16_suppl.2550 Arroyo-Rodenas, J. et al. Effect of CD22-directed CAR-T cells secreting anti-CD19 T cell engagers on control of leukemia progression compared to tandem anti-CD19/CD22 CAR-T cells. J. Clin. Oncol. 42 , 2550–2550 (2024).

409. Silva, H. et al. CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual targeting antibody overcome antigen heterogeneity in AML. Blood 720–731 (2024). 10.1182/blood.2023023210 PMC11863708 39571145

410. Yan Z A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells Cell Oncol. 2024 47 1879 1895 10.1007/s13402-024-00971-5 PMC12973974 39008193 Yan, Z. et al. A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells. Cell Oncol. 47 , 1879–1895 (2024). 10.1007/s13402-024-00971-5 PMC12973974 39008193

411. Silva-Santos B Mensurado S Coffelt SB γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer Nat. Rev. Cancer 2019 19 392 404 10.1038/s41568-019-0153-5 31209264 PMC7614706 Silva-Santos, B., Mensurado, S. & Coffelt, S. B. γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer. Nat. Rev. Cancer 19 , 392–404 (2019). 31209264 10.1038/s41568-019-0153-5 PMC7614706

412. Xin W Structures of human γδ T cell receptor–CD3 complex Nature 2024 630 222 229 10.1038/s41586-024-07439-4 38657677 PMC11153141 Xin, W. et al. Structures of human γδ T cell receptor–CD3 complex. Nature 630 , 222–229 (2024). 38657677 10.1038/s41586-024-07439-4 PMC11153141

413. Sun L Su Y Jiao A Wang X Zhang B T cells in health and disease Signal Transduct. Target Ther. 2023 8 235 10.1038/s41392-023-01471-y 37332039 PMC10277291 Sun, L., Su, Y., Jiao, A., Wang, X. & Zhang, B. T cells in health and disease. Signal Transduct. Target Ther. 8 , 235 (2023). 37332039 10.1038/s41392-023-01471-y PMC10277291

414. Ribot JC Lopes N Silva-Santos B γδ T cells in tissue physiology and surveillance Nat. Rev. Immunol. 2021 21 221 232 10.1038/s41577-020-00452-4 33057185 Ribot, J. C., Lopes, N. & Silva-Santos, B. γδ T cells in tissue physiology and surveillance. Nat. Rev. Immunol. 21 , 221–232 (2021). 33057185 10.1038/s41577-020-00452-4

415. Mensurado S Blanco-Domínguez R Silva-Santos B The emerging roles of γδ T cells in cancer immunotherapy Nat. Rev. Clin. Oncol. 2023 20 178 191 10.1038/s41571-022-00722-1 36624304 Mensurado, S., Blanco-Domínguez, R. & Silva-Santos, B. The emerging roles of γδ T cells in cancer immunotherapy. Nat. Rev. Clin. Oncol. 20 , 178–191 (2023). 36624304 10.1038/s41571-022-00722-1

416. Mensurado S CD155/PVR determines acute myeloid leukemia targeting by Delta One T cells Blood 2024 143 1488 1495 10.1182/blood.2023022992 38437507 PMC11033583 Mensurado, S. et al. CD155/PVR determines acute myeloid leukemia targeting by Delta One T cells. Blood 143 , 1488–1495 (2024). 38437507 10.1182/blood.2023022992 PMC11033583

417. Di Lorenzo B Broad cytotoxic targeting of acute myeloid leukemia by polyclonal delta one T cells Cancer Immunol. Res. 2019 7 552 558 10.1158/2326-6066.CIR-18-0647 30894378 Di Lorenzo, B. et al. Broad cytotoxic targeting of acute myeloid leukemia by polyclonal delta one T cells. Cancer Immunol. Res. 7 , 552–558 (2019). 30894378 10.1158/2326-6066.CIR-18-0647

418. Veglia F Perego M Gabrilovich D Myeloid-derived suppressor cells coming of age Nat. Immunol. 2018 19 108 119 10.1038/s41590-017-0022-x 29348500 PMC5854158 Veglia, F., Perego, M. & Gabrilovich, D. Myeloid-derived suppressor cells coming of age. Nat. Immunol. 19 , 108–119 (2018). 29348500 10.1038/s41590-017-0022-x PMC5854158

419. Li K Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer Signal Transduct. Target Ther. 2021 6 362 10.1038/s41392-021-00670-9 34620838 PMC8497485 Li, K. et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct. Target Ther. 6 , 362 (2021). 34620838 10.1038/s41392-021-00670-9 PMC8497485

420. Lasser SA Ozbay Kurt FG Arkhypov I Utikal J Umansky V Myeloid-derived suppressor cells in cancer and cancer therapy Nat. Rev. Clin. Oncol. 2024 21 147 164 10.1038/s41571-023-00846-y 38191922 Lasser, S. A., Ozbay Kurt, F. G., Arkhypov, I., Utikal, J. & Umansky, V. Myeloid-derived suppressor cells in cancer and cancer therapy. Nat. Rev. Clin. Oncol. 21 , 147–164 (2024). 38191922 10.1038/s41571-023-00846-y

421. Bronte V Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards Nat. Commun. 2016 7 12150 10.1038/ncomms12150 27381735 PMC4935811 Bronte, V. et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat. Commun. 7 , 12150 (2016). 27381735 10.1038/ncomms12150 PMC4935811

422. Di, S. et al. Combined adjuvant of Poly I:C improves antitumor effects of CAR-T cells. Front. Oncol. 9 , 1208 (2019). 10.3389/fonc.2019.00241 PMC6481273 31058074

423. Xu Y Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15 Blood 2014 123 3750 3759 10.1182/blood-2014-01-552174 24782509 PMC4055922 Xu, Y. et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 123 , 3750–3759 (2014). 24782509 10.1182/blood-2014-01-552174 PMC4055922

424. Singh H Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies Cancer Res. 2011 71 3516 3527 10.1158/0008-5472.CAN-10-3843 21558388 PMC3096697 Singh, H. et al. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res. 71 , 3516–3527 (2011). 21558388 10.1158/0008-5472.CAN-10-3843 PMC3096697

425. Avanzi MP IL-18 secreting CAR T cells enhance cell persistence, induce prolonged B cell aplasia and eradicate CD19+ tumor cells without need for prior conditioning Blood 2016 128 816 10.1182/blood.V128.22.816.816 Avanzi, M. P. et al. IL-18 secreting CAR T cells enhance cell persistence, induce prolonged B cell aplasia and eradicate CD19+ tumor cells without need for prior conditioning. Blood 128 , 816 (2016).27301861

426. Sockolosky JT Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes Science 2018 359 1037 1042 10.1126/science.aar3246 29496879 PMC5947856 Sockolosky, J. T. et al. Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science 359 , 1037–1042 (2018). 29496879 10.1126/science.aar3246 PMC5947856

427. Chalmers ZR Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden Genome Med. 2017 9 34 10.1186/s13073-017-0424-2 28420421 PMC5395719 Chalmers, Z. R. et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 9 , 34 (2017). 28420421 10.1186/s13073-017-0424-2 PMC5395719

428. Assi, R., Kantarjian, H., Ravandi, F. & Daver, N. Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Curr. Opin. Hematol . 25 111–117 (2018). 10.1097/MOH.0000000000000401 29206680

429. Williams P The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia Cancer 2019 125 1470 1481 10.1002/cncr.31896 30500073 PMC6467779 Williams, P. et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer 125 , 1470–1481 (2019). 30500073 10.1002/cncr.31896 PMC6467779

430. Mardiana, S. & Gill, S. CAR T cells for acute myeloid leukemia: state of the art and future directions. Front. Oncol. 10 , 577285 (2020). 10.3389/fonc.2020.00697 PMC7218049 32435621

431. Song W Zhang M Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies Clin. Immunol. 2020 214 108382 10.1016/j.clim.2020.108382 32169439 Song, W. & Zhang, M. Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies. Clin. Immunol. 214 , 108382 (2020). 32169439 10.1016/j.clim.2020.108382

432. Lemoine J Ruella M Houot R Overcoming intrinsic resistance of cancer cells to CAR T-cell killing Clin. Cancer Res. 2021 27 6298 6306 10.1158/1078-0432.CCR-21-1559 34253582 PMC11260069 Lemoine, J., Ruella, M. & Houot, R. Overcoming intrinsic resistance of cancer cells to CAR T-cell killing. Clin. Cancer Res. 27 , 6298–6306 (2021). 34253582 10.1158/1078-0432.CCR-21-1559 PMC11260069

433. Karlsson H Approaches to augment CAR T-cell therapy by targeting the apoptotic machinery Biochem. Soc. Trans. 2016 44 371 376 10.1042/BST20150253 27068942 Karlsson, H. Approaches to augment CAR T-cell therapy by targeting the apoptotic machinery. Biochem. Soc. Trans. 44 , 371–376 (2016). 27068942 10.1042/BST20150253

434. Mazzone R Zwergel C Mai A Valente S Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy Clin. Epigenet. 2017 9 59 10.1186/s13148-017-0358-y PMC5450222 28572863 Mazzone, R., Zwergel, C., Mai, A. & Valente, S. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy. Clin. Epigenet. 9 , 59 (2017). 10.1186/s13148-017-0358-y PMC5450222 28572863

435. Wang Y Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming Nat. Commun. 2021 12 409 10.1038/s41467-020-20696-x 33462245 PMC7814040 Wang, Y. et al. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming. Nat. Commun. 12 , 409 (2021). 33462245 10.1038/s41467-020-20696-x PMC7814040

436. James SR Link PA Karpf AR Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b Oncogene 2006 25 6975 6985 10.1038/sj.onc.1209678 16715135 James, S. R., Link, P. A. & Karpf, A. R. Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b. Oncogene 25 , 6975–6985 (2006). 16715135 10.1038/sj.onc.1209678

437. Zhou J Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells J. Cancer Res. Clin. Oncol. 2017 143 1371 1380 10.1007/s00432-017-2394-6 28321548 PMC11819064 Zhou, J. et al. Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells. J. Cancer Res. Clin. Oncol. 143 , 1371–1380 (2017). 28321548 10.1007/s00432-017-2394-6 PMC11819064

438. Khan O TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion Nature 2019 571 211 218 10.1038/s41586-019-1325-x 31207603 PMC6713202 Khan, O. et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature 571 , 211–218 (2019). 31207603 10.1038/s41586-019-1325-x PMC6713202

439. Otáhal, P. et al. Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells. Oncoimmunology 5 , e1226723 (2016). 10.1080/2162402X.2015.1115940 PMC4839314 27141398

440. Works M Anti–B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide Mol. Cancer Ther. 2019 18 2246 2257 10.1158/1535-7163.MCT-18-1146 31395689 Works, M. et al. Anti–B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide. Mol. Cancer Ther. 18 , 2246–2257 (2019). 31395689 10.1158/1535-7163.MCT-18-1146

441. Ai K Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies J. Hematol. Oncol. 2024 17 105 10.1186/s13045-024-01625-7 39501358 PMC11539560 Ai, K. et al. Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies. J. Hematol. Oncol. 17 , 105 (2024). 39501358 10.1186/s13045-024-01625-7 PMC11539560

442. PRODH2-mediated proline metabolism boosts CAR T-cell effector function. Cancer Discov. 12 , 1405 (2022). 10.1158/2159-8290.CD-RW2022-054 35652211

443. Ye L A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy Cell Metab. 2022 34 595 614.e14 10.1016/j.cmet.2022.02.009 35276062 PMC8986623 Ye, L. et al. A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. Cell Metab. 34 , 595–614.e14 (2022). 35276062 10.1016/j.cmet.2022.02.009 PMC8986623

444. Yang, Q. et al. Superior antitumor immunotherapy efficacy of kynureninase modified CAR-T cells through targeting kynurenine metabolism. Oncoimmunology 11 , 2093402 (2022). 10.1080/2162402X.2022.2055703 PMC8959528 35355679

445. Heslop HE Data mining for second malignancies after CAR-T Blood 2024 143 2023 2024 10.1182/blood.2024024446 38753361 Heslop, H. E. Data mining for second malignancies after CAR-T. Blood 143 , 2023–2024 (2024). 38753361 10.1182/blood.2024024446

446. Hamilton MP Risk of second tumors and T-cell lymphoma after CAR T-cell therapy N. Engl. J. Med. 2024 390 2047 2060 10.1056/NEJMoa2401361 38865660 PMC11338600 Hamilton, M. P. et al. Risk of second tumors and T-cell lymphoma after CAR T-cell therapy. N. Engl. J. Med. 390 , 2047–2060 (2024). 38865660 10.1056/NEJMoa2401361 PMC11338600

447. Strati P Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma Haematologica 2021 106 2667 2672 10.3324/haematol.2020.254045 32732355 PMC8485681 Strati, P. et al. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica 106 , 2667–2672 (2021). 32732355 10.3324/haematol.2020.254045 PMC8485681

448. Elsallab M Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA adverse events reporting system Blood 2024 143 2099 2105 10.1182/blood.2024024166 38483155 Elsallab, M. et al. Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA adverse events reporting system. Blood 143 , 2099–2105 (2024). 38483155 10.1182/blood.2024024166

449. National Library of Medicine (US). NCT04134117 . Tisagenlecleucel in primary CNS lymphoma. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT04134117?cond=NCT04134117&rank=1 (2019).

450. Frigault MJ Tisagenlecleucel demonstrates safety, efficacy and CNS trafficking in primary CNS lymphoma Blood 2021 138 258 258 10.1182/blood-2021-148444 Frigault, M. J. et al. Tisagenlecleucel demonstrates safety, efficacy and CNS trafficking in primary CNS lymphoma. Blood 138 , 258–258 (2021).

451. Dietrich, J. et al. CAR-T cell therapy in recurrent primary CNS lymphoma (PCNSL): a phase 2 clinical trial (S27.009). Neurology 98 , S27.009 (2022).

452. National Library of Medicine (US). NCT03630159 . Study of tisagenlecleucel in combination with pembrolizumab in R/R diffuse large B-cell lymphoma patients (PORTIA). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT03630159?cond=tisagenlecleucel&checkSpell=&rank=9 (2018).

453. Jaeger U Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with R/R DLBCL: phase 1b PORTIA study results Blood Adv. 2023 7 2283 2286 10.1182/bloodadvances.2022007779 36044388 PMC10225880 Jaeger, U. et al. Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with R/R DLBCL: phase 1b PORTIA study results. Blood Adv. 7 , 2283–2286 (2023). 36044388 10.1182/bloodadvances.2022007779 PMC10225880

454. National Library of Medicine (US). NCT03876028 . Study of tisagenlecleucel in combination with ibrutinib in R/R diffuse large B-cell lymphoma patients. ClinicalTrials.gov [Internet] . https://clinicaltrials.gov/study/NCT03876028?cond=tisagenlecleucel&checkSpell=&page=2&rank=11 (2019).

455. national library of medicine (us). nct06003179. optimizing lymphodepletion to improve outcomes in patients receiving cell therapy with kymriah (LOKI). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT06003179?cond=tisagenlecleucel&checkSpell=&page=3&rank=22 (2023).

456. National Library of Medicine (US). NCT05310591 . Combination of an anti-PD1 antibody with tisagenlecleucel reinfusion in children, adolescents and young adults with acute lymphoblastic leukemia after loss of persistence (CAPTiRALL). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT05310591?cond=tisagenlecleucel&checkSpell=&page=2&rank=16 (2022).

457. National Library of Medicine (US). NCT03876769 . Study of efficacy and safety of tisagenlecleucel in HR B-ALL EOC MRD positive patients (CASSIOPEIA). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT03876769?cond=NCT03876769&rank=1 (2018).

458. Buechner, J. et al. Chimeric antigen receptor T-cell therapy in paediatric B-cell precursor acute lymphoblastic leukaemia: curative treatment option or bridge to transplant? Front. Pediatr. 9 (2022). 10.3389/fped.2021.784024 PMC8823293 35145941

459. National Library of Medicine (US). NCT03568461 .Efficacy and safety of tisagenlecleucel in adult patients with refractory or relapsed follicular lymphoma (ELARA). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT03568461?cond=NCT03568461&rank=1&tab=results (2018).

460. National Library of Medicine (US). NCT04234061 . Clinical Trial to Assess The efficacy and safety of the combination of tisagenlecleucel and ibrutinib in mantle cell lymphoma (TARMAC). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT04234061?cond=tisagenlecleucel&checkSpell=&page=2&rank=18&tab=table (2020).

461. National Library of Medicine (U.S.). NCT02445248 . Study of efficacy and safety of CTL019 in adult DLBCL patients (JULIET). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT02445248?cond=NCT02445248&rank=1 (2015).

462. Schuster SJ Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study Lancet Oncol. 2021 22 1403 1415 10.1016/S1470-2045(21)00375-2 34516954 Schuster, S. J. et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 22 , 1403–1415 (2021). 34516954 10.1016/S1470-2045(21)00375-2

463. National Library of Medicine (US). NCT03610724 . Phase II open label trial to determine safety & efficacy of tisagenlecleucel in pediatric non-Hodgkin lymphoma patients. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT03610724?cond=NCT03610724&rank=1 (2018).

464. National Library of Medicine (U.S.). NCT02228096 . Study of efficacy and safety of CTL019 in pediatric ALL patients (ENSIGN). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT02228096?tab=results (2014).

465. Awasthi R Long term durable responses in relapsed/refractory (R/R) ALL, DLBCL, and FL patients treated with tisagenlecleucel and its association with persistence of CAR T-cells Blood 2023 142 4872 4872 10.1182/blood-2023-181663 Awasthi, R. et al. Long term durable responses in relapsed/refractory (R/R) ALL, DLBCL, and FL patients treated with tisagenlecleucel and its association with persistence of CAR T-cells. Blood 142 , 4872–4872 (2023).

466. Laetsch TW Tisagenlecleucel in pediatric and young adult patients with down syndrome-associated relapsed/refractory acute lymphoblastic leukemia Leukemia 2022 36 1508 1515 10.1038/s41375-022-01550-z 35422096 Laetsch, T. W. et al. Tisagenlecleucel in pediatric and young adult patients with down syndrome-associated relapsed/refractory acute lymphoblastic leukemia. Leukemia 36 , 1508–1515 (2022). 35422096 10.1038/s41375-022-01550-z

467. Thudium Mueller K Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma Blood Adv. 2021 5 4980 4991 10.1182/bloodadvances.2020003844 34432863 PMC9153050 Thudium Mueller, K. et al. Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Blood Adv. 5 , 4980–4991 (2021). 34432863 10.1182/bloodadvances.2020003844 PMC9153050

468. National Library of Medicine (US). NCT05460533 . A second infusion (early reinfusion) of tisagenlecleucel in children and young adults with B-cell acute lymphoblastic leukemia(B-ALL). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT05460533?cond=tisagenlecleucel&checkSpell=&page=2&rank=19 (2022).

469. National Library of Medicine (US). NCT04225676 . Study of efficacy and safety of reinfusion of tisagenlecleucel in pediatric and young adult patients with acute lymphoblastic leukemia (ALL). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT04225676?cond=NCT04225676&rank=1 (2020).

470. Boyer MW ALL-026: evaluating efficacy and safety of tisagenlecleucel reinfusion following loss of B-cell aplasia in pediatric and young adult patients with acute lymphoblastic leukemia: HESTER phase II study Clin. Lymphoma Myeloma Leuk. 2021 21 S262 S263 10.1016/S2152-2650(21)01641-4 Boyer, M. W. et al. ALL-026: evaluating efficacy and safety of tisagenlecleucel reinfusion following loss of B-cell aplasia in pediatric and young adult patients with acute lymphoblastic leukemia: HESTER phase II study. Clin. Lymphoma Myeloma Leuk. 21 , S262–S263 (2021).

471. Boyer MW HESTER: A phase II study evaluating efficacy and safety of tisagenlecleucel reinfusion in pediatric and young adult patients with acute lymphoblastic leukemia experiencing loss of B-cell aplasia Blood 2020 136 23 24 10.1182/blood-2020-136340 Boyer, M. W. et al. HESTER: A phase II study evaluating efficacy and safety of tisagenlecleucel reinfusion in pediatric and young adult patients with acute lymphoblastic leukemia experiencing loss of B-cell aplasia. Blood 136 , 23–24 (2020).

472. National Library of Medicine (US). NCT04161118 . Tisagenlecleucel in elderly patients with first-relapsed or primary refractory aggressive B-cell non-Hodgkin lymphoma (TIGER-CTL019). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT04161118?term=tisagenlecleucel&rank=19 (2019).

473. National Library of Medicine (US). NCT04156659 . Study of tisagenlecleucel in chinese pediatric and young adult subjects with relapsed or refractory B-cell ALL. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT04156659?cond=tisagenlecleucel&checkSpell=&page=2&rank=13 (2019).

474. National Library of Medicine (US). NCT04456023 . Study of tisagenlecleucel in chinese adult patients with relapsed or refractory diffuse large b-cell non-Hodgkin lymphoma (DLBCL). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT04456023?cond=tisagenlecleucel&checkSpell=&page=2&rank=17 (2020).

475. National Library of Medicine (US). NCT03570892 . Tisagenlecleucel in adult patients with aggressive B-cell non-Hodgkin lymphoma. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT03570892?cond=NCT03570892&rank=1 (2018).

476. Bishop MR Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma N. Engl. J. Med. 2022 386 629 639 10.1056/NEJMoa2116596 34904798 Bishop, M. R. et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N. Engl. J. Med. 386 , 629–639 (2022). 34904798 10.1056/NEJMoa2116596

477. National Library of Medicine (US). NCT05888493 . A phase III trial comparing tisagenlecleucel to standard of care (SoC) in adult participants with R/R follicular lymphoma (LEDA). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT05888493?term=tisagenlecleucel&rank=21&tab=table (2023).

478. National Library of Medicine (US). NCT04094311 . Study of out of specification for tisagenlecleucel. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT04094311?cond=tisagenlecleucel&checkSpell=&rank=2 .(2021)

479. National Library of Medicine (US). NCT05199961 . Quality of life of adults with diffuse large B-cell lymphoma treated with tisagenlecleucel. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT05199961?term=tisagenlecleucel&rank=22 (2022).

480. National Library of Medicine (US). NCT05541341 . Effectiveness and safety of tisagenlecleucel therapy in brazilian patients with B-lymphocyte malignancies. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT05541341?cond=tisagenlecleucel&checkSpell=&rank=6 (2022).

481. National Library of Medicine (US). NCT03153462 . Axicabtagene ciloleucel expanded access study (ZUMA-9). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT03153462?cond=Axicabtagene%20ciloleucel&sort=StudyFirstPostDate&rank=23 (2017).

482. Jacobson CA Outcomes of patients (Pts) in ZUMA-9, a multicenter, open-label study of axicabtagene ciloleucel (axi-cel) in relapsed/refractory large B cell lymphoma (R/R LBCL) for expanded access and commercial out-of-specification (OOS) product Blood 2020 136 2 3 10.1182/blood-2020-136136 Jacobson, C. A. et al. Outcomes of patients (Pts) in ZUMA-9, a multicenter, open-label study of axicabtagene ciloleucel (axi-cel) in relapsed/refractory large B cell lymphoma (R/R LBCL) for expanded access and commercial out-of-specification (OOS) product. Blood 136 , 2–3 (2020).

483. National Library of Medicine (US). NCT04608487 . Axi-cel in CNS lymphoma. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT04608487?cond=Axicabtagene%20ciloleucel&sort=StudyFirstPostDate&rank=15 (2020).

484. Nayak L A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL) J. Clin. Oncol. 2024 42 2006 2006 10.1200/JCO.2024.42.16_suppl.2006 Nayak, L. et al. A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL). J. Clin. Oncol. 42 , 2006–2006 (2024).

485. National Library of Medicine (US). NCT05077527 . Immune cell therapy (CAR-T) for the treatment of patients with HIV and B-cell non-Hodgkin lymphoma. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT05077527?cond=Axicabtagene%20ciloleucel&sort=StudyFirstPostDate&rank=13 (2021).

486. National Library of Medicine (US). NCT05794958 . Evaluate safety of axicabtagene ciloleucel reinfusion (axi-cel-2) in patients with relapsed and/or refractory second line high-risk non-Hodgkin lymphoma after standard of care Axi-Cel. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT05794958?cond=NCT05794958.%20&rank=1 (2023).

487. National Library of Medicine (US). NCT05950802 . Optimizing lymphodepletion to improve outcomes in patients receiving cell therapy with yescarta (ODIN). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT05950802?cond=yescarta&rank=1 (2023).

488. National Library of Medicine (US). NCT03704298 . Safety and efficacy of axicabtagene ciloleucel in combination with utomilumab in adults with refractory large B-cell lymphoma (ZUMA-11). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT03704298?cond=Axicabtagene%20ciloleucel&sort=StudyFirstPostDate&rank=21 (2018).

489. National Library of Medicine (US). NCT04314843 . Study of lenzilumab and axicabtagene ciloleucel in participants with relapsed or refractory large B-cell lymphoma (ZUMA-19). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT04314843?cond=Axicabtagene%20ciloleucel&sort=StudyFirstPostDate&rank=17 (2020).

490. Kenderian SS ZUMA-19: A phase 1/2 multicenter study of lenzilumab use with axicabtagene ciloleucel (axi-cel) in patients (Pts) with relapsed or refractory large B cell lymphoma (R/R LBCL) Blood 2020 136 6 7 10.1182/blood-2020-135988 Kenderian, S. S. et al. ZUMA-19: A phase 1/2 multicenter study of lenzilumab use with axicabtagene ciloleucel (axi-cel) in patients (Pts) with relapsed or refractory large B cell lymphoma (R/R LBCL). Blood 136 , 6–7 (2020).32614958

491. Oluwole OO ZUMA-19: A phase 1/2 study of axicabtagene ciloleucel plus lenzilumab in patients with relapsed or refractory large B-cell lymphoma Blood 2022 140 10318 10320 10.1182/blood-2022-167688 Oluwole, O. O. et al. ZUMA-19: A phase 1/2 study of axicabtagene ciloleucel plus lenzilumab in patients with relapsed or refractory large B-cell lymphoma. Blood 140 , 10318–10320 (2022).

492. National Library of Medicine (US). NCT03105336 . A phase 2 multicenter study of axicabtagene ciloleucel in subjects with relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT03105336?cond=Axicabtagene%20ciloleucel&sort=StudyFirstPostDate&rank=24 (2017).

493. Neelapu SS Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5) Blood 2024 143 496 506 10.1182/blood.2023021243 37879047 PMC10934297 Neelapu, S. S. et al. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood 143 , 496–506 (2024). 37879047 10.1182/blood.2023021243 PMC10934297

494. Ghione P Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma Blood 2022 140 851 860 10.1182/blood.2021014375 35679476 PMC9412012 Ghione, P. et al. Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. Blood 140 , 851–860 (2022). 35679476 10.1182/blood.2021014375 PMC9412012

495. Leslie, L. et al. P1159 ZUMA-24 Preliminary analysis: a phase 2 study of axicabtagene ciloleucel in the outpatient setting with prophylactic corticosteroids in patients with relapsed/refractory large B-cell lymphoma. In Eha 2024 2093402 (2024).

496. Leslie L Pb2346: ZUMA-24: a phase 2, open-label, multicenter study of axicabtagene ciloleucel in patients with relapsed/refractory large B-cell lymphoma given with corticosteroids in the outpatient setting Hemasphere 2023 7 e50042ff 10.1097/01.HS9.0000976104.50042.ff Leslie, L. et al. Pb2346: ZUMA-24: a phase 2, open-label, multicenter study of axicabtagene ciloleucel in patients with relapsed/refractory large B-cell lymphoma given with corticosteroids in the outpatient setting. Hemasphere 7 , e50042ff (2023).

497. National Library of Medicine (US). NCT05459571 . Study of axicabtagene ciloleucel given with steroids in participants with relapsed or refractory large B-cell lymphoma (ZUMA-24). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT05459571?cond=NCT05459571&rank=1 .

498. Neelapu SS A phase 2, open-label, multicenter study evaluating the safety and efficacy of axicabtagene ciloleucel in combination with either rituximab or lenalidomide in patients with refractory large B-cell lymphoma (ZUMA-14) Blood 2019 134 4093 4093 10.1182/blood-2019-126369 Neelapu, S. S. et al. A phase 2, open-label, multicenter study evaluating the safety and efficacy of axicabtagene ciloleucel in combination with either rituximab or lenalidomide in patients with refractory large B-cell lymphoma (ZUMA-14). Blood 134 , 4093–4093 (2019).

499. Strati P Axicabtagene ciloleucel (axi-cel) in combination with rituximab (Rtx) for the treatment (Tx) of refractory large B-cell lymphoma (R-LBCL): outcomes of the phase 2 ZUMA-14 study J. Clin. Oncol. 2022 40 7567 7567 10.1200/JCO.2022.40.16_suppl.7567 Strati, P. et al. Axicabtagene ciloleucel (axi-cel) in combination with rituximab (Rtx) for the treatment (Tx) of refractory large B-cell lymphoma (R-LBCL): outcomes of the phase 2 ZUMA-14 study. J. Clin. Oncol. 40 , 7567–7567 (2022).

500. National Library of Medicine (US). NCT04002401 . Safety and efficacy of axicabtagene ciloleucel in combination with rituximab in participants with refractory large B-cell lymphoma (ZUMA-14). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT04002401?cond=Axicabtagene%20ciloleucel&sort=StudyFirstPostDate&rank=18 (2019).

501. National Library of Medicine (US). NCT03761056 . Study to evaluate the efficacy and safety of axicabtagene ciloleucel as first-line therapy in participants with high-risk large B-cell lymphoma. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/search?cond=Axicabtagene%20ciloleucel&sort=StudyFirstPostDate (2018).

502. Neelapu SS Primary analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel (axi-cel) as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL) Blood 2021 138 739 739 10.1182/blood-2021-148009 Neelapu, S. S. et al. Primary analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel (axi-cel) as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL). Blood 138 , 739–739 (2021).

503. Neelapu SS Interim analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel (axi-cel) as first-line therapy in patients (pts) with high-risk large B cell lymphoma (LBCL) Blood 2020 136 49 49 10.1182/blood-2020-134449 Neelapu, S. S. et al. Interim analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel (axi-cel) as first-line therapy in patients (pts) with high-risk large B cell lymphoma (LBCL). Blood 136 , 49–49 (2020).

504. Neelapu SS ZUMA-12: a phase 2 multicenter study of axicabtagene ciloleucel (axi-cel) as a first-line therapy in patients (pts) with high-risk large B-cell lymphoma (LBCL) J. Clin. Oncol. 2019 37 TPS7574 TPS7574 10.1200/JCO.2019.37.15_suppl.TPS7574 Neelapu, S. S. et al. ZUMA-12: a phase 2 multicenter study of axicabtagene ciloleucel (axi-cel) as a first-line therapy in patients (pts) with high-risk large B-cell lymphoma (LBCL). J. Clin. Oncol. 37 , TPS7574–TPS7574 (2019).

505. Neelapu SS Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial Nat. Med 2022 28 735 742 10.1038/s41591-022-01731-4 35314842 PMC9018426 Neelapu, S. S. et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat. Med 28 , 735–742 (2022). 35314842 10.1038/s41591-022-01731-4 PMC9018426

506. Chavez JC 3-year analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel (axi-cel) as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL) Blood 2023 142 894 894 10.1182/blood-2023-174510 Chavez, J. C. et al. 3-year analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel (axi-cel) as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL). Blood 142 , 894–894 (2023).

507. National Library of Medicine (US). NCT06218602 . Pilot trial of fecal microbiota transplantation for lymphoma patients receiving axicabtagene ciloleucel therapy. ClinicalTrials.gov [Internet https://clinicaltrials.gov/study/NCT06218602?cond=Axicabtagene%20ciloleucel&sort=StudyFirstPostDate&rank=4 (2024).

508. National Library of Medicine (US). NCT06043323 . A phase II study of axicabtagene ciloleucel, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in combination with radiotherapy (RT) in relapsed/refractory follicular lymphoma. ClinicalTrials.gov [Internet https://clinicaltrials.gov/study/NCT06043323?cond=Axicabtagene%20ciloleucel&sort=StudyFirstPostDate&rank=6 (2023).

509. National Library of Medicine (US). NCT06213311 . A study of axicabtagene ciloleucel and glofitamab as second-line therapy for relapsed or refractory patients with large B cell lymphoma. ClinicalTrials.gov [Internet https://clinicaltrials.gov/study/NCT06213311?cond=Axicabtagene%20ciloleucel&sort=StudyFirstPostDate&rank=5 (2024).

510. National Library of Medicine (US). NCT03391466 . Study of effectiveness of axicabtagene ciloleucel compared to standard of care therapy in patients with relapsed/refractory diffuse large B cell lymphoma (ZUMA-7). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT03391466?cond=Axicabtagene%20ciloleucel&sort=StudyFirstPostDate&rank=22 (2017).

511. Ghobadi A Outcomes of subsequent anti-lymphoma therapies in patients (pts) with large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel) or standard of care (SOC) in the second-line (2L) ZUMA-7 study Blood 2022 140 1595 1597 10.1182/blood-2022-158303 Ghobadi, A. et al. Outcomes of subsequent anti-lymphoma therapies in patients (pts) with large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel) or standard of care (SOC) in the second-line (2L) ZUMA-7 study. Blood 140 , 1595–1597 (2022).

512. Locke FL Association of metabolic tumor volume (MTV) and clinical outcomes in second-line (2L) relapsed/refractory (R/R) large B-cell lymphoma (LBCL) following axicabtagene ciloleucel (axi-cel) versus standard-of-care (Soc) therapy in ZUMA-7 Blood 2022 140 638 640 10.1182/blood-2022-158492 Locke, F. L. et al. Association of metabolic tumor volume (MTV) and clinical outcomes in second-line (2L) relapsed/refractory (R/R) large B-cell lymphoma (LBCL) following axicabtagene ciloleucel (axi-cel) versus standard-of-care (Soc) therapy in ZUMA-7. Blood 140 , 638–640 (2022).

513. Westin JR Survival with axicabtagene ciloleucel in large B-cell lymphoma N. Engl. J. Med. 2023 389 148 157 10.1056/NEJMoa2301665 37272527 Westin, J. R. et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N. Engl. J. Med. 389 , 148–157 (2023). 37272527 10.1056/NEJMoa2301665

514. Westin JR Safety and efficacy of axicabtagene ciloleucel versus standard of care in patients 65 years of age or older with relapsed/refractory large B-cell lymphoma Clin. Cancer Res. 2023 29 1894 1905 10.1158/1078-0432.CCR-22-3136 36999993 PMC10183830 Westin, J. R. et al. Safety and efficacy of axicabtagene ciloleucel versus standard of care in patients 65 years of age or older with relapsed/refractory large B-cell lymphoma. Clin. Cancer Res. 29 , 1894–1905 (2023). 36999993 10.1158/1078-0432.CCR-22-3136 PMC10183830

515. National Library of Medicine (US). NCT05605899 . Study to compare axicabtagene ciloleucel with standard of care therapy as first-line treatment in participants with high-risk large B-cell lymphoma (ZUMA-23). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT05605899?cond=NCT05605899&rank=1 (2022).

516. National Library of Medicine (US). NCT05371093 . Study of axicabtagene ciloleucel versus standard of care therapy in participants with relapsed/refractory follicular lymphoma (ZUMA-22). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT05371093?cond=NCT05371093&rank=1 (2022).

517. Flinn IW P1107: ZUMA-22: a phase 3, randomized controlled study of axicabtagene ciloleucel versus standard-of-care therapy in patients with relapsed or refractory follicular lymphoma Hemasphere 2023 7 e6350662 10.1097/01.HS9.0000971324.63506.62 Flinn, I. W. et al. P1107: ZUMA-22: a phase 3, randomized controlled study of axicabtagene ciloleucel versus standard-of-care therapy in patients with relapsed or refractory follicular lymphoma. Hemasphere 7 , e6350662 (2023).

518. National Library of Medicine (US). NCT06609304 . Axicabtagene ciloleucel for consolidation after first-line treatment of high-risk large B-cell lymphoma (axi-cel). ClinicalTrials.gov [Internet https://clinicaltrials.gov/study/NCT06609304?cond=Axicabtagene%20ciloleucel&sort=StudyFirstPostDate&rank=1 (2024).

519. National Library of Medicine (US). NCT05800067 . Axi-cel retreatment in relapsed/refractory LBCL. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT05800067?cond=Axicabtagene%20ciloleucel&sort=StudyFirstPostDate&rank=7 (2022).

520. Goy A Outcomes of patients with relapsed/refractory mantle cell lymphoma (R/R MCL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-2 and ZUMA-18, an expanded access study Blood 2023 142 106 106 10.1182/blood-2023-174273 Goy, A. et al. Outcomes of patients with relapsed/refractory mantle cell lymphoma (R/R MCL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-2 and ZUMA-18, an expanded access study. Blood 142 , 106–106 (2023).37053547

521. National Library of Medicine (US). NCT04162756 . Study of brexucabtagene autoleucel (KTE-X19) for the treatment of individuals with relapsed/refractory B-cell malignancies (ZUMA-18). ClinicalTrials.gov [Internet] (2019).

522. NCT05776134 . Expanded access study for the treatment of patients with commercially out-of-specification brexucabtagene autoleucel. ClinicalTrials.gov [Internet] .

523. National Library of Medicine (US). NCT05993949 . Study of brexucabtagene autoleucel plus dasatinib in adults with acute lymphoblastic leukemia. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT05993949?cond=brexucabtagene%20autoleucel&rank=3 (2023).

524. Davids MS ZUMA-8: a phase 1 study of KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed/refractory chronic lymphocytic leukemia Blood 2022 140 7454 7456 10.1182/blood-2022-167868 Davids, M. S. et al. ZUMA-8: a phase 1 study of KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed/refractory chronic lymphocytic leukemia. Blood 140 , 7454–7456 (2022).

525. Flinn I ZUMA-8: a phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) J. Clin. Oncol. 2019 37 TPS7566 TPS7566 10.1200/JCO.2019.37.15_suppl.TPS7566 Flinn, I. et al. ZUMA-8: a phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). J. Clin. Oncol. 37 , TPS7566–TPS7566 (2019).

526. National Library of Medicine (US). NCT03624036 . Study to evaluate the safety and tolerability of brexucabtagene autoleucel (KTE-X19) in people with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (ZUMA-8). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT03624036?cond=brexucabtagene%20autoleucel&rank=9#publications (2018).

527. National Library of Medicine (U.S.). NCT02625480 . Study evaluating brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent participants with relapsed/refractory B-precursor acute lymphoblastic leukemia or relapsed/refractory B-cell non-Hodgkin lymphoma (ZUMA-4). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT02625480?cond=brexucabtagene%20autoleucel&rank=10 (2015).

528. Wayne AS Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia Haematologica 2022 108 747 760 10.3324/haematol.2022.280678 PMC9973494 36263840 Wayne, A. S. et al. Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia. Haematologica 108 , 747–760 (2022). 10.3324/haematol.2022.280678 PMC9973494 36263840

529. National Library of Medicine (U.S.). NCT02614066 . A study evaluating the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in adult subjects with relapsed/refractory B-precursor acute lymphoblastic leukemia (ZUMA-3) (ZUMA-3). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT02614066?cond=NCT02614066&rank=1 (2015).

530. Shah BD KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results Blood 2021 138 11 22 10.1182/blood.2020009098 33827116 PMC9999039 Shah, B. D. et al. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood 138 , 11–22 (2021). 33827116 10.1182/blood.2020009098 PMC9999039

531. Shah BD KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study Lancet 2021 398 491 502 10.1016/S0140-6736(21)01222-8 34097852 PMC11613962 Shah, B. D. et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 398 , 491–502 (2021). 34097852 10.1016/S0140-6736(21)01222-8 PMC11613962

532. National Library of Medicine (US). NCT06287229 . Phase Ib/II study assessing the clinical activity and safety of brexucabtagene autoleucel as a consolidation in patients with relapsed/refractory (R/R) and newly diagnosed b-cell acute lymphocytic leukemia (ALL) post cytoreduction with mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT06287229?cond=brexucabtagene%20autoleucel&rank=2 (2024).

533. National Library of Medicine (US). NCT05537766 . Study of brexucabtagene autoleucel in adults with rare B-cell malignancies (ZUMA-25). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT05537766?cond=brexucabtagene%20autoleucel&rank=5 (2022).

534. Wayne AS ZUMA-4: A phase 1/2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in pediatric and adolescent subjects with relapsed/refractory B-precursor acute lymphoblastic leukemia (R/R ALL) J. Clin. Oncol. 2016 34 TPS7075 TPS7075 10.1200/JCO.2016.34.15_suppl.TPS7075 Wayne, A. S. et al. ZUMA-4: A phase 1/2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in pediatric and adolescent subjects with relapsed/refractory B-precursor acute lymphoblastic leukemia (R/R ALL). J. Clin. Oncol. 34 , TPS7075–TPS7075 (2016).

535. Wang M ZUMA-2: Phase 2 multicenter study evaluating efficacy of kte-C19 in patients with relapsed/refractory mantle cell lymphoma J. Clin. Oncol. 2018 36 TPS3102 TPS3102 10.1200/JCO.2018.36.15_suppl.TPS3102 Wang, M. et al. ZUMA-2: Phase 2 multicenter study evaluating efficacy of kte-C19 in patients with relapsed/refractory mantle cell lymphoma. J. Clin. Oncol. 36 , TPS3102–TPS3102 (2018).

536. National Library of Medicine (U.S.). NCT02601313 . Study of brexucabtagene autoleucel (KTE-X19) in participants with relapsed/refractory mantle cell lymphoma (cohort 1 and cohort 2) (ZUMA-2). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT02601313?cond=brexucabtagene%20autoleucel&rank=12 (2015).

537. National Library of Medicine (US). NCT06553872 . Phase 2 open label randomized study of pirtobrutinib and brexucabtagene autoleucel in R/R MCL. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT06553872?cond=brexucabtagene%20autoleucel&rank=1 (2024).

538. National Library of Medicine (US). NCT04880434 . Study of brexucabtagene autoleucel (KTE-X19) in participants with relapsed/refractory mantle cell lymphoma (cohort 3) (ZUMA-2). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT04880434?cond=NCT04880434&rank=1 (2021).

539. van Meerten T Primary analysis of ZUMA-2 cohort 3: brexucabtagene autoleucel (brexu-cel) in patients (pts) with relapsed/refractory mantle cell lymphoma (R/R MCL) who were naive to bruton tyrosine kinase inhibitors (BTKi) Blood 2024 144 748 748 10.1182/blood-2024-198021 van Meerten, T. et al. Primary analysis of ZUMA-2 cohort 3: brexucabtagene autoleucel (brexu-cel) in patients (pts) with relapsed/refractory mantle cell lymphoma (R/R MCL) who were naive to bruton tyrosine kinase inhibitors (BTKi). Blood 144 , 748–748 (2024).

540. National Library of Medicine (US). NCT03274219 . Study of bb21217 in multiple myeloma. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT03274219?cond=idecabtagene%20vicleucel&rank=17 (2017).

541. Alsina M Updated results from the phase I CRB-402 study of anti-Bcma CAR-T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma: correlation of expansion and duration of response with T cell phenotypes Blood 2020 136 25 26 10.1182/blood-2020-140410 Alsina, M. et al. Updated results from the phase I CRB-402 study of anti-Bcma CAR-T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma: correlation of expansion and duration of response with T cell phenotypes. Blood 136 , 25–26 (2020).

542. National Library of Medicine (US). NCT04771078 . Expanded access protocol (EAP) for participants receiving idecabtagene vicleucel that is nonconforming for commercial release. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT04771078?cond=NCT04771078&rank=1 .

543. Paul B Idecabtagene vicleucel (ide-cel) in patients (pts) with newly diagnosed multiple myeloma (NDMM) with an inadequate response to front-line autologous stem cell transplantation (ASCT): karMMa-2 cohort 2c extended follow-up Blood 2024 144 3388 3388 10.1182/blood-2024-200829 Paul, B. et al. Idecabtagene vicleucel (ide-cel) in patients (pts) with newly diagnosed multiple myeloma (NDMM) with an inadequate response to front-line autologous stem cell transplantation (ASCT): karMMa-2 cohort 2c extended follow-up. Blood 144 , 3388–3388 (2024).

544. National Library of Medicine (US). NCT06048250 . Mezigdomide (CC-92480) post idecabtagene vicleucel in treating patients with relapsed multiple myeloma. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT06048250?cond=idecabtagene%20vicleucel&rank=7 (2023).

545. Anderson JLD Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results J. Clin. Oncol. 2021 39 8016 8016 10.1200/JCO.2021.39.15_suppl.8016 Anderson, J. L. D. et al. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results. J. Clin. Oncol. 39 , 8016–8016 (2021).

546. Raje NS KarMMa-7, a phase 1/2, dose-finding and dose-expansion study of combination therapies with idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy for relapsed/refractory multiple myeloma (rrmm) Blood 2021 138 4830 4830 10.1182/blood-2021-147412 Raje, N. S. et al. KarMMa-7, a phase 1/2, dose-finding and dose-expansion study of combination therapies with idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy for relapsed/refractory multiple myeloma (rrmm). Blood 138 , 4830–4830 (2021).

547. National Library of Medicine (US). NCT04855136 . Safety and efficacy of bb2121 (ide-cel) combinations in multiple myeloma (KarMMa-7). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT04855136?cond=idecabtagene%20vicleucel&rank=13 (2021).

548. National Library of Medicine (US). NCT06518551 . Elotuzumab + iberdomide + dexamethasone post ide-cel in rrmm. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT06518551?cond=idecabtagene%20vicleucel&rank=3 (2024).

549. National Library of Medicine (US). NCT05032820 . MM CAR-T to upgrade response BMTCTN1902. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT05032820?cond=idecabtagene%20vicleucel&rank=12 (2021).

550. National Library of Medicine (US). NCT06523621 . Nivolumab in multiple myeloma patients after idecabtagene vicleucel. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT06523621?cond=idecabtagene%20vicleucel&rank=2 (2024).

551. National Library of Medicine (US). NCT05393804 . A study of whether ide-cel (bb2121) can be made from people with multiple myeloma who have had a hematopoietic cell transplant. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT05393804?cond=idecabtagene%20vicleucel&rank=10 (2022).

552. National Library of Medicine (US). NCT06179888 . Iberdomide versus observation off therapy after idecabtagene vicleucel CAR-T for multiple myeloma. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT06179888?cond=idecabtagene%20vicleucel&rank=4 (2023).

553. National Library of Medicine (US). NCT06045806 . A study to compare the efficacy and safety of idecabtagene vicleucel with lenalidomide maintenance therapy versus lenalidomide maintenance therapy alone in adult participants with newly diagnosed multiple myeloma who have suboptimal response after autologous stem cell transplantation (KarMMa-9). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT06045806?cond=idecabtagene%20vicleucel&rank=8 (2023).

554. Raje N MM-493 Efficacy and safety of idecabtagene vicleucel (ide-cel) with lenalidomide (R) maintenance versus R maintenance alone in adult patients with newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous stem cell transplantation (ASCT): phase 3 KarMMa-9 trial Clin. Lymphoma Myeloma Leuk. 2024 24 S562 S563 10.1016/S2152-2650(24)01690-2 Raje, N. et al. MM-493 Efficacy and safety of idecabtagene vicleucel (ide-cel) with lenalidomide (R) maintenance versus R maintenance alone in adult patients with newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous stem cell transplantation (ASCT): phase 3 KarMMa-9 trial. Clin. Lymphoma Myeloma Leuk. 24 , S562–S563 (2024).

555. National Library of Medicine (US). NCT06698887 . A study to evaluate the long-term safety of idecabtagene vicleucel treatment in adults with newly diagnosed multiple myeloma in korea. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT06698887?cond=idecabtagene%20vicleucel&rank=1 (2024).

556. Abramson JS Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001 Blood 2024 143 404 416 10.1182/blood.2023020854 37890149 Abramson, J. S. et al. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood 143 , 404–416 (2024). 37890149 10.1182/blood.2023020854

557. Abramson JS Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study Blood 2023 141 1675 1684 10.1182/blood.2022018730 36542826 PMC10646768 Abramson, J. S. et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood 141 , 1675–1684 (2023). 36542826 10.1182/blood.2022018730 PMC10646768

558. Abramson JS Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL J. Clin. Oncol. 2018 36 7505 7505 10.1200/JCO.2018.36.15_suppl.7505 Abramson, J. S. et al. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. J. Clin. Oncol. 36 , 7505–7505 (2018).

559. National Library of Medicine (US). NCT02631044 . Study evaluating the safety and pharmacokinetics of JCAR017 in B-cell non-Hodgkin lymphoma (TRANSCEND-NHL-001). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT02631044?intr=Lisocabtagene%20maraleucel&rank=20 (2015).

560. Ogasawara K In vivo cellular expansion of lisocabtagene maraleucel and association with efficacy and safety in relapsed/refractory large B-cell lymphoma Clin. Pharm. Ther. 2022 112 81 89 10.1002/cpt.2561 PMC9311712 35156195 Ogasawara, K. et al. In vivo cellular expansion of lisocabtagene maraleucel and association with efficacy and safety in relapsed/refractory large B-cell lymphoma. Clin. Pharm. Ther. 112 , 81–89 (2022). 10.1002/cpt.2561 PMC9311712 35156195

561. National Library of Medicine (US). NCT05075603 . Relapsed/refractory large B-cell lymphoma with NT-I7 Post-CD19 CAR T-cell therapy. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT05075603?cond=NCT05075603&rank=1 (2021).

562. Siddiqi T Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL Blood 2022 139 1794 1806 10.1182/blood.2021011895 34699592 PMC10652916 Siddiqi, T. et al. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood 139 , 1794–1806 (2022). 34699592 10.1182/blood.2021011895 PMC10652916

563. Siddiqi T Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study Lancet 2023 402 641 654 10.1016/S0140-6736(23)01052-8 37295445 PMC11753452 Siddiqi, T. et al. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study. Lancet 402 , 641–654 (2023). 37295445 10.1016/S0140-6736(23)01052-8 PMC11753452

564. National Library of Medicine (US). NCT03331198 . Study evaluating safety and efficacy of JCAR017 in subjects with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT03331198?intr=Lisocabtagene%20maraleucel&rank=19 (2017).

565. National Library of Medicine (US). NCT03743246 . A study to evaluate the safety and efficacy of JCAR017 in pediatric subjects with relapsed/refractory (R/R) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT03743246?cond=jcar017&sort=StudyFirstPostDate&limit=25&rank=5 (2018).

566. National Library of Medicine (US). NCT03483103 . Lisocabtagene maraleucel (JCAR017) as SECOND-LINE THERApy (TRANSCEND-PILOT-017006). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT03483103?intr=Lisocabtagene%20maraleucel&rank=18 (2018).

567. Ernst, M. et al. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Cochrane Database of Systematic Reviews (2021). 10.1002/14651858.CD013365.pub2 PMC8436585 34515338

568. Ghosh N Comparative effectiveness of lisocabtagene maraleucel (liso-cel) in PILOT in patients (pt) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) for whom transplant was not intended (TNI) versus conventional second-line (2L) chemotherapy regimens in the real world Blood 2022 140 10430 10431 10.1182/blood-2022-159686 Ghosh, N. et al. Comparative effectiveness of lisocabtagene maraleucel (liso-cel) in PILOT in patients (pt) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) for whom transplant was not intended (TNI) versus conventional second-line (2L) chemotherapy regimens in the real world. Blood 140 , 10430–10431 (2022).

569. National Library of Medicine (US). NCT03484702 . Trial to determine the efficacy and safety of JCAR017 in adult participants with aggressive B-cell non-Hodgkin lymphoma (TRANSCENDWORLD). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT03484702?intr=Lisocabtagene%20maraleucel&rank=17&tab=results (2018).

570. National Library of Medicine (US). NCT03744676 . A safety trial of lisocabtagene maraleucel (JCAR017) for relapsed and refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) in the outpatient setting (TRANSCEND-OUTREACH-007). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT03744676?cond=Lisocabtagene%20maraleucel&sort=StudyFirstPostDate&limit=25&page=1&rank=10 (2018).

571. Godwin JE Outreach: preliminary safety and efficacy results from a phase 2 study of lisocabtagene maraleucel (liso-cel) in the nonuniversity setting J. Clin. Oncol. 2021 39 e19513 e19513 10.1200/JCO.2021.39.15_suppl.e19513 Godwin, J. E. et al. Outreach: preliminary safety and efficacy results from a phase 2 study of lisocabtagene maraleucel (liso-cel) in the nonuniversity setting. J. Clin. Oncol. 39 , e19513–e19513 (2021).

572. Linhares Y OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL Blood Adv. 2024 8 6114 6126 10.1182/bloodadvances.2024013254 39347584 PMC11652776 Linhares, Y. et al. OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL. Blood Adv. 8 , 6114–6126 (2024). 39347584 10.1182/bloodadvances.2024013254 PMC11652776

573. National Library of Medicine (US). NCT05583149 . Acalabrutinib + liso-cel in R/R aggressive B-cell lymphomas. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT05583149?cond=Lisocabtagene%20maraleucel&sort=StudyFirstPostDate&limit=25&page=1&rank=7 (2022).

574. National Library of Medicine (US). NCT05672173 . Lisocabtagene maraleucel, nivolumab and ibrutinib for the treatment of richter’s transformation. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT05672173?cond=Lisocabtagene%20maraleucel&sort=StudyFirstPostDate&limit=25&page=1&rank=4 (2023).

575. National Library of Medicine (US). NCT05873712 . Zanubrutinib and lisocabtagene maraleucel for the treatment of Richter’s syndrome. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT05873712?cond=Lisocabtagene%20maraleucel&sort=StudyFirstPostDate&limit=25&page=1&rank=3 (2023).

576. National Library of Medicine (US). NCT04245839 . A study to evaluate the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (NHL) (TRANSCEND FL). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT04245839?cond=jcar017&sort=StudyFirstPostDate&limit=25&rank=3 (2020).

577. National Library of Medicine (US). NCT03575351 . A study to compare the efficacy and safety of JCAR017 to standard of care in adult subjects with high-risk, transplant-eligible relapsed or refractory aggressive B-cell non-Hodgkin lymphomas (TRANSFORM). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT03575351?cond=Lisocabtagene%20maraleucel&sort=StudyFirstPostDate&limit=25&page=1&rank=11&tab=results (2018).

578. Kamdar M Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial Lancet 2022 399 2294 2308 10.1016/S0140-6736(22)00662-6 35717989 Kamdar, M. et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 399 , 2294–2308 (2022). 35717989 10.1016/S0140-6736(22)00662-6

579. Kamdar MK Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study J. Clin. Oncol. 2024 42 7013 7013 10.1200/JCO.2024.42.16_suppl.7013 Kamdar, M. K. et al. Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study. J. Clin. Oncol. 42 , 7013–7013 (2024).

580. National Library of Medicine (US). NCT06313996 . A study to evaluate the efficacy and safety of liso-cel compared to standard of care in adults with relapsed or refractory follicular lymphoma. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT06313996?cond=Lisocabtagene%20maraleucel&sort=StudyFirstPostDate&limit=25&page=1&rank=1 (2024).

581. National Library of Medicine (US). NCT06205290 . A study to compare the efficacy and safety of lisocabtagene maraleucel vs investigator’s choice options in adult participants with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, whose disease has failed treatment with both BTKi and BCL2i therapies. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT06205290?cond=Lisocabtagene%20maraleucel&sort=StudyFirstPostDate&limit=25&page=1&rank=2 (2023).

582. National Library of Medicine (US). NCT06623630 . Lymphodepleting total body irradiation (TBI) plus cyclophosphamide prior to ciltacabtagene autoleucel (carvykti; cilta-cel) for multiple myeloma (MM) patients with impaired renal function. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT06623630?cond=ciltacabtagene%20autoleucel&rank=1 (2024).

583. National Library of Medicine (U.S.). NCT03090659 . LCAR-B38M Cells in treating relapsed/refractory (R/R) multiple myeloma (LEGEND-2). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT03090659?cond=ciltacabtagene%20autoleucel&sort=StudyFirstPostDate&limit=25&rank=15 (2017).

584. Zhao W-H Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2) J. Hematol. Oncol. 2022 15 86 10.1186/s13045-022-01301-8 35794616 PMC9261106 Zhao, W.-H. et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J. Hematol. Oncol. 15 , 86 (2022). 35794616 10.1186/s13045-022-01301-8 PMC9261106

585. Zhao W-H A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma J. Hematol. Oncol. 2018 11 141 10.1186/s13045-018-0681-6 30572922 PMC6302465 Zhao, W.-H. et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J. Hematol. Oncol. 11 , 141 (2018). 30572922 10.1186/s13045-018-0681-6 PMC6302465

586. Xu J Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial J. Hematol. Oncol. 2024 17 23 10.1186/s13045-024-01530-z 38659046 PMC11040812 Xu, J. et al. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial. J. Hematol. Oncol. 17 , 23 (2024). 38659046 10.1186/s13045-024-01530-z PMC11040812

587. Liu R Outcomes in patients with multiple myeloma receiving salvage treatment after BCMA -specific CAR-T therapy: A retrospective analysis of LEGEND-2 Br. J. Haematol. 2024 204 1780 1789 10.1111/bjh.19340 38369805 Liu, R. et al. Outcomes in patients with multiple myeloma receiving salvage treatment after BCMA -specific CAR-T therapy: A retrospective analysis of LEGEND-2. Br. J. Haematol. 204 , 1780–1789 (2024). 38369805 10.1111/bjh.19340

588. Berdeja JG Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study Lancet 2021 398 314 324 10.1016/S0140-6736(21)00933-8 34175021 Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 398 , 314–324 (2021). 34175021 10.1016/S0140-6736(21)00933-8

589. National Library of Medicine (US). NCT03548207 . A study of JNJ-68284528, a chimeric antigen receptor T cell (CAR-T) therapy directed against B-cell maturation antigen (BCMA) in participants with relapsed or refractory multiple myeloma (CARTITUDE-1). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT03548207?cond=ciltacabtagene%20autoleucel&sort=StudyFirstPostDate&limit=25&rank=14 (2018).

590. National Library of Medicine (US). NCT05347485 . A study of JNJ-68284528 out-of-specification (OOS) for commercial release in participants with multiple myeloma. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT05347485?cond=ciltacabtagene%20autoleucel&rank=6 (2022).

591. National Library of Medicine (US). NCT03758417 . A study of LCAR-B38M CAR-T cells, a chimeric antigen receptor T-cell (CAR-T) therapy directed against B-cell maturation antigen (BCMA) in chinese participants with relapsed or refractory multiple myeloma (CARTIFAN-1). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT03758417?cond=ciltacabtagene%20autoleucel&sort=StudyFirstPostDate&limit=25&rank=13 (2018). 10.1186/s13045-018-0681-6 PMC6302465 30572922

592. Mi J-Q Phase II, open-label study of ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor–T-cell therapy, in chinese patients with relapsed/refractory multiple myeloma (CARTIFAN-1) J. Clin. Oncol. 2023 41 1275 1284 10.1200/JCO.22.00690 36269898 Mi, J.-Q. et al. Phase II, open-label study of ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor–T-cell therapy, in chinese patients with relapsed/refractory multiple myeloma (CARTIFAN-1). J. Clin. Oncol. 41 , 1275–1284 (2023). 36269898 10.1200/JCO.22.00690

593. National Library of Medicine (US). NCT04133636 . A study of JNJ-68284528, a chimeric antigen receptor T cell (CAR-T) therapy directed against B-cell maturation antigen (BCMA) in Participants with multiple myeloma (CARTITUDE-2). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT04133636?cond=ciltacabtagene%20autoleucel&rank=12 (2019).

594. Cohen AD Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents Blood 2023 141 219 230 10.1182/blood.2022015526 36095849 PMC10562529 Cohen, A. D. et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood 141 , 219–230 (2023). 36095849 10.1182/blood.2022015526 PMC10562529

595. National Library of Medicine (US). NCT06550895 . A study of ciltacabtagene autoleucel and talquetamab for the treatment of participants with high-risk multiple myeloma (MonumenTAL-8). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT06550895?cond=ciltacabtagene%20autoleucel&rank=4 (2024).

596. National Library of Medicine (US). NCT06574126 . Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma (CAR-HiRiSMM). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT06574126?cond=ciltacabtagene%20autoleucel&rank=3 (2024).

597. National Library of Medicine (US). NCT06577025 . A study of different sequences of cilta-cel, talquetamab in combination with daratumumab and teclistamab in combination with daratumumab following induction with daratumumab, bortezomib, lenalidomide and dexamethasone in participants with standard-risk newly diagnosed multiple myeloma (aMMbition). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT06577025?cond=ciltacabtagene%20autoleucel&rank=2 (2024).

598. National Library of Medicine (US). NCT04181827 . A study comparing JNJ-68284528, a CAR-T therapy directed against B-cell maturation antigen (BCMA), versus pomalidomide, bortezomib and dexamethasone (pvd) or daratumumab, pomalidomide and dexamethasone (DPd) in participants with relapsed and lenalidomide-refractory multiple myeloma (CARTITUDE-4). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT04181827?cond=ciltacabtagene%20autoleucel&rank=11 (2019).

599. National Library of Medicine (US). NCT04923893 . A study of bortezomib, lenalidomide and dexamethasone (VRd) followed by cilta-cel, a CAR-T therapy directed against BCMA versus VRd followed by lenalidomide and dexamethasone (Rd) therapy in participants with newly diagnosed multiple myeloma for whom ASCT is not planned as initial therapy (CARTITUDE-5). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT04923893?cond=ciltacabtagene%20autoleucel&rank=9 (2021).

600. Dytfeld D Bortezomib, lenalidomide and dexamethasone (VRd) followed by ciltacabtagene autoleucel versus Vrd followed by lenalidomide and dexamethasone (Rd) Maintenance in patients with newly diagnosed multiple myeloma not intended for transplant: a randomized, phase 3 study (CARTITUDE-5) Blood 2021 138 1835 1835 10.1182/blood-2021-146210 Dytfeld, D. et al. Bortezomib, lenalidomide and dexamethasone (VRd) followed by ciltacabtagene autoleucel versus Vrd followed by lenalidomide and dexamethasone (Rd) Maintenance in patients with newly diagnosed multiple myeloma not intended for transplant: a randomized, phase 3 study (CARTITUDE-5). Blood 138 , 1835–1835 (2021).

601. National Library of Medicine (US). NCT05257083 . A study of daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) followed by ciltacabtagene autoleucel versus daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) followed by autologous stem cell transplant (ASCT) in participants with newly diagnosed multiple myeloma (CARTITUDE-6). ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT05257083?cond=ciltacabtagene%20autoleucel&rank=7 (2022).

602. National Library of Medicine (US). NCT05201781 . A long-term study for participants previously treated with ciltacabtagene autoleucel. ClinicalTrials.gov [Internet] https://clinicaltrials.gov/study/NCT05201781?cond=ciltacabtagene%20autoleucel&rank=8 (2022).

603. Ehninger G Phase 1 dose escalation study of the rapidly switchable universal CAR-T therapy Unicar-T-CD123 in relapsed/refractory AML Blood 2022 140 2367 2368 10.1182/blood-2022-168877 Ehninger, G. et al. Phase 1 dose escalation study of the rapidly switchable universal CAR-T therapy Unicar-T-CD123 in relapsed/refractory AML. Blood 140 , 2367–2368 (2022).

604. Wermke M Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML Blood 2021 137 3145 3148 10.1182/blood.2020009759 33624009 PMC8176767 Wermke, M. et al. Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML. Blood 137 , 3145–3148 (2021). 33624009 10.1182/blood.2020009759 PMC8176767

605. Feldmann A A novel revcar platform for switchable and gated tumor targeting Blood 2019 134 5611 5611 10.1182/blood-2019-128436 Feldmann, A. et al. A novel revcar platform for switchable and gated tumor targeting. Blood 134 , 5611–5611 (2019).

606. A. Ehninger, et al. Preclinical characterization of switchable allogeneic chimeric antigen receptor T cells to support first in human clinical study in CD123-positive hematologic and lymphatic malignancies. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4095.

607. Sallman DA Phase 1/1b safety study of Prgn-3006 Ultracar-T in patients with relapsed or refractory CD33-positive acute myeloid leukemia and higher risk myelodysplastic syndromes Blood 2021 138 825 10.1182/blood-2021-152692 Sallman, D. A. et al. Phase 1/1b safety study of Prgn-3006 Ultracar-T in patients with relapsed or refractory CD33-positive acute myeloid leukemia and higher risk myelodysplastic syndromes. Blood 138 , 825 (2021).

608. Zuo S C-JUN overexpressing CAR-T cells in acute myeloid leukemia: preclinical characterization and phase I trial Nat. Commun. 2024 15 6155 10.1038/s41467-024-50485-9 39039086 PMC11263573 Zuo, S. et al. C-JUN overexpressing CAR-T cells in acute myeloid leukemia: preclinical characterization and phase I trial. Nat. Commun. 15 , 6155 (2024). 39039086 10.1038/s41467-024-50485-9 PMC11263573

609. Wang Q Treatment of CD33-directed Chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia Mol. Ther. 2015 23 184 191 10.1038/mt.2014.164 25174587 PMC4426796 Wang, Q. et al. Treatment of CD33-directed Chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol. Ther. 23 , 184–191 (2015). 25174587 10.1038/mt.2014.164 PMC4426796

610. Shah N., et al. G. Phase 1/2 study of donor-derived anti-CD33 chimeric antigen receptor expressing T cells (VCAR33 ALLO) in patients with relapsed or refractory acute myeloid leukemia after allogeneic hematopoietic cell transplantation (trial in progress). Presented at the 65 th ASH annual meeting and exposition; December 9-12, San Diego, USA. 2023. Abstract nr 4862.

611. Canesin G., et al. G-CSF/plerixafor dual-mobilized donor derived CD33CAR T-cells as potent and effective AML therapy in pre-clinical models. Presented at 63rd ASH annual meeting & exposition, December 11–14, 2021. Abstract nr 1716.

612. Moeller R, K. S. S. J. Construction and evaluation of interleukin 3 (IL3)-zetakine–redirected cytolytic T cells for treatment of CD123-expressing acute myeloid leukemia. Presented at SITC 2021, November 10–14, 2021. Abstract nr 871.

613. Cooper TM Pediatric and young adult leukemia adoptive therapy (PLAT)-08: A phase 1 study of SC-DARIC33 in pediatric and young adults with relapsed or refractory CD33+ AML J. Clin. Oncol. 2022 40 TPS7078 TPS7078 10.1200/JCO.2022.40.16_suppl.TPS7078 Cooper, T. M. et al. Pediatric and young adult leukemia adoptive therapy (PLAT)-08: A phase 1 study of SC-DARIC33 in pediatric and young adults with relapsed or refractory CD33+ AML. J. Clin. Oncol. 40 , TPS7078–TPS7078 (2022).

614. Petrov JC Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia Leukemia 2018 32 1317 1326 10.1038/s41375-018-0075-3 29515236 PMC5990523 Petrov, J. C. et al. Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia. Leukemia 32 , 1317–1326 (2018). 29515236 10.1038/s41375-018-0075-3 PMC5990523

615. Daver NG A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify) J. Clin. Oncol. 2024 42 TPS6586 TPS6586 10.1200/JCO.2024.42.16_suppl.TPS6586 Daver, N. G. et al. A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify). J. Clin. Oncol. 42 , TPS6586–TPS6586 (2024).

616. Liu F First-in-human CLL1-CD33 compound CAR T cell therapy induces complete remission in patients with refractory acute myeloid leukemia: update on phase 1 clinical trial Blood 2018 132 901 901 10.1182/blood-2018-99-110579 Liu, F. et al. First-in-human CLL1-CD33 compound CAR T cell therapy induces complete remission in patients with refractory acute myeloid leukemia: update on phase 1 clinical trial. Blood 132 , 901–901 (2018).

617. Chen L Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia Leukemia 2017 31 1830 1834 10.1038/leu.2017.147 28496177 PMC5558867 Chen, L. et al. Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Leukemia 31 , 1830–1834 (2017). 28496177 10.1038/leu.2017.147 PMC5558867

618. Karbowski CM Nonclinical safety assessment of AMG 553, an investigational anti-FLT3 CAR-T therapy J. Clin. Oncol. 2019 37 7032 7032 10.1200/JCO.2019.37.15_suppl.7032 Karbowski, C. M. et al. Nonclinical safety assessment of AMG 553, an investigational anti-FLT3 CAR-T therapy. J. Clin. Oncol. 37 , 7032–7032 (2019).

619. Karbowski C Nonclinical safety assessment of AMG 553, an investigational chimeric antigen receptor T-cell therapy for the treatment of acute myeloid leukemia. Toxicol. Sci. 2020 177 94 107 10.1093/toxsci/kfaa098 32589753 PMC7553704 Karbowski, C. et al. Nonclinical safety assessment of AMG 553, an investigational chimeric antigen receptor T-cell therapy for the treatment of acute myeloid leukemia. Toxicol. Sci. 177 , 94–107 (2020). 32589753 10.1093/toxsci/kfaa098 PMC7553704

620. Cui, Q. et al. Case report: CD38-directed CAR-T cell therapy: a novel immunotherapy targeting CD38-positive blasts overcomes TKI and chemotherapy resistance of myeloid chronic myeloid leukemia in blastic phase. Front. Immunol. 13 , 1012981 (2022). 10.3389/fimmu.2022.1012981 PMC9744919 36524116

621. Murad JM Manufacturing development and clinical production of NKG2D chimeric antigen receptor–expressing T cells for autologous adoptive cell therapy Cytotherapy 2018 20 952 963 10.1016/j.jcyt.2018.05.001 30180944 PMC6127861 Murad, J. M. et al. Manufacturing development and clinical production of NKG2D chimeric antigen receptor–expressing T cells for autologous adoptive cell therapy. Cytotherapy 20 , 952–963 (2018). 30180944 10.1016/j.jcyt.2018.05.001 PMC6127861

622. Carrabba MG Phase I-IIa clinical trial to assess safety and efficacy of MLM-CAR44.1, a CD44v6-directed CAR-T in relapsed/refractory acute myeloid leukemia (AML) and multiple myeloma (MM) Blood 2018 132 5790 5790 10.1182/blood-2018-99-117974 Carrabba, M. G. et al. Phase I-IIa clinical trial to assess safety and efficacy of MLM-CAR44.1, a CD44v6-directed CAR-T in relapsed/refractory acute myeloid leukemia (AML) and multiple myeloma (MM). Blood 132 , 5790–5790 (2018).

623. Salman H Preclinical targeting of human acute myeloid leukemia using CD4-specific chimeric antigen receptor (CAR) T Cells and NK Cells J. Cancer 2019 10 4408 4419 10.7150/jca.28952 31413761 PMC6691696 Salman, H. et al. Preclinical targeting of human acute myeloid leukemia using CD4-specific chimeric antigen receptor (CAR) T Cells and NK Cells. J. Cancer 10 , 4408–4419 (2019). 31413761 10.7150/jca.28952 PMC6691696

624. Pei K Anti-CLL1-based CAR T-cells with 4-1-BB or CD28/CD27 stimulatory domains in treating childhood refractory/relapsed acute myeloid leukemia Cancer Med. 2023 12 9655 9661 10.1002/cam4.5916 37031462 PMC10166968 Pei, K. et al. Anti-CLL1-based CAR T-cells with 4-1-BB or CD28/CD27 stimulatory domains in treating childhood refractory/relapsed acute myeloid leukemia. Cancer Med. 12 , 9655–9661 (2023). 37031462 10.1002/cam4.5916 PMC10166968

625. Zhang H Characteristics of anti-CLL1-based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis Leukemia 2022 36 2596 2604 10.1038/s41375-022-01703-0 36151140 Zhang, H. et al. Characteristics of anti-CLL1-based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis. Leukemia 36 , 2596–2604 (2022). 36151140 10.1038/s41375-022-01703-0

626. Hazelton W Ghorashian S Pule M Nanobody-based tri-specific chimeric antigen receptor to treat acute myeloid leukaemia Blood 2020 136 10 11 10.1182/blood-2020-141214 Hazelton, W., Ghorashian, S. & Pule, M. Nanobody-based tri-specific chimeric antigen receptor to treat acute myeloid leukaemia. Blood 136 , 10–11 (2020).